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Abstract 
Tuberculosis (TB) is responsible for more than one million human deaths per year 
globally, more than any other disease caused by a bacterial pathogen. Although 
effective treatments exist, the long duration of the current treatment regimen as well 
as associated drug toxicities can lead to patient non-compliance. This has resulted in 
the spread of drug resistance which is highlighted by the isolation of extensively 
drug-resistant strains of Mycobacterium tuberculosis complex in all regions of the 
globe. The management of drug-resistant TB cases requires an extended treatment 
duration of 18 months minimum post sputum-culture conversion, using drugs that 
are more frequently linked to adverse side-effects. Therefore, there is a need to 
identify new drugs that shorten treatment time, and also exhibit better tolerance in 
patients. 
This thesis describes the screening of crude marine extract libraries for the 
identification of novel anti-tubercular compounds. The libraries consisted of extracts 
from New Zealand marine organisms that were screened for growth inhibitory 
activity using a surrogate TB model organism M. smegmatis, and subsequently were 
validated against M. tuberculosis.  Bioassay-guided fractionation led to the 
identification of two new compounds as well as a mixture of known compounds. In 
addition to anti-mycobacterial activity, the spectrum of activity of the isolated 
compounds was also investigated.  
Fractionation of the liver extract of the blobfish Psychrolutes marcidus led to the 
identification of a mixture of four common fatty acids as the major bioactive 
components. Testing each of the fatty acids individually identified palmitic acid as 
the most active component against M. tuberculosis H37Ra. This is at odds with 
current understanding of the fatty acid parameters required for bioactivity in terms of 
chain length and degree of unsaturation. 
Bioassay-guided fractionation of a Latrunculia sp. sponge extract led to the isolation 
of a novel taurinated terpene rimarikiamide A (98). This compound was initially 
believed to be responsible for the observed anti-mycobacterial activity, however, 
further purification led to partitioning of the anti-mycobacterial activity away from 
98. The taurinated terpene rimarikiamide A was nevertheless tested for activity in 
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mammalian cell lines and was found to exhibit higher levels of growth inhibition 
towards HL-60 cells with respect to HEK cells. 
Working with Xiphophora chondrophylla, a New Zealand brown alga, led to the 
identification of the amino alcohol 3-epi-xestoaminol C (156) a stereoisomer of a 
known compound, as the active principle. This compound displayed the same level 
of activity in all microorganisms tested, however it proved to be more active against 
HL-60 cells. To further investigate the mode of action of 156, chemical genetics was 
employed to indicate the relevant genetic networks that the compound interacts with. 
This led to the identification of expected pathways such as lipid metabolism as well 
as cytoskeletal organization, which have been linked to this class of compounds. 
Furthermore this work also identified new processes such as RNA catabolism, 
protein targeting and phosphorylation in addition to several unknown processes. 
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1.1  Tuberculosis 
1.1.1 Disease 
Mycobacterium tuberculosis was first identified as the cause of tuberculosis (TB) by 
Robert Koch in 1882 [1]. TB is an ancient disease, with evidence of its persistence 
through time recorded in the remains of 3000 year old ancient Egyptian populations [2]. 
The earliest evidence of humans infected with TB can be dated back to a 9,000 year old 
Neolithic settlement in the Eastern Mediterranean [3].  
TB primarily affects the lungs, with common symptoms such as fever, night sweats, 
fatigue, coughing, in severe cases bloody and weight loss [4]. Without appropriate 
treatment 70% of pulmonary TB infections are terminal [5]. Extra-pulmonary TB is a 
form that infects any part of the body other than the lungs  including the skin, the 
central nervous system and the reproductive organs [6].  The most severe form of extra-
pulmonary TB is miliary TB, which occurs when bacteria infiltrate blood circulation 
and can affect multiple organs [7]. This form of the disease has a high mortality rate, 
15-20% in children and 25%-50% in adults [7]. 
1.1.2 Disease statistics 
While the overall mortality rates associated with TB is decreasing, in 2012 8.6 million 
cases of TB and 1.3 million deaths due to TB were reported by the World Health 
Organisation (WHO) [8]. Controlling this disease is hindered by the latent form of TB, 
which is currently believed to affect a third of the world population [9]. In latent TB 
infection bacilli stay dormant and do not cause active disease, individuals with this form 
of TB have a 10% risk of developing active TB during their lifetime, each of whom will 
go on to infect 10-15 people [9]. In New Zealand (NZ) a total of 661 cases of TB were 
identified in 2010 [10]. NZ has a much higher incidence of TB (6.6 per 100, 000) 
compared to Australia and the United States of America [10]. Among cases of NZ born 
patients over 50% were of Maori ethnicity compared to 19% for patients of European 
ethnicity [10].  
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1.1.3 Mycobacteria 
Mycobacteria are rod shaped non-motile bacteria that can be differentiated using acid 
fast staining. The acid fastness is unique, due to the high mycolic acid content in the cell 
walls of mycobacteria, which retain the carbol-fuchsin dye after decolourising with 
acidic alcohol [11, 12]. These bacteria are widespread in diverse environments ranging 
from soil to water [13], and are generally categorised into two groups, fast-growing and 
slow-growing. Fast growing mycobacteria show defined colonies on agar within seven 
days of inoculation [14]. These include M. smegmatis, M. fortuitum and M. abscessus, 
which are responsible for post-surgical as well as skin and soft tissue infections [15]. 
This group also includes M. phlei and M. aurum, which are generally considered as 
non-infectious mycobacteria, although there have been reported cases of these strains 
causing disease in immunocompromised patients [16, 17]. 
Slow-growing mycobacteria take longer than seven days to show visible growth [14], 
this group includes M. tuberculosis, M. bovis, M. africanum and M. leprae, which 
belong to the Mycobacterium tuberculosis complex (MTB complex), referring to a 
group of mycobacteria that can cause tuberculosis in either human or animal hosts. 
Other slow growers include M. avium, M. kansasii and M. marinum all of which cause 
varying types of skin lesions [15].  
Details of two species of mycobacteria that were utilised in this research are described 
below. 
1.1.3.1 Mycobacterium smegmatis 
This species of mycobacteria is widespread in soil [18], although generally considered 
to be non-pathogenic it can be an opportunistic pathogen resulting in post-surgical 
infections [19]. Due to its low pathogenicity as well fast replication time, this species is 
the work horse for mycobacterial research [20]. The ease of genetic manipulation as 
well as similarities in drug susceptibility to pathogenic mycobacteria make 
M. smegmatis an appropriate model organism for studying clinically relevant 
mycobacteria [21, 22]. 
 
 
4 
 
1.1.3.2 Mycobacterium tuberculosis  
Mycobacterium tuberculosis H37Rv and H37Ra were both derived from their virulent 
parent strain H37 [23]. As such, H37Ra shares a high similarity to the virulent strain 
H37Rv, although as a result  of 53 insertion and 21 deletion events, H37Ra has a 
genome 8,445 bp larger than H37Rv [23]. In addition, the genome of H37Ra differs 
even further due to 76 single nucleotide variance in 32 genes. These genetic variances 
are believed to account for the avirulence of H37Ra, the difference in colony 
morphology and decreased survival inside macrophages as well as under anaerobic 
conditions [23]. Although H37Rv is considered the standard laboratory strain, the lack 
of pathogenicity of H37Ra makes it an ideal model of TB that can be used in PC2 
facilities.   
1.1.4 Disease and pathogenesis 
TB spreads through aerosols when an infected individual coughs, spits or sneezes [9]. 
Upon entry into the lung, bacilli are engulfed by resident alveolar macrophages, 
although research has also identified that other phagocytic cells such as dendritic cells 
and neutrophils are also responsible for the uptake of bacteria [24]. This process is 
mediated through several different receptors that recognise and bind to mycobacterial 
cell wall components [24]. M. tuberculosis can modulate the host immune response in 
multiple ways, one of which is preventing the maturation of the phagosome [24]. 
Further modulation by bacilli ensure that necrosis rather than apoptosis is induced in 
infected host cells, which recruits more non-infected macrophages and facilitates further 
replication of bacilli [24].  
The uptake of bacilli and migration of infected macrophages to a different site is 
followed by the concomitant formation of granulomas, which is a clear sign of 
tuberculosis pathology in patients [24]. Within a granuloma, activated macrophages and 
other inflammatory cells destroy everything including host tissue in order to control 
intracellular growth of bacilli, this is termed caseous necrosis [25]. It should be noted 
that not all mycobacteria are destroyed within granulomas, instead a state of balance 
between the host defence and pathogen’s progress is met [24]. By recruiting immune 
cells the host is able to control the spread of bacteria, while the bacilli are able to use the 
newly recruited immune cells to replicate [24]. 
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The connection of caseous necrotic tissue to the airway within a patient is what leads to 
active TB. The change from anoxic conditions to an oxygen rich environment leads to 
an increase in bacterial growth and eventually patient mortality if left untreated [25]. 
When caseous necrotic tissue that contains dormant bacilli are released into the airway, 
bacilli are able to spread to other areas of the lung and start replicating extracellularly 
[25]. It is at this point where the disease becomes contagious, as bacteria are now able to 
be spread when infected individuals cough or sneeze [26]. Newly exposed bacteria are 
taken up by macrophages, through necrosis these infected macrophages eventually 
destroy neighbouring tissue and create a new area of caseous tissue. Cycles of increased 
infection followed by resolution forms scar tissue, causing permanent damage to the 
lung leading to mortality [25]. The ability of M. tuberculosis to modulate the immune 
system and proliferate within immune cells highlights the reason behind the resilience 
of the bacteria through time. Fortunately, effective treatments exist to manage a TB 
infection. 
1.2  Current treatment regimen 
Direct observed therapy short course (DOTS) is the current standard treatment for TB. 
DOTS lasts for six months to treat drug susceptible TB and can take up to 20 months to 
treat multi-drug resistant TB (MDR-TB) [27]. DOTS can be either universal or 
selective; in selective DOTS the treatment can be self-administered, whereas in 
universal DOTS the entire course of treatment is monitored by health professionals [28]. 
A recent study comparing the two methods has indicated that universal DOTS results in 
far less occurrence of drug resistant TB arising within patients, with isolates from 
selective DOTS being five times more likely to be resistant [28].  
DOTS consists of an intensive and a continuation phase. The intensive phase lasts for 
two months, using a combination of pyrazinamide, rifampicin, ethambutol and isoniazid. 
This is followed by four months of the continuation phase using a combination of 
isoniazid and rifampicin [27]. 
Rifampicin (1) is a bactericidal drug that inhibits transcription through its interaction 
with the DNA dependent RNA-polymerase  subunit [29]. Pyrazinamide (2) is believed 
to disrupt the membrane potential and decrease intracellular pH, leading to inactivation 
of many important cellular pathways [30]. Ethambutol (3) works to inhibit arabinosyl 
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transferases that are important for cell wall synthesis [31], while isoniazid (4) inhibits 
cell wall synthesis as well, but does so by inhibiting fatty acid synthesis [32]. The use of 
a combination of drugs with different modes of action reduces the risk of drug 
resistance arising as well as limits the chance of relapse among patients [33, 34]. 
 
1 
 
2 
 
3 
 
4 
Patient non-adherence, poor treatment management due to lack of funding, over-
burdened health systems as well as socioeconomic factors all contribute to ineffective 
application of DOTS and consequently the rise of drug resistance [35, 36]. The 
treatment of tuberculosis is compounded by the effects of Human Immunodeficiency 
Virus (HIV) [35]. HIV positive patients are more likely to develop TB and have a 
higher rate of mortality [37]. Drug-drug interactions are the main issue when treating 
co-infected individuals. The use of rifampicin becomes problematic in situations where 
patients are taking either protease inhibitors or non-nucleoside reverse transcriptase 
inhibitors for HIV, as well as receiving DOTS [38]. Rifampicin causes an increase in 
CYP3A4, a cytochrome P450 enzyme, which decreases the plasma levels of the anti-
retroviral drugs, thus limiting their activity [39]. These types of complex drug-drug 
interaction must be addressed and stress the need for more effective treatments. 
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Table 1.1 Current first and second line anti-tuberculosis drugs  
 Mechanism of action 
First-line drugs  
Isoniazid (4) Inhibits mycolic acid synthesis by targeting Enoyl-[acyl-carrier-
protein] reductase 
Rifampicin (1) Inhibits transcription by targeting RNA polymerase beta subunit 
Pyrazinamide (2) Inhibits translation and trans-translation, acidifies cytoplasm 
targets S1 component of 30S ribosomal subunit. 
Ethambutol (3) Inhibits arabinogalactan biosynthesis by targeting arabinosyl 
transferases 
Second-line 
drugs 
 
Para-amino 
salicylic acid (5) 
Inhibits folate biosynthesis by inhibiting dihydropteroate 
synthase 
Streptomycin (6) Inhibits protein synthesis by inhibiting S12 and 16S rRNA 
components of the 30S ribosomal subunit 
Ethionamide (7) Inhibits mycolic acid biosynthesis by targeting Enoyl-[acyl-
carrier-protein] reductase 
Ofloxacin (8) Inhibits DNA supercoiling by targeting DNA gyrase and 
topoisomerase 
Capreomycin (9) Inhibits protein synthesis forming an interbridge B2a between 
the 30S and 50S ribosomal subuints. 
Kanamycin (10) Inhibits protein synthesis by targeting the 30S ribosomal 
subunit 
Amikacin (11) Inhibits protein synthesis by targeting the 30S ribosomal 
subunit 
Cycloserine (12) Inhibits peptidoglycan synthesis by targeting D-alanine 
racemase and ligase  
Tuberculosis treatment drugs and their primary mechanism of action. Table adapted 
with permission from Cole et al. [40].    
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1.2.1 Vaccination 
At present, the only way to prevent a TB infection is the use of the live attenuated strain 
M. bovis BCG (Bacillus Calmette-Guerin) as a vaccine [41]. It is derived from virulent 
M. bovis, which primarily infects cattle [42]. Thirteen  years of passaging cultures of 
M. bovis led to developing BCG and the vaccine has been shown to reduce the risk of 
TB by 50% [42, 43]. Furthermore, BCG also decreases the risks of developing more 
harmful forms of TB such as miliary TB and TB meningitis [7]. Until a more effective 
vaccine can be developed chemotherapeutics continue to be the most effective control 
for TB. 
1.3  Drug resistance 
The discovery of 6 in 1943 was believed to herald the end of this persistent disease [44], 
however this was not to be, with resistance evident as early as the first clinical trial [44]. 
TB is now established all around the world and drug resistant forms of the disease are 
widespread [9]. Drug resistance can occur through many pathways including drug 
inactivation, modification of the drug target, drug efflux pumps or by using alternative 
pathways to overcome drug mediated effects [45](Table 1.2). In addition, the high 
mycolic acid content of mycobacterial cell walls protect the bacilli by decreasing the 
permeability to chemotherapeutic agents [46]. 
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Table 1.2 Common mechanisms of drug resistance to first line anti-TB drugs 
Drug Mechanism of resistance 
 
Isoniazid 
 
Mutation within the gene katG [47], through its 
peroxidase and catylase activity KatG is normally 
responsible for the activatation of the pro-drug [48]. 
Other mutations such as ahpC and inhA have also been 
linked to isoniazid resistance [47]. 
 
Rifampicin Resistance is linked to mutations in the rpoB gene at 
codon positions 531, 526 and 516, which affects the 
binding of rifampicin to its target binding site in the  
subunit of RNA polymerase [49]. 
 
Pyrazinamide As the exact target has not been identified, the 
consequent mechanism of pyrazinamide resistance has 
not been fully elucidated, although mutations within the 
pncA gene, which is believed to activate the pro-drug, 
have been implicated in resistance [50]. 
 
Ethambutol Mutation within the embCAB operon, with mutations in 
embB, which encodes for an arabinosyl transferase, 
accounting  for most cases of resistance [51]. 
 
The current definitions of drug resistance in TB include: mono-resistance, polydrug 
resistance, rifampicin resistance, multi drug resistance and extensive drug resistance 
[52]. Mono-resistance refers to resistance against only one first-line anti-TB drug, while 
polydrug resistance is resistance to more than one first-line drug that does not include 
rifampicin or isoniazid [52].  
Multi-drug resistant TB (MDR-TB) refers to strains resistant against multiple drugs but 
has to include resistance to rifampicin and isoniazid [52]. For extensive drug resistant 
TB (XDR-TB), in addition to the resistance profile of MDR-TB, the strain should also 
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display resistance to any fluoroquinolone and at least one of the second-line injectable 
drugs [52]. Rifampicin resistance includes any strain that displays resistance to 
rifampicin and may include mono, poly, multi or extensive drug resistant strains [52]. 
Compared to the cure rate for drug susceptible TB (85-87%) the cure rate for MDR-TB 
is much lower at 48% [8]. Reports of MDR-TB cases started to rise in the 1990s [53, 
54]. Approximately 450,000 cases of MDR-TB were reported in 2012, 9.6% of which 
were XDR-TB [8]. Recently, the emergence of a new strain unofficially termed totally 
drug resistant TB (TDR-TB) has been reported from Iran, India and Italy, this further 
highlights the threat that TB still imposes upon society [55-57]. TDR-TB has displayed 
resistance to all first and second line drugs, making a TDR-TB infection nearly 
impossible to cure with current drugs. The need for a new classification for this 
emerging strain has not yet been deemed necessary by the WHO [58].  
MDR-TB strains were first reported in the 1990s [59], their required treatment uses 
drugs that are more expensive and have more adverse side effects [60]. XDR-TB was 
first detected in strains of TB collected between 2000-2004 [59]. This form of the 
disease is even more difficult to cure and if patients are immunocompromised they have 
much higher chance of mortality, which can be as high as 98% [61]. With a treatment 
efficacy as low as 20% for XDR-TB, patients have a much lower chance for survival [8]. 
In New Zealand, there have been a total of 28 MDR- TB cases in the past 13 years, as 
well as one reported case of XDR-TB in 2010 [62]. 
 
MDR and XDR-TB as well as the emergence of TDR-TB stress the need for better 
treatments for TB now more than ever before. The promising drug candidates listed 
below highlight the response to address the need for new and more effective drugs. 
These include the new class of anti-mycobacterial compounds, PA-824 (13) and 
OPC-67683 (14), nitroimidiazole drugs, which are in Phase II and III clinical trials, 
respectively [40]. These drugs are active against both replicating and non-replicating 
bacteria. When these drugs undergo reduction, damaging reactive nitrogen species are 
produced, resulting in the observed inhibitory activity [63]. 
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SQ-109 (15) is an ethylenediamine analogue of ethambutol (3), with a differing mode of 
activity. The current proposed target for this drug is the trehalose monomycalate 
transporter, which supplies mycolic acid during cell wall synthesis [64].  
 
15 
PNU-100480 (16), an oxazolidinone, is a derivative of linezolid that inhibits protein 
synthesis by binding to the 23S rRNA within the 50S ribosomal subunit [65]. This drug 
is currently under Phase II clinical trials [40]. 
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The final example highlights a drug that has passed through the drug development 
process and has gained orphan drug status to treat MDR and XDR-TB. The 
diarylquinoline TMC-207 (17, bedaquiline) inhibits the ATP-synthase subunit c and 
was approved by the FDA in December 2012 [66, 67].  
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Even with the wealth of novelty in the current pipeline [40], the high attrition rate of 
new candidate drugs undergoing the drug approval process, requires a constant 
supplement to the pipeline with new potent compounds [68]. Natural products can 
provide a source of such compounds. 
1.4  Natural product chemistry 
Natural product chemistry tends to focus on the identification of novel secondary 
metabolites [69, 70]. By definition, these metabolites are not essential for the viability 
of the organism, rather they may aid the organism by providing a competitive 
advantage [71].  It has been postulated that some of these compounds may be produced 
by symbiotic bacteria, as is the case for bryostatin-1, which is currently under clinical 
trials for its role as an anti-cancer agent and also as a treatment for Alzheimer’s disease 
[69]. The bryostatins were first isolated from the bryozoan Bugula neritina, however the 
genes for the biosynthesis of this compound can be identified in the symbiotic 
bacterium Candidatus Endobugula sertula [72]. In plants, some compounds isolated are 
produced by endophytic fungi, as in the case of taxol [73]. The biogenesis of these 
metabolites usually employ alternative pathways to primary metabolism such as the 
non-ribosomal peptide synthetase or polyketide synthetase pathways [74]. These 
pathways are open to modifications by molecular biology tools and can also be used as 
genetic markers to identify microbes that may be potential sources of unique 
compounds [69, 75].  
1.4.1 Terrestrial sources  
Throughout history natural products have provided treatments for ailments with the 
earliest record for the use of natural remedies being documented on clay tablets from 
Mesopotamia dating back to 2600 BC [76]. Morphine represents the first commercial 
14 
 
pure drug and penicillin the first antibiotic [76]. Approximately 74% of all approved 
antibacterial drugs identified in the 1981-2010 time frame originated from natural 
products [77]. This highlights the wealth of natural products and reveals their potential 
for the future. 
1.4.1.1 Natural products as anti-TB drugs 
The potential of natural products for the treatment of TB can be highlighted by the fact 
that many of the current TB drugs that have been used for decades originated as a result 
of natural product research. Streptomycin, the first drug that was used to fight TB, was 
isolated from Streptomyces griseus [78]. Isoniazid and pyrazinamide are examples of 
two very effective first line drugs, which were identified due to their structural 
similarities to the natural product nicotinamide that demonstrated anti-tubercular 
effects [79]. Rifamycin, a polyketide isolated from the bacterium Amycolatopsis 
rifamycinica, provided a lead to rifampicin, a gold standard anti-tubercular compound 
that is currently used for its bactericidal activity [80, 81].  
 p-Aminosalicylic acid, a second line drug, was a product of research that observed the 
natural product salicylic acid increased oxygen uptake in M. tuberculosis; this led to 
screening of analogues of salicylic acid to identify competitive inhibitors in the pathway 
that salicylic acid was interacting with [82]. Cycloserine, another second line drug, is a 
cell wall synthesis inhibitor and was first isolated from Streptomyces orchidaceus [83, 
84]. The second line aminoglycoside drug kanamycin, a protein synthesis inhibitor, 
which later provided the lead for the protein synthesis inhibitor amikacin, was isolated 
from Streptomyces kanamyceticus [85]. Capreomycin, a cyclic peptide often grouped 
with the aminoglycosides, is another protein synthesis inhibitor that was isolated from 
Streptomyces capreolus [86]. 
 
Given the fact that more than nine of the current anti-tubercular drugs have originated 
from natural products, it is appreciable that they provide a beneficial source for future 
anti-tubercular drugs. However considering rifampicin, the most recent first line anti-TB 
drug, was discovered nearly 55 years ago [87], there is a significant demand to find new 
and more effective drugs. 
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1.4.2 Marine environment 
Scientists have searched the terrestrial environment for antibiotics since the 
serendipitous discovery of penicillin in 1928 [88]. Researching un-investigated 
environments may prove useful in identifying novel chemical scaffolds to provide leads 
for efficacious drugs. In 2011, 1152 new compounds were reported from marine 
organisms [89]. The marine environment contains organisms producing an array of 
distinctive molecules,
 
which can be illustrated by the abundance of such structures 
reported by researchers [89].  
 
From the coasts of New Zealand, specific lipids isolated from the green lipped mussel 
may provide an effective treatment for asthma and other inflammatory diseases [90, 91]. 
Peloruside A (18) was isolated from the sea sponge Mycale hentscheli collected in the 
Marlborogh Sounds of New Zealand. This metabolite shows anti-mitotic activity,
 
making it of interest in the study for anti-cancer therapies [92].  
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Another interesting discovery was from Conus magus, a cone snail that paralyses its 
prey using a poison tipped barb. From this poison, a painkiller called ziconotide (19), 
was developed and is currently marketed as Prialt for the treatment of chronic pain. This 
was the first marine drug to be approved by the FDA [93]. From Ecteinascidia turbinata, 
a sea squirt, a compound ecteinascidin 743 (20) that PharmaMar has brand-named 
Yondelis®  has gained approval from the European Medicines Agency for its anti-tumor 
activity against soft-tissue sarcomas and ovarian cancer [69].  
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A more recent addition to the list of approved drugs that have been derived from the 
marine environment is Eribulin (halaven, 21 ), which gained approval for the treatment 
of metastatic breast cancer [94]. This compound is a synthetic analogue of halichondrin 
B originally isolated from the Japanese sponge Halichondria okadai [95]. 
 
21 
More recently, Jensen and Fenical have worked on a marine microbiology discovery 
program and have discovered a group of obligate marine actinomycetes belonging to the 
genus Salinospora [96]. There are now well above 2000 strains of this genus 
identified [97]. With this wealth of biodiversity one can imagine the potential to identify 
unique new compounds. This potential is reinforced by the fact that there are currently 
13 marine chemical entities at different stages of clinical trials, with the majority 
focusing towards treatments for cancer [98]. 
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1.4.2.1 Marine natural products as anti-tubercular 
agents 
In literature pertaining to the TB field, it seems that most active marine extracts tend to 
come from sea sponges, most probably due to the fact these organisms contain vast 
numbers of symbionts [99]. Some novel structures that have been identified to inhibit 
mycobacteria include homopseudopteroxazole (22), a diterpene alkaloid isolated from 
the Caribbean  gorgonian octocoral Pseudopterogorgia elisabethae [100]. 
Halicyclamine A (23), obtained from an Indonesian sea sponge Haliclona sp. has shown 
bactericidal activity against M. bovis, M. smegmatis and M. tuberculosis [101]. From 
the Caribbean sponge Svenzea zeai, two abeo-sterols, parguesterol A (24) and B (25) 
were isolated with reported MIC values of 7.8 and 11.2 g/mL against M. tuberculosis 
H37Rv as well as reported IC50 values of  52 g/mL in Vero cells for both 
compounds [102].  
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Pseudopyronines A (26) and B (27), isolated from a marine Pseudomonas. sp F92S91 
[103], displayed inhibitory activity against M. tuberculosis, with pseudopyronine B a 
greater inhibitior of InhA, a fatty acid biosynthesis enzyme [104]. Manzamine A (28) 
isolated form a Haliclona sp. sponge [105], and manzamines E (29) and F (30) isolated 
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from an Okinawan Xestospongia sp sponge [106],  displayed respective MIC values of 
1.53, 3.76 and 2.56 g/mL against M. tuberculosis H37Ra [107].  
 
26 R =  
27 R =
  
 
28 
 
29 R = H 
30 R = OH 
The marine fungus Aspergillus versicolor was isolated from a marine sediment from the 
Bohai Sea, China, which led to the identification of brevianamide S (31), this compound 
displayed an MIC of 6.25 g/mL against BCG [108]. Trichoderins A (32), A1 (33) 
and B (34) were isolated from a Trichoderma sp., a marine sponge-derived fungus with 
MIC values of 0.12, 2.0 and 0.13 g/mL respectively against M. tuberculosis H37Rv 
[109]. Abyssomicin C (35) and atrop-abyssomicin C (36), isolated from a marine 
Verrucosispora strain AB-18-032 [110], displayed MIC values of 3.6 and 7.2 M 
against M. tuberculosis H37Rv [111]. 
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Considering the growth of marine microbial research, it is believed that scientists have 
only studied a small fraction of this valuable environment for structurally novel 
compounds  [69]. The function of these compounds could be vital by providing cures or 
bio-probes to ascertain important information on biological processes [93]. 
1.4.3 Screening for natural products 
1.4.3.1 Bioassay-guided fractionation 
The classical approach to natural product isolation has been bioassay-guided 
fractionation [112]. The serendipitous isolation of penicillin heralded the era of 
bioassay-guided fractionation, an approach that has never ceased to be a valuable 
resource for finding bioactive compounds. This approach involves screening crude 
extracts for activity, following which fractionation is performed on an active sample. 
The subsequent fractions are tested for bioactivity, the most active fractions are further 
purified and tested again, and the process is repeated in iterative fashion until the 
bioactive compounds have been isolated. The purities of the fractions are monitored 
using spectroscopic methods. This approach requires a set drug target or desired 
biological activity or a pathway to investigate, with a well-designed and optimised assay. 
These assays may be simple whole cell assays looking for growth inhibition of 
clinically relevant pathogens [69], or more complex biochemical assays that may 
require extensive optimizations prior to screening [113]. This technique is considered 
destructive as each bioassay requires the expenditure of compound. Another common 
issue with this classical approach is that it often leads to the isolation of known 
compounds, especially if the source of the extract has been explored in earlier research 
[114]. Furthermore this approach can lead to novel compounds being completely 
ignored as they maybe inactive in the assay system being employed. In some cases, 
compounds with detergent-like or promiscuous activity are identified as hits and are 
undesired as they are often cytotoxic and do not make ideal drug leads [115]. In rare 
cases, activity may be due to two or more compound working in synergy or with 
additive effects, further fractionation in such situations can lead to a loss of activity. The 
strength in this approach lies in the fact that a bioactivity of interest is able to be 
pursued throughout all stages of isolation. To avoid the issue of re-isolation, this 
approach can be complimented with spectroscopic analysis to prevent further 
fractionation of extracts with chemical profiles of known compounds [114].  
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Figure 1.1 Bioassay-guided fractionation 
The basic approach to bioassay-guided fractionation for novel compounds. 
 
  
1.4.3.2 Structure-guided isolation 
An alternative approach to bioassay-guided fractionation is structure-guided isolation. 
This approach is often employed in groups where applying a bioassay after each point 
of fractionation is often not feasible either due to lack of expertise or lack of appropriate 
facilities. The robustness of this approach can be observed by the fact that throughout 
the fractionation process, the compound of interest can able to be tracked using either 
nuclear magnetic resonance (NMR) spectroscopy, liquid chromatography coupled to 
mass spectroscopy (LC-MS) or high performance liquid chromatography linked to a 
diode array detector (DAD-HPLC). In essence, the bioassay is replaced by an analytical 
instrument such as a NMR spectrometer and rather than bioactivity, the chemical 
signatures of unusual secondary metabolites are tracked. When dealing with small levels 
of compound, highly sensitive spectrometers are required. The downfall of this 
approach is that since activity was never the primary goal, large masses of compound 
must be sacrificed to different assays in order to identify the compound’s bioactivity. If 
the compound of interest has been isolated in low quantities this may not allow for it to 
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be studied in enough suitable assays. This expenditure of compound in multiple assays 
can be circumvented if the compound is used in an assay that can monitor its effects on 
a genome wide scale, such as the Saccharomyces cerevisiae deletion mutant library 
[116]. 
 
Figure 1.2 Structure-guided isolation. 
The principles of structure-guided isolation of novel compounds. 
 
  
1.4.4 Structure-activity relationships and 
mechanism of action studies 
After isolation of a novel compound, the next stage of the drug discovery process 
involves structure-activity relationship (SAR) and mechanism of action (MOA) studies. 
While SAR studies are vital in pinpointing the pharmacophore responsible for 
bioactivity within a compound, MOA studies answer the important question of how a 
compound causes an observed activity. 
SAR involves chemical modification of the lead compound to generate analogues that 
are then tested in the assay of interest. In addition to identifying functionalities crucial 
for bioactivity, it could also identify functional groups of the molecule that are open for 
modification in order to improve activity or other properties (such as solubility) when 
compared to the parent compound [113]. 
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One approach for MOA studies involves attaching the drug of interest to sepharose 
beads and using affinity chromatography on cell extracts to purify proteins that bind to 
the protein-bound solid phase support [117]. Alternatively, genetic approaches can also 
be used with the underlying commonality of using or generating mutant strains. One 
approach involves genome sequencing of resistant mutants to identify mutations 
conferring drug resistance [118]. This is generally followed by validation assays, which 
can involve restoring normal functionality of the mutated gene in order to see a return in 
sensitivity to the compound of interest [51]. Another approach involves overexpressing 
the drug target to either purify protein to perform biochemical assays or to induce 
phenotypic effects on drug sensitivity [66]. As some compounds may have no specific 
target or may target an essential gene, no specific mutants will be detected and this is a 
limitation to this approach.  
If the target is unknown a genome-wide approach can be employed, which involves 
screening of the compound of interest against mutant libraries in order to find mutants 
that interact with the drug. Following the identification of mutants, validation through 
dose response curves is performed, which allows for the top mutants to be chosen. 
These mutants are then sequenced to identify the specific gene that has been mutated. 
Once this information is inferred, a genetic network can then be established to identify 
which pathways may be perturbed by the compound of interest. This approach generates 
an immense amount of data which can then be used to carry out follow up validation 
and rescue assays to study the effects of each mutation. 
1.4.4.1 Saccharomyces cerevisiae and chemical 
genetics 
Saccharomyces cerevisiae (baker’s yeast) is an important tool for mode of action studies 
by chemical genetics [119]. Yeast can exist in diploid or haploid states, and extensive 
genetic manipulation has led to generation of libraries of homozygous diploid deletion 
mutants of non-essential genes, heterozygous diploid knock-outs that include essential 
genes and haploid libraries for the two mating types of yeast [120]. Each knockout 
mutant has its gene replaced by a kanamycin resistance gene flanked by a 20 nucleotide 
long sequence unique for each mutant similar to barcodes [121]. Flanking these 
‘barcodes’ are two lengths of nucleotides at the 5’ and 3’ ends. These nucleotide 
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sequences are identical and allow for the use of just one set of primers to bind to and 
amplify the sequence in between [121].   
These libraries have led to the development of multiple approaches for MOA studies, 
such as haploinsufficiency profiling (HIP), homozygous deletion profiling (HOP), 
synthetic lethality analysed by microarray (SLAM) and synthetic genetic array (SGA) 
[122]. 
HIP involves knocking out one of the two genes that code for a particular function 
within the yeast [123]. Having one less copy results in a decreased amount of the gene 
product, therefore strains are more sensitive to inhibitors that target that particular gene 
[123]. This approach is carried out in a pooled format where the mutants are grown in a 
liquid culture in either the presence or absence the drug, following which polymerase 
chain reaction amplification of the two different pools of mutants and microarray 
analysis of the oligomers allows for the identification of mutants that are most sensitive 
to the drug [124]. This approach allows inferences to be made on the actual drug target 
as the strains used in this approach are heterozygous knock outs and include essential 
genes. 
HOP involves treating the library of mutants with drug followed by microarray analysis 
to identify an expression profile. These are compared to the expression profile with 
homozygous knockouts, which as a consequence are non-essential gene knock-outs. 
The closest matching deletion profiles allow for conclusions to be drawn as to which 
pathways the drug of interest is interacting with [125].  
SLAM and SGA use haploid strains of yeast and work on the principle of synthetic 
lethality. This is the phenomenon where two mutations on their own have no effect on 
viability, however if the two mutations exist in the same cell then this results in cell 
death. In this way, profiles have been generated for libraries that have an additional 
“query” mutation introduced to identify synthetic lethal genetic interactions [122]. 
SLAM exploits the use of the unique tags by performing the experiment in a pooled 
format and analysing for the absence of drug exposed mutants using microarray analysis 
[126]. SGA monitors the growth of each mutant on agar and identifies growth defects in 
mutants exposed to drug [127]. Both approaches assume a drug can replace the role of a 
genetic mutation. Should this hold true, then synthetic lethal profiles observed for the 
drug exposed mutants should be possible to match to the profile of a query gene’s 
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interactions. Using this approach conclusions can be drawn on pathways the drug 
interacts with or perturbs. 
1.5  Research goals 
 
The aims of this research were to isolate novel anti-mycobacterial compounds from 
marine organisms. This would be achieved through: 
Aim I: Detecting anti-mycobacterial activity from screens of New Zealand marine 
organism extract libraries.  
Aim II: Purification and identification of anti-mycobacterial bioactives using 
bioassay-guided fractionation and spectroscopic structural characterization. 
Aim III: Determination of the mechanism of action via studies of novel anti-
Mycobacterium tuberculosis inhibitors. 
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Chapter 2       Materials and Methods   
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2.1  Media and culture conditions 
2.1.1 LB broth  
LB broth (Duchefa Biochemie low salt) was made up as per instructions on the 
container, 20 g to 1 L of ddH2O, autoclaved at 121 °C for 30 min and stored at room 
temperature before use.  
2.1.1.1 Media supplements 
Additional antibiotics and supplements were added as required for certain strains of 
bacteria and have been listed when used in later sections. 
Antibiotics were purchased from Sigma and were dissolved in an appropriate solvent or 
ddH2O at desired concentrations and filtered through a 0.22 m syringe filter. Antibiotic 
stock solutions were aliquoted into microfuge tubes and stored at -20 °C. 
Isopropyl--D-thigalactopyranoside (IPTG) was made up with ddH2O at 100 mg/mL 
filtered through a 0.22 m syringe filter and stored at -20 °C. 
D-Arabinose and D-xylose were made up to a 100 mg/mL and a 10% w/v solution 
respectively in ddH2O, filtered through a 0.22 m syringe filter and stored at -20 °C until 
use. 
Glycerol was made up to 50% (v/v) with ddH2O, sterilised in an autoclave at 121 °C for 
30 min and was added to media when required, prior to autoclaving. 
Tween 80 was made up to 10% (v/v) with ddH2O and sterilised in an autoclave at 121 °C 
for 30 min. This was added to media when required prior to autoclaving. 
Sodium oleate was made by adding 12.5 mL of 2 M NaOH and 6.0 mL oleic acid to 
481.5 mL of ddH2O. This solution was filtered through a 0.22 m millipore filter, stored 
at room temperature and the container was wrapped in aluminium foil. 
OADC enrichment supplement for 7H9 media was made by adding 8.5 g NaCl to 925 
mL ddH2O that was stirred until the salt has dissolved, 50 g of bovine serum albumin 
Fraction V was then added as well as 20 g of dextrose and 50 mL of a 1% sodium oleate 
solution. The pH was adjusted to 7.0 and this solution was filtered through a 0.22 m 
millipore filter and stored at 4 °C. 
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2.1.1.2 LB broth for M. smegmatis 
LB broth (section 2.1.1) was prepared with additional supplements 0.1% (v/v) 
Tween 80 and D-arabinose 100 g/mL and autoclaved at 121 °C for 30 min. After the 
broth had reached room temperature, kanamycin sulphate was added to achieve either a 
final 50 g/mL or 20 g/mL concentration. This was done in a sterile PC2 laminar flow 
hood following which media was stored at 4 °C. When making media to culture 
electro-competent cells or carry out transformations, D-arabinose and antibiotics were 
omitted from media, which was stored at room temperature before use. 
2.1.2 7H9 media 
Middlebrook 7H9 media was made as per instructions on the container (4.7 g per 
900 mL) and autoclaved at 121 °C for 30 min. After the broth had cooled to room 
temperature it was supplemented with 10% (v/v) OADC (section 2.1.1.1). This was 
done in a sterile PC2 laminar flow hood following which media was stored at 4 °C. 
2.1.3 Tissue culture media 
RPMI-1640 media was purchased from Invitrogen and supplemented with 0.22 m 
filtered 10% FCS and 1% of Pen/Strep (100 units/mL of penicillin and 100 units/mL of 
streptomycin). Handling of media was carried out in a sterile PC2 laminar flow hood 
and stored at 4 °C until use. 
2.2  Phosphate buffered saline 
Phosphate buffered saline (PBS) solution was made by adding 8 g of NaCl, 0.2 g of KCl, 
1.42 g of Na2HPO4 and 0.27 g of KH2PO4 to 900 mL of ddH2O. The pH of the solution 
was adjusted to 7.0 using 1 M solutions of HCl and NaOH, and the final volume made 
up to 1.0 L before autoclaving the solution at 121 °C for 30 min. The solution was 
stored at room temperature. 
2.3  Staining procedures 
Cells were stained to observe the purity of culture using the methods describe below. 
Dyes and staining solutions were purchased from BD Biosciences.  
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2.3.1 Gram staining 
A 10 L aliquot of culture was smeared and air dried onto a slide. The slide was 
covered in Gram Crystal Violet solution for one minute and washed with water, 
following which the slide was covered in Stabilized Gram Iodine solution for one 
minute. The slide was then washed with water and decolourised using Gram 
Decolourizer for 10 sec. Finally Gram safranin was used to cover the slide for 30 sec 
and washed off with water and air dried. Cover slips were placed on slides and slides 
observed under 100 x oil immersion using a light microscope. 
2.3.2 Acid fast staining 
A 10 L aliquot of culture was smeared and air died onto a slide. The slide was covered 
in TB Carbol Fuchsin KF solution for five minutes and washed with water, following 
which the slide was decolourised using TB Decolorizer solution for 10 sec. Finally TB 
Brilliant Green solution was used to counter stain the slide for 30 sec and washed off 
with water and air dried. Cover slips were placed on slides and slides were observed 
under 100 x oil immersion using a light microscope. 
2.3.3 Fluorescent microscopy 
Green Fluorescent Protein (GFP) expressing cells (5 L) were prepared on a slide and 
coverslip and observed under a 100 x oil immersion using a fluorescein isothiocyanate 
(FITC) filter in an Olympus® Research Microscope AX70 Provis, equipped with an 
OlympusR DP70 Digital Microscope Camera. 
2.4  Transformation of mycobacteria  
2.4.1 Plasmids 
Table 2.1 Plasmids used in this study 
Plasmid Characteristics Selection Reference 
pLL192_hsp60 Constant expression of GFP. Strep 50 g/mL, 
Kan 50 g/mL 
[128] 
pCG79  Contains the Tn611 transposon 
shuttle vector and a temperature 
sensitive mycobacterial origin of 
replication  
Kan 20g/mL [129] 
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2.4.2 Creating electro-competent Mycobacterium 
smegmatis  
Mycobacterium smegmatis, mc2155 (ATCC700084); was the strain of mycobacteria 
used in this research and was sourced from Dr. Desmond Collins, AgResearch Limited, 
New Zealand. M. smegmatis was streaked out onto LB agar plates and grown for 3-5 
days until colonies appeared. A loop full of colonies were then used to inoculate 10 mL 
of LB broth (section 2.1.1.2) and incubated at 37 °C in a shaking incubator at 200 rpm 
overnight. This culture was then sub-inoculated into 100 mL of LB broth (section 
2.1.1.2). Growth was measured once every 1.5 h using optical density (OD) measured at 
600 nm. Once an OD600 between 0.5-1.0 absorbance units (AU) was achieved, cells 
were incubated on ice for 20 min and centrifuged at 2700 x g at 4 °C for 15 min. After 
discarding the supernatant, cells were washed and pelleted a further two times with 50 
mL and 20 mL of ice cold 10% glycerol with a 15 min incubation on ice in between. 
After pelleting cells a third time, cells were re-suspended in 4 mL of ice cold 10% 
glycerol and 200 L aliquots of the competent cells were stored in 1.5 mL tubes 
at -80 °C. 
2.4.2.1 Transformation of Mycobacterium smegmatis 
To electroporation cuvettes 200 L of electro-competent (e-) cells (section 2.4.2) and 
200 L of 10% glycerol was added. To the e- cells 5 L of either the plasmid 
pLL192_hsp60 or pCG79 was added. As a negative control 5 L of MQ H2O was added. 
Cells were electroporated at the following settings, voltage: 2500 V, capacitance: 25 C, 
resistance: 1000 Ω, cuvette width: 2 mm. Following electroporation a 600 L aliquot of 
LB broth without antibiotics (section 2.1.1.2) was added to the cuvettes immediately 
and cells were transferred into sterile 1.5 mL centrifuge tubes. Cells were allowed to 
recover overnight at 37 °C at 200 rpm. The following day cells were plated out onto LB 
agar with appropriate antibiotics (Table 2.1). Appearance of colonies only for the 
mycobacteria carrying plasmids following 2-3 days of incubation indicated a successful 
electroporation. Colonies were then inoculated in LB broth for mycobacteria (section 
2.1.1.2) with appropriate antibiotic (Table 2.1). The overnight cultures were then tested 
for purity using acid fast staining and fluorescence using a fluorescent microscope 
(section 2.3.2 & 2.3.3). Freezer stocks of cultures were then made by adding 600 L of 
cells to 400 L of 50% glycerol, following which cells were stored at -80 °C.  
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2.5  Bacteria and mammalian cell line 
culturing 
 
Table 2.2 Mycobacteria used in this study 
Strain Use 
M. smegmatis  
pLL192_hsp60 Library screening and dose response assays, 
pCG79 Transposon mutant library screening 
M. tuberculosis  
H37Ra ATCC25177 Dose response assays 
 
2.5.1 Culturing of Mycobacterium smegmatis 
Freezer stocks of M. smegmatis carrying either the pLL192_hsp60 or pCG79 plasmid 
were streaked out on LB agar with an appropriate drug and incubated for 48 h at 37 °C. 
Following the appearance of colonies a 5 L inoculating loop was used to scoop 
bacteria into 10 mL of LB broth (section 2.1.1.2). After growth incubation for 24 h 
these cultures were checked for purity using either acid fast staining or fluorescence 
(section 2.3.2 & 2.3.3) before being used for bioassay. 
2.5.2 Mycobacterium tuberculosis H37Ra 
M. tuberculosis H37Ra ATCC25177 was grown on 7H10 plates for 3-4 weeks at 37 °C, 
after which colonies were picked and cultured in 7H9 media (section 2.1.2). After 
approximately 14 days, cells from these cultures were checked for purity using acid fast 
staining (section 2.3.2) following which they were used for bioassay. 
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2.5.3 Staphylococcus aureus, Escherichia coli and 
Pseudomonas aeruginosa. 
Table 2.3 Fast growing bacterial strains 
Strain Characteristic Culture 
conditions 
Use 
S. aureus    
ATCC25923 
Clinical isolate, no resistance 
marker 
LB Dose response 
assays 
Newman 
 
Expresses GFP, erythromycin 
(Em) resistance  
LB, 0.5% 
(w/v) xylose, 
Em 
50 g/mL 
 
Library 
screening 
E. coli    
ATCC25922 
Clinical isolate, no resistance 
marker 
LB Dose response 
assays 
 DH5/ pOT11 
 
IPTG induced expression of 
GFP, chloramphenicol (Chl) 
resistance 
LB, Chl 25 
g/mL, IPTG 
(100 g/mL) 
 
Library 
screening 
P. aeruginosa    
PAO1 Opportunistic human pathogen, 
no resistance marker 
LB Dose response 
assays 
 
Freezer stocks of cultures were streaked onto LB agar (Duchefa Biochemie) with 
appropriate antibiotics (Table 2.3). After incubating the plates overnight a 5 L 
inoculating loop was used to scoop colonies into 10 mL of LB broth with appropriate 
antibiotics and supplements (Table 2.3). Cultures were incubated overnight in a 37 °C 
shaking incubator at 200 rpm. Gram staining was used to check the purity of the 
cultures (section 2.3.1) which were used to for bioassay. 
2.5.4 HL-60 cells 
The HL-60 cells used in this research were supplied by Dr. John Miller, VUW; and 
were sourced from Dr. Graeme Findlay, University of Auckland. HL-60 cells were 
thawed out from frozen stocks and transferred to 15 mL tubes containing 9 mL of 
RPMI-1640 supplemented media (section 2.1.3). Cells were pelleted at 300 x g for 5 
min and the supernatant was discarded. The pellet was then resuspended in 10 mL of 
media and transferred to a 25 cm3 flask. Cells were incubated at 37 °C and 5% CO2 and 
after reaching approximately 80% confluence cells were pelleted at 300 x g. Cells were 
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then resuspended in 5 mL of media and 10 L of cells were added to 10 L of trypan 
blue to count the number of viable cells using a haemocytometer. 
2.5.5 HEK cells 
Human embryonic kidney-293 (HEK) cells were supplied by Dr. Bronwyn Kivell VUW; 
and were sourced from (ATCC, Manassas, VA, USA). HEK cells were thawed as stated 
above and cultured in 10 mL of media (section 2.1.3) until they had reached ~80% 
confluence. Following this, media was discarded from the flask and cells were 
trypsinised with 1 mL of trypsin for 2-3 min, media was then added to the flask to 
deactivate the trypsin. After centrifuging cells for 5 min at 300 x g, the media was 
decanted out and the cells were resuspended in 5 mL of media. Cell counts were 
performed as stated above (section 2.5.4).  
Freshly cultured HL-60 and HEK cells were used to set up assays described in this 
research. This was done to avoid any issues that may arise from using cells that have 
undergone several passages. 
2.5.6 Marine extract libraries 
The NIWA library was a four plate library donated by Drs Vicky Webb and Sally 
Anderson. The library was generated as a nutraceutical library, which contained extracts 
of vertebrate as well as invertebrates collected from New Zealand waters, and did not 
include algae. Marine organisms were dissected and extracts were generated of each 
organ. The library plates contained either water, ethanol or ethyacetate extracts and 
comprised unknown masses per well. 
The VUW MNP library was generated in Dr. Rob Keyzers laboratory using extracts of 
invertebrates, which also included algae. Samples were collected by Dr. Peter Northcote 
from New Zealand coastal waters and were extracted in methanol. Extracts were dried 
down and redissolved to generate solutions of known concentrations after which 
aliquots were transferred to a 96 well plate to generate a library plate of 50 g per well. 
The locations from where samples were collected are on record, and voucher samples 
were generated from each sample used to generate the library. 
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2.6 Assay protocols 
2.6.1 Assay measurements 
Fluorescence and OD measurements of assays were measured using a PerkinElmer 
EnSpire, 2300 multilable reader. OD was measured at 600 nm taking an average of 16 
points per well (4x4 circle) for mycobacteria, and a single point per well for all other 
cells. GFP fluorescence was measured at excitation (ex): 488 nm and emission 
(em): 597 nm taking an average of 16 points per well (4x4 circle) for mycobacteria, and 
a single point per well for all other cells. GFP was used as a measure of bacterial 
viability, as only live cells would be expected to express GFP and cells inhibited in 
growth will not. 
After GFP and OD was measured, a 30 L aliquot of a 0.02 % (w/v) solution of 
resazurin were added to each well of the assay plates. After 2 h for M.  smegmatis, or 20 
min for S. aureus, E. coli, and P. aeruginosa, fluorescence of resazurin was measured at 
ex: 530 nm and em: 590 nm taking a single point measurement per well. For 
M. tuberculosis H37Ra plates were incubated for 24 h before measuring resazurin 
fluorescence. This additional method to measure growth was also used to add further 
support for measuring inhibition. Resazurin is a dye that is reduced by actively 
metabolizing bacteria and in the process goes from a non-fluorescent blue to a 
fluorescent pink, which can be exploited as a measure of bacterial viability [130].  
 
2.6.2 Screening of marine extract libraries 
Marine extract libraries were resuspended in DMSO and aliquoted in 96-well plates 
with 50 L of broth with a maximum final concentration of 2.5% (v/v) DMSO. To this 
50 L of either M. smegmatis, S. aureus, or E. coli were added to wells to achieve a 
final OD600 of 0.01 AU. Screening was carried out such that 80 extracts were screened 
per 96-well plate. In the wells of column 1, 100 L MQ H2O was added to maintain a 
humid environment and prevent evaporation and column 12 comprised of a set of 
controls in duplicate: media alone, media+cells, media+cells and solvent, media+cells 
and a positive control (ethambutol 250 M or tetracycline 250 M) (Figure 2.1). Plates 
were sealed using breathable SealPlate® plate seals (Interlab) and incubated for 96 h at 
37 °C in a shaking incubator at 200 rpm.  
35 
 
 
 
 
Figure 2.1 General set up of a 96-well plate for screening marine extract libraries 
 
Following the assay, plates were measured for GFP and resazurin fluorescence as 
described in section 2.6.1.  
 
2.6.3 Bacteriostatic assay  
Samples were serial diluted two fold in appropriate media in 96-well plates to test the 
range of concentrations at which they were active. To the outer 36 wells of a 96-well 
plate, 100 L of MQ was added and to the inner 60 wells except those of column two, 
50 L of media was added. The wells of column two were made up to a final volume of 
100 L by adding the appropriate amounts of media and sample to give an initial two 
fold higher starting concentration of extract. Following this 50 L of the mixture was 
aspirated from the wells of column two and pipetted to column three, this step was 
repeated until the wells of column 11 and the final 50 L was discarded. To these plates, 
50 L of cells were added to achieve a final OD600 of 0.01 AU. Plates were sealed and 
incubated for 96 h at 37 °C in a shaking incubator at 220 rpm. 
Marine extracts MQ H2O 
Hits 
Media 
alone 
Media
+ 
cells 
Solvent 
control 
Positive 
control 
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As a positive control for inhibition, every assay had either rifampicin for M. smegmatis 
or tetracycline for S. aureus, E. coli, and P. aeruginosa, starting at 250 M. Negative 
controls included media alone and cells grown without the presence of any inhibitors. 
Solvent controls were also included. Plates were measured for GFP, OD and resazurin 
fluorescence as described in section 2.6.1.  
2.6.4 Bacteriostatic assay set up in M. tuberculosis 
H37Ra 
Sample dilutions and plate set up was identical to section 2.6.3, using 7H9 media with 
supplements (section 2.1.2). This was followed by addition of cells to plates to achieve 
a final OD600 of 0.005 AU, after which plates are sealed and incubated for 7 days at 
37 °C at 200 rpm. Streptomycin starting at 25 M was used a positive control. 
Following incubation, plates are unsealed in a laminar flow hood and 30 L of a 0.02 % 
(w/v) of resazurin was added to each well and plates were resealed and incubated a 
further 24 h at 37 °C in a stationary incubator. Resazurin fluorescence was measured as 
described in section 2.6.1.  
 
2.6.5 Stationary phase assay protocol in 
M. tuberculosis H37Ra 
Following the method described by Bassett et al. cultures of M. tuberculosis H37Ra 
were grown for 30 days, pelleted for 10 min at 2700 x g and resuspended in a volume of 
sterile PBS (section 2.2) to a final OD600 of 1.0 AU. Plate set up was identical to section 
2.6.3 using sterile PBS. To the plates, 50 L of the diluted cells were added to achieve a 
final OD600 of 0.5 AU. Plates were sealed and incubated for 96 h at 37 °C at 200 rpm 
after which 30 L of a 0.02 % (w/v) of resazurin was added to each well and plates 
were resealed [131]. Resazurin fluorescence was measured as described in section 2.6.1.  
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2.6.5.1 Statistics for library screening 
Z-factors were calculated for each assay and used as a measure of the validity of the 
screens. The range of the Z-factor can be between 0 – 1, where 0 indicates an invalid 
assay due to overlap between positive and negative controls and 1 indicates a perfect 
assay. Values of 0.5 or above are considered acceptable. 
 
 
 
 
Figure 2.2 Z- factor calculation 
 represents the mean of the positive or negative controls and  is the standard 
deviation of the positive and negative controls. 
2.6.5.2 Reporting inhibitory values 
Where possible, IC50 values that have been reported are based on calculated values after 
using the stats software package GraphPad Prism V. 5.00 for Windows. As sigmoidal 
curves were not possible in all cases of dose response assays, MIC90 values have been 
listed. MIC90 values reported throughout this thesis are based on the lowest 
concentration at which 90% or greater growth inhibition is observed directly in all wells 
of the biological replicates. Minimum inhibitory concentration (MIC) values in this 
thesis are the concentration at which ≥98% inhibition is observed in all wells of the 
biological replicate. 
2.6.6 HL-60 MTT assay  
Samples were serial diluted two-fold in RPMI media using the same method as 
described in section 2.6.3, following which 50 L of cells at 2 x 105 cells/mL were then 
added to plates to achieve a final cell number per well of 1 x 105 cells/mL. Plates were 
incubated for 48 h at 37 °C and 5% CO2. Internal controls included solvent controls, 
media with cells and media alone.  After 48 h, 20 L of MTT (5 mg/mL in PBS) was 
added to each well and plates were wrapped with cling wrap and incubated for 2 h. 
Following incubation with MTT, 100 L of solubiliser (45% DMF, 10% SDS at pH 4.5) 
Z = 1-  3 (positive + negative) 
│positive – negative │ 
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was added to all wells and plates were incubated overnight. The next day, OD of plates 
was measured at 570 nm. 
2.6.7 HEK MTT assay 
Cells were diluted to 1 x 105 cells/mL; 100 L of cells was then added to the inner 60 
wells of a 96-well plate, and plates were then incubated for 24 h. The following day, 
100 L of media was taken out of each initial well and the volume of that well was 
made up to 200 L with the appropriate amount of desired drug. From this initial well, 
100 L was taken out and added to the next well, after thorough pipetting, 100 l was 
taken out from this second well and the process was repeated to achieve the desired 
number of serial dilutions. Internal controls were incorporated as stated in the protocol 
of HL-60 cells in section 2.6.6. Plates were incubated for 72 h at 37 °C and 5% CO2. 
After incubation, MTT and solubiliser was added to plates as stated above in section 
2.6.6. 
2.7  Chemistry protocols 
 
Reversed-phase column chromatography was performed using Supelco Diaion® HP20 
and HP20ss poly(styrene-divinylbenzene) (PSDVB) resins. Normal-phase column 
chromatography was performed using Supelco Discovery® DSC-DIOL functionalised 
silica: 3-(2,3-dihydroxy-propoxy)-propyl-silica (Diol).  
 
To perform HPLC two systems were used, a Rainin Dynamax SD-200 solvent delivery 
system with 25 mL pump heads and a Varian Prostar 335 photodiode array detector for 
UV/Vis detection. The second HPLC system was an Agilent Technologies 1260 Infinity 
HPLC equipped with a quaternary pump, a thermostated column compartment and 
diode array detector (DAD). Following the DAD, a QuicksplitTM flow splitter directs 5% 
of the flow to an Agilent 380-evaporative light scattering detector (ELSD) with 95% of 
the flow directed towards collection. 
 
The columns used in this research were reversed-phase, either a C18 analytical 
(Phenomenex Prodigy, 4.6 x 250 mm, 5 m particle size) or semi-preparative 
(Phenomenex Prodigy, 10.0 x 250 mm, 10 m particle size) columns. 
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HPLC-grade solvents were used for all work (purchased from Fisher Scientific) except 
for hexanes and dichloromethane, which were Optima® grade. Water was distilled prior 
to use and for HPLC the water was further filtered through a membrane with a pore size 
of 0.45 m before use. The solvent compositions used are all reported as the % v/v. 
TLC analyses were performed using Machery-Nagel Polygram® Sil G/UV254 plates and 
visualised under UV light (254 nm and 350 nm). TLC plates were then visualised by 
dipping in 5% conc. H2SO4 in methanol (v/v) followed by 0.1% vanillin in ethanol (w/v) 
and heated for analysis. 
 
NMR spectra were obtained using a Varian DirectDrive spectrometer equipped with a 
triple resonance HCN cryogenic probe operating at 600 MHz for 1H and 150 MHz for 
13C nuclei. 19F spectra were acquired using a Varian Inova 300 MHz NMR at 280 MHz. 
The chemical shifts of 1H and 13C spectra were referenced to the residual solvent peaks 
(CDCl3: C 77.0, H 7.26; CD3OD: C 49.0, H 3.31; d6 DMSO: C 39.5, H 2.50). All 
NMR solvents were purchased from Aldrich with the exception of deuterated methanol, 
which was purchased from Cambridge Isotope Laboratories Inc.  
 
NMR quantifications of masses less than 1 mg were performed with an internal 
nitromethane (CH3NO2) standard and using the acquisition parameters described by 
West [132]. 
 
HRESIMS results were obtained from an Agilent 6530 Q-TOF mass spectrometer 
equipped with an Agilent 1260 HPLC for solvent delivery utilising a JetStreamTM 
electrospray ionisation source in positive and negative ion modes. Water and 
acetonitrile (MeCN) solvents were both made up as 5 mM solutions with ammonium 
formate. 
 
For sponge identification, the organic matter was dissolved by immersing a small piece 
of sponge (1 cm3) in a boiling tube and adding concentrated HNO3 to cover the sample. 
Spicules that remained after this were then washed by suspending them in water and 
then centrifuging them to allow the water to be decanted. This process was repeated 
twice and the third time a MeOH wash was carried out. The spicules were then 
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visualised using an Olympus® Research Microscope AX70 Provis equipped with an 
OlympusR DP70 Digital Microscope Camera and these images were compared with 
descriptions in the literature to classify the sponge. 
 
2.8 General NMR data acquisition 
protocols 
 
1H:    number of scans 64 
d1 relaxation delay 0.01 s 
Acquisition time 6.08 s 
Spectral width 0.0 ppm - 9.0 ppm 
 
13C:     number of scans 19776 
d1 relaxation delay 0.01 s 
Acquisition time 1.73 s 
Spectral width -10.0 - 230.0 ppm 
 
19F:     number of scans 52 
d1 relaxation delay 1.00 s 
Acquisition time 1.00 s 
Spectral width -200.0 – 30.0 ppm 
 
COSY:    number of scans 1 
number of increments 512 
d1 relaxation delay 2.0 s 
Acquisition time 0.25 s 
Spectral width 0.0 ppm - 9.0 ppm 
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HSQC:    number of scans 8 
number of increments 512 
d1 relaxation delay 1.5 s 
Acquisition time 0.19 s 
Spectral width 0.0 ppm - 9.0 ppm 1H dimension 
Spectral width 0.0 ppm – 160.0 ppm 13C dimension 
 
HMBC:   number of scans 16 
number of increments 512 
d1 relaxation delay 0.8 s 
Acquisition time 0.25 s 
Spectral width 0.0 ppm - 9.0 ppm 1H dimension 
Spectral width 0.0 ppm – 160.0 ppm 13C dimension 
 
1D NOE:   number of scans 128 
d1 relaxation delay 1.5 s 
Acquisition time 3.04 s 
Spectral width 0.0 ppm - 9.0 ppm  
Mixing time 0.5 s 
 
1D TOCSY:    number of scans 3000 
d1 relaxation delay 1.5 s 
Acquisition time 3.40 s 
Spectral width -2.0 ppm – 14.0 ppm  
Mixing time 0.2 s 
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2D ROESY:   number of scans 16 
number of increments 1024 
d1 relaxation delay 1.5 s 
Acquisition time 0.15 s 
Spectral width 0.0 ppm - 8.0 ppm  
Mixing time 0.5 s 
 
 
2.9  Column chromatography 
2.9.1 Cyclic loading 
To carry out cyclic loading, biomass samples were cut into approximately 3 cm3 pieces 
and allowed to steep in methanol (MeOH) overnight. The MeOH from the first steep 
was decanted into a container and fresh MeOH was poured onto the sample which was 
allowed to steep again overnight. Column beds of HP20 (reversed-phase polystyrene-
divinylbenzene copolymer) were set up based on the principle that 1 kg of sponge has 
8 g of extractable compounds, and approximately 25 mg of extractable compounds can 
bind onto 1 mL of HP20. Extracts were filtered through Büchner funnels with celite and 
filter paper, and extract was passed through the column at a flow rate of 4 mL/min. 
Following this, a two-fold dilution of the eluent was carried out with H2O, this was then 
passed through the column again. Dilution of eluent was carried out by adding small 
volumes of H2O at a time, with care taken to avoid unwanted precipitation. If 
precipitation occurred, the solution was passed through the column again, before adding 
the rest of the volume of H2O. These cycles of dilution and passing the solution through 
the column were repeated until a final MeOH concentration of 12.5% was passed 
through the column. Columns were eluted with 20%, 40%, 60%, 80% and 100% 
mixtures of acetone in water. The 100% acetone fraction was evaporated under reduced 
pressure, while the other fractions were subject to backloading. 
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2.9.2 Backloading 
Backloading was employed to avoid issues with bumping and long evaporating times 
when drying down solvent mixtures that contain large volumes of water. HP20 acetone 
fractions were diluted two fold with ddH2O before passing them through a smaller HP20 
column. Columns were eluted with three column volumes of MeOH and acetone, which 
was collected in a round bottom flask and evaporated under reduced pressure. The mass 
in the flask was dissolved in a small amount of a solvent mix of 4:1 MeOH: 
dichloromethane (DCM), which was then transferred to a pre-weighed glass sample vial. 
The vial was then evaporated in vacuo to obtain the absolute dry weight.  
2.9.3 HP20ss chromatography 
Columns were set up using the same principle for HP20 of 25 mg of extractable 
material binding to 1 mL of resin, therefore for example for 100 mg of a sample that 
needed to be fractionated, 4 mL of beads was used. This ‘loaded HP20ss’ was then 
transferred on the top of a larger column bed of HP20ss which was approximately three 
times the volume of the loaded HP20ss. Columns were eluted with appropriate solvent 
mixtures as described in the relevant methods sections at a flow rate of 1.5 mL/min.  
2.9.4 DIOL column chromatography 
Columns of the normal phase DIOL stationary phase (2,3-dihydroxy-propoxypropyl-
derivatised silica gel.), were set up similarly to HP20ss columns, however the loading 
capacity estimate used was 10 mg of compounds bind onto 1 mL of material.  Columns 
were eluted with appropriate solvent mixtures as described in the relevant methods 
sections at a flow rate of 1.5 mL/min. 
2.9.5 LH20 chromatography 
For all LH20 size exclusion columns run, 100 mL of resin were soaked in appropriate 
running solvents overnight before setting up the column. Flow rates for all columns 
were maintained at approximately 0.2 mL/min. Fractions were collected in 10 mL test 
tubes using an automatic fraction collector. 
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Chapter 3       Screening and 
validations 
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3.1  Background 
 
In the preliminary research described in this chapter, libraries of crude marine extracts 
were screened to identify potential new sources of antitubercular activity. Two marine 
extract libraries were screened in 96-well plate format. The first was kindly donated by 
the National Institute of Water and Atmospheric Research (NIWA), with the second 
generated at VUW. For the NIWA library, the sample mass per well was unknown and 
varied between extracts. Validation as well as furthering of “hit” extracts with observed 
bioactivity depended on re-collection and re-extraction of the marine specimens. In 
contrast, the VUW marine natural product (MNP) library was generated in house with a 
constant mass per well across all crude extracts. Furthermore, biological samples were 
readily available should any be identified as hits. 
As stated earlier, drug resistance in TB poses a serious health problem. In addition to 
this, general bacterial resistance to antibiotics pose a problem that must be addressed. A 
recent report by the Centers for Disease Control and Prevention estimated 
approximately 2 million people are infected with drug resistant bacteria leading to 
23,000 deaths in America [133]. In NZ the rate of methicillin resistant S. aureus is 26.1 
per 100 000, and 195.7 per 100 000 for extended-spectrum β-lactamase producing 
Enterobacteriaceae in 2012 [134, 135].  In order to address drug resistance there is a 
need to identify new more effective antibiotics. This section highlights current problems 
with screening natural products as well as some approaches used to identify novel 
antibiotics.  
3.1.1 Current issues when screening for new 
antibiotics 
High-throughput screening (HTS) of natural products for antibiotics is not the most 
actively pursued research avenue by pharmaceutical companies [115]. There are certain 
aspects associated with screening of natural extracts for antibiotic activity that deter 
pharmaceutical companies from this field of research. First, accessibility to the samples 
proves a major hurdle, as it is often restricted due to intellectual property concerns of 
the governments involved [114, 136]. Increased extinction of species that are sources of 
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structural novelty due to human activities adds further restraints in sourcing material for 
drug discovery [137]. Drug companies need reliable access to the natural resource as 
well as patent control of any potential drug, to ensure ownership for the product upon 
which they have invested time and resources. In addition, seasonal variation and 
environmental changes are known to affect the production of metabolites of interest; 
this majorly affects reproducibility of natural product isolation during scale-up 
processes [138].  
Provided such obstacles are overcome, the complexities of natural products chemistry 
are still left to be considered. For example, in a crude fraction it is possible that 
bioactivity may be due to a mixture of two or more compounds [114]. Following a 
rigorous purification process, the bioactive metabolite could be present in very low 
amounts, or be unstable. The presence of multiple stereogenic centres complicates 
matters even more, not only for structural elucidation but in the downstream process of 
identifying an economically viable synthetic route [114]. In such cases, structural 
elucidation of the metabolite can be even more complex, requiring uncommon NMR 
experiments or chemical derivatisation. 
Re-isolation is another common issue encountered when screening natural products, 
where HTS that focus on activity alone may result in the re-isolation of so-called 
“promiscuous” known compounds, making the investigation redundant. For example, 
streptomycin is produced by ~ 1% of all actinomycetes, subsequently there is a high 
chance that projects focusing on soil bacteria will lead to the isolation of this well-
known compound [139]. Repeat isolations of known compounds is a waste of both time 
and resources, a further disincentive for pharmaceutical companies to invest in this 
temperamental field [71].  
The final test for a potential drug is how it performs in clinical trials. In total, the 
development of a new drug can take up to 15 years and cost up to a billion dollars [113, 
140]. The high standards of regulatory authorities result in a high attrition rate during 
clinical trials; this means a vast amount of time and resources are devoted to drug 
candidates that may eventually  fall out of the development pipeline [141]. 
Further reasons behind the waning interest of large pharmaceutical companies in 
antibacterial research is that there is a better return on investment in other disease 
research areas [115]. Antibiotics are taken for a short period of time and cure the disease, 
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however treating chronic disease provide a better return as patients have to consume the 
medication for the remainder of their life [142, 143]. Furthermore the expiry of patents 
for many drugs means that big Pharma have to compete with generic manufacturers 
[144]. For these reasons antibacterial research is no longer in vogue with Pharma, 
resulting in a decrease of commercially available, structurally unique antibiotics. 
It is mainly due to cost cutting that recent screens have tended to focus on libraries 
comprising known chemical scaffolds, which has resulted is a lack of structurally 
diverse antibiotics [143, 145]. To avoid resistance, combinatorial synthesis provides a 
powerful tool, by modifying a parent compound to introduce variation and improve 
activity [146]. However, the fact remains that it is still the same parent scaffold that is 
being used and there are certain limits as to how many modifications can be made to 
each compound [143]. As known chemical scaffolds tend to show less complexity 
compared to natural products, screening libraries of know chemical entities has 
decreased the number of novel antibiotics [147]. This is particularly concerning given 
the increasing reports of antibiotic resistance [148]. 
3.2  Screening natural products 
Having noted the obstacles natural product research faces, this avenue should not be 
viewed as a dead end. The role of natural products in human health has been crucial for 
thousands of years [76]. Plant derived natural products have been especially crucial and 
the WHO estimate that a majority of the global population still rely on traditional 
medicines [76]. Anti-infective agents such as the -lactams, tetracyclins, 
aminoglycosides, macrolides and streptogramins all play crucial roles in controlling 
various bacterial infections, and they all are a result of natural product research [76]. 
The majority of current antibiotics were discovered during the ‘golden era’ of antibiotic 
research spanning from the 1930s to the 1970s [149]. Following this timeframe the 
number of new classes of antibiotics dwindled, until the 2000s where five new classes 
of antibiotic were approved (linezolid, daptomycin, retapamulin, fidaxomicin, and 
bedaquiline) [149]. Of the 49 compounds under clinical development as antibiotics, 25 
are of synthetic origin and 22 are of natural origin including peptide derived compounds 
[149]. Though these number may seem unfavourable for natural products, if we look at 
structural novelty, there are only a total of six novel truly synthetic compounds 
compared to 11 of natural product origin [149]. These examples illustrate the 
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effectiveness of natural products as a source of chemical diversity, even when the 
number of companies actively engaged in antibiotic research has drastically declined 
[149].  
There needs to be a clear reason for more focus in this field. There is now a slow rise in 
incentive for the field of antibiotic research, the US Generating Antibiotic Incentives act 
provides an automatic priority review and a 5-7 year market exclusivity for antibiotics 
that target qualifying pathogens [149]. The Innovative Medicines Initiative-New Drugs 
for Bad Bugs is a $280 million dollar fund to identify new antibiotics that target Gram-
negative bacteria [149]. These highlight important first steps and will require further 
commitments which will help towards drawing more research into this vital field. 
3.2.1 Overcoming the challenges in natural 
product research 
As stated earlier, approximately 74% of all approved antibacterial drugs identified 
between 1981-2010 originated from natural products [77]. Natural products therefore 
still remain a vital source for novel therapeutics [77]. Though the field remains 
temperamental, it is crucial that innovative methods are developed to uncover the yet 
undiscovered bioactive compounds that already exist, a few such methods are described 
below.  
Cubist Pharmaceuticals have developed a method to screen multiple soil fermentation 
broths against strains of bacteria that are resistant to known antibiotics, to avoid 
isolating known compounds [139]. This approach involves screening more than 107 
strains of actinomycetes a year, using Ca2+-alginate macro-droplet beads in which 
bacteria are grown to produce secondary metabolites. In order to avoid re-isolating 
known compounds, these cultures are screened for inhibitory activity against an E. coli 
strain modified to be resistant to many known antibiotics [139].  
Another technique, developed by Merck, employed the use of two strains of S. aureus, 
one wild-type and the other expressing anti-sense mRNA for FabF, an enzyme essential 
for bacterial fatty acid biosynthesis. The latter strain was sensitised towards fatty acid 
biosynthesis inhibitors. The two strains were then screened against a library of natural 
extracts and the hits specific to the anti-sense expressing mutant led to the eventual 
isolation of two unique compounds, platensimycin A (37), an inhibitor of FabF fatty 
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acid acyl carrier protein synthase II [150], and platencin (38), a dual FabF/FabH 
inhibitor [151]. 
 
37 
 
38
 
Bugni et al. developed methods that involved the application of hyphenated techniques 
to allow for the fractionation, analysis and preparation of semi-crude extracts for 
screens. HPLC coupled with mass spectrometry followed by the collection of 
compounds in HTS plates allowed for the semi-purification and identification of novel 
compounds with anti-tumor activity against breast cancer. This technique also separated 
the compounds from general cytotoxic compounds, which would be observed using 
traditional bioassay-guided techniques [152]. 
Genome mining is another method that can be employed to identify structurally diverse 
compounds. This technique is generally applied when dealing with secondary 
metabolites of microbial origin. It entails genome sequencing, followed by 
bioinformatics profiling to identify pathways involved in production of unique 
molecules. Using this method salinosporamide K (39) was discovery from 
Salinospora pacifica [153]. Additionally, cryptic biosynthetic pathways can be 
identified, and compounds that are not normally produced can be induced through 
genetic manipulation. By inducing the constant expression of a regulatory gene within 
the polyketide synthase (PKS) gene cluster of Streptomyces ambofaciens, 
stambomycins A-D, which were not produced under normal culture conditions, were 
able to be isolated [154]. 
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These examples highlight natural products and the importance they play in identifying 
the next generation of bioactive molecules. Two common screening approaches towards 
drug discovery are described below. 
3.2.1.1 Whole cell screening  
Whole cell screening involves measuring the growth of bacteria in the presence of 
potential inhibitors. Optical density (OD), green fluorescent protein (GFP) fluorescence, 
as well as dyes that measure metabolism such as resazurin, are often employed as 
measures of growth [130, 155]. Whole cell screening has led to the identification of 
many current anti-tubercular drug candidates, such as PA-824 (13), a nitroimidazofuran 
[156] and TMC-207 (17), a diarylquinoline that has gained approval for the treatment of 
MDR-TB [118]. The benefit of this approach is that factors such as cell wall penetration, 
pro-drug activation and drug efflux pumps can be accounted for. However, the pitfall of 
this approach is that it is unable to account for general cytotoxicity, which is a 
parameter that must be evaluated at some stage. Modification of screening conditions 
can also be used to replicate conditions that represent in vivo environments [155]. For 
example, a macrophage infection model can be used to replicate the pathogenesis of TB 
and allow for screening and identification of inhibitors active under these conditions 
[157]. In this model, toxicity of the compounds towards eukaryotic cells can be 
accounted for, however the mode of the action of the drug still has to be elucidated. 
 
3.2.1.2 Targeted screening 
The genomic era spurred the idea of target screening; as genomes of pathogenic bacteria 
were sequenced it allowed for the identification of essential genes, and therefore new 
targets to guide the search for new antibiotics [115].  
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Enzyme/biochemical assays allow for the screening of inhibitors of a particular cellular 
process. Though effective, these assays are unable to account for the complexities of a 
whole cell [158], and the compound may not be active when tested in whole cell assays 
[159]. SQ-641 (40), a drug currently in pre-clinical development to treat tuberculosis, 
was discovered using a screen to target phospho-N-acetylmuramyl-pentapeptide-
translocase. It was later also found to inhibit growth of Mycobacterium smegmatis [40, 
160]. 
 
40 
Targeted screens also include anti-sense screens as described earlier in the isolation of 
platensimycin A [150]. This method, which involves the controlled expression of anti-
sense RNA of a desired gene, makes the strain sensitive to inhibitors that target the gene 
of interest.  
3.2.1.3 Anti-tubercular drug screening at VUW 
The assay protocols developed in our laboratory were established by Drs. Miller and 
O’Toole. The general method involved a liquid screen of chemical libraries of known 
compounds such as the LOPAC, Spectrum Collection, and the NIH Diversity and 
Natural Products Set II libraries against M. smegmatis. By using GFP and OD, bacterial 
growth was measured, followed by validation of hits using dose response curves. In this 
protocol, culture conditions were altered in order to identify compounds that were active 
under various starvation conditions that emulated tuberculosis pathogenesis [155]. The 
96-well plate liquid assay to screen for anti-mycobacterial activity is widely used and a 
well-established method [161, 162] .  
As stated screening libraries of know compounds introduces very little variation in 
chemical structures. Diverse chemical scaffolds are a priority when dealing with 
diseases as imposing as TB [163]. Natural products have provided, and will continue to 
be, a source of structural novelty and the focus of this thesis was to utilise this powerful 
resource to identify such compounds. 
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Applying this assay protocol, the current project involved screening NZ marine extract 
libraries for anti-mycobacterial activity against M. smegmatis. The strains of 
M. smegmatis employed were modified to express a GFP gene and also included a 
kanamycin resistance gene, which allows for the selective growth of this strain and 
hence reduces contamination risks by other bacteria [155]. M. smegmatis offers the 
advantage of a faster doubling time and poses a low health risk compared to the slower 
growing pathogenic mycobacteria. The extract libraries used were generated from New 
Zealand marine vertebrates and invertebrates. Following the identification of hit extracts, 
validation of anti-mycobacterial activity was performed in M. tuberculosis H37Ra. 
Following the selection of samples, a bioassay-guided approach was implemented 
focusing on the identification of potentially novel anti-mycobacterial compounds. 
3.3  Methods 
3.3.1 Marine extract library screening 
Libraries were screened as described in section 2.6.2, with specific details for the NIWA 
library and VUW MNP library mentioned here. Six 96-well plates of a pre-existing 
marine extract library donated from NIWA were re-suspended in DMSO (500 L). 
From these mother plates, daughter plates were created containing 100 L aliquots of 
dissolved extract and were used to screen for activity. As mentioned earlier, the library 
from NIWA was generated with an unquantified and varying amount of extract present 
in each well. To screen the library, 2.5 L aliquots from each well of a daughter plate 
were added to 50 L of media, followed by 50 L of bacteria. The VUW MNP library 
was screened such that the final concentration of crude extracts was 100 g/mL per well. 
The VUW MNP library was screened against M. smegmatis, S. aureus and E. coli. The 
final OD for bacteria used in screens was 0.01 AU. 
3.3.2 Validation 
Hits identified from screens were validated using dose response assays as described in 
sections 2.6.3 and 2.6.4. In brief, aliquots of crude extracts were diluted two-fold in 
appropriate media for either M. smegmatis or M. tuberculosis H37Ra, resulting in a 
50 L final volume of media and extract. Bacterial cultures were diluted to ODs of 0.02 
AU for M. smegmatis or 0.01 AU for M. tuberculosis H37Ra with 50 L aliquots added 
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to each well. For each validation assay, plates with a dilution series of a solvent control 
and a known anti-tubercular drug (either streptomycin or rifampicin) as positive control 
were included. 
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3.4  Results 
Results of screening the NIWA marine extract library and VUW MNP library are 
depicted below in graphical format (Figure 3.1 and 3.2). Growth inhibition is 
represented using GFP measurement on the X axis and resazurin fluorescence on the Y 
axis. A hit was defined as greater than 80% inhibition of growth as indicated by using 
both GFP and resazurin. This is indicated by hits that fall within the black squares in 
both scatter plots. Z-factors were calculated for these screens with values above 0.5 
considered statistically acceptable [164]. Following screening results, tables depict the 
activity of the validated hits from both screens. As sigmoidal curves were not possible 
for these crude extracts, MIC90 values have been listed.  
 
Figure 3.1 M. smegmatis screening results from the NIWA library 
Scatterplot depicting the growth inhibitory effects of all extracts from the NIWA library 
against M. smegmatis pLL192_hsp60. Hits (indicated by asterisks) fall within the 80% 
cut off indicated by black square. The NIWA library screen was performed in triplicate, 
error bars have been excluded from the scatter plots to allow for better visualisation of 
data. The Z-factors calculated for the NIWA screens were Z = 0.92 (GFP) and Z = 0.59 
(resazurin). 
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Figure 3.2 M. smegmatis screening results from the VUW MNP library 
Scatterplot depicting the growth inhibitory effects of all extracts from the VUW MNP 
library against M. smegmatis pLL192_hsp60. Hits (indicated by asterisks) fall within 
the 80% cut off indicated by black square. Of the three VUW MNP library plates two 
screened in duplicate and one was in a single screen as this plate was used to optimise 
screening concentrations. Error bars have been excluded from the scatter plots to allow 
for better visualisation of data. The Z-factor for the VUW MNP screens were Z= 0.90 
(GFP) and Z= 0.78 (resazurin). 
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Table 3.1 Top hits from NIWA Library 
Sample MIC90 (g/mL) vs. M. tuberculosis 
H37Ra  
Lipkius holthuisi (shrimp body without 
carapace) 
600  
Starfish intestine 400  
Red star fish intestine 250  
Paralomis hystrix (spiky crab intestines) 400  
Hoplostethus mediterraneus (silver roughy 
intestines) 
400  
Psychrolutes marcidus (blob fish intestines) 400  
Psychrolutes marcidus (blob fish liver) 600  
Neolithodes brodiei (red crab intestines) 1350  
Validation of the hits from the NIWA library against M. tuberculosis H37Ra using dose 
response curves, MIC90 values are the lowest concentration of extract tested that 
displayed > 90% growth inhibition. 
 
Table 3.2 Top hits from VUW MNP library 
Sample MIC90 (g/mL) vs. M. tuberculosis 
H37Ra  
PTN 3_37C, unknown Tongan black 
ascidian 
200  
PTN 3_40B, unknown Tongan purple 
ascidian 
NT 
PTN 2_50B, unknown Hen and Chicken 
Islands (Northland) Brown sponge 
200  
PTN 2_45H, unknown Tutakaka sponge IA 
PTN 2_45I, unknown Tutakaka sponge IA 
MNP_0999, Haliclona sp. sponge NT** 
PTN 2_56C, Latrunculia sp. sponge 6.25  
PTN 2_93D, Xiphophora condrophylla 200  
NT: not tested in M. tuberculosis H37Ra, ** MIC90 in M. smegmatis 25 g/mL, IA: 
MIC90 not achievable at the highest concentration tested (200 g/mL). Validation of the 
hits from the VUW MNP library against M. tuberculosis H37Ra using dose response 
curves, MIC90 values are the lowest concentration of extract tested that displayed > 90% 
growth inhibition. 
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Spectrum of activity Compound 
A PTN 2_41E, PTN 4_13H 
B PTN 3_40B, PTN 3_37C    
C  
D  
E  
F PTN2_56C, PTN2_50B 
G MNP_0999, PTN 2_93D, PTN 2_45I, PTN 
2_45H 
 
Figure 3.3 Spectrum of activity and overlap of hits from VUW MNP library screen. 
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Table 3.3 Hits further investigated 
Sample Species MIC90   
Red Crab 
 
M. smegmatis 1% v/v 
M. tuberculosis H37Ra 1350 g/mL 
Hen and Chicken islands 
brown sponge 
PTN 3_50B 
M. smegmatis 62.5 g/mL 
M. tuberculosis H37Ra ≥ 200 g/mL 
Psychrolutes marcidus 
 
M. smegmatis 1% v/v 
M. tuberculosis H37Ra 600g/mL 
Latrunculia sp.* 
PTN 2_56C 
 
M. smegmatis 100 g/mL 
M. tuberculosis H37Ra 6.25 g/mL 
Xiphophora chondrophylla 
PTN 2_93D 
M. smegmatis ≥200 g/mL 
M. tuberculosis H37Ra ≥ 200 g/mL 
Comparison of activity of hit extracts in two species of mycobacteria using dose 
response curves, MIC90 values are the lowest concentration of extract tested that 
displayed > 90% growth inhibition. *Based on comparisons of MIC90 values, this 
extract shows a specificity for M. tuberculosis H37Ra. 
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3.5  Discussion 
The results from the NIWA library screening performed against M. smegmatis are 
provided in Figure 3.1 and for the VUW MNP library in Figure 3.2. GFP and resazurin 
fluorescence measurements were used as a measure of cell replication. OD was not used 
as measurements become unreliable due to the coloured nature of crude extracts, which 
contribute to OD measurements. In the NIWA library screen it is noted that many data 
points are negative values, where the resulting growth is higher with respect to control 
wells, indicating the possibility of growth promotion by the extracts in question. As the 
Z-factors calculated for the NIWA screens were above 0.5 this screen can be considered 
statistically acceptable (Figure 3.1) [164].  
As stated earlier, the NIWA library was generated with an unknown mass of extract per 
well and as such, the library of extracts was dissolved in a constant solvent volume (500 
L DMSO). Following this the library was screened at a set (2.5% v/v) concentration of 
extract per well. This concentration was chosen as this is the highest concentration of 
DMSO that M. smegmatis can tolerate without solvent effects inhibiting cell growth. 
The unknown mass per well posed a risk of overestimating the activity of extracts that 
were present at higher masses in some wells than others. Once hits were identified, they 
were validated in dose response assays. These hits were validated by drying 100 L 
aliquots of the dissolved extract to identify the dry mass (masses ranged between 10-
100 mg) before re-dissolving samples to perform dose response curves. Table 3.1 
indicates the validation of the top hits from the NIWA library against M. tuberculosis 
H37Ra.  
During optimisation of screening the VUW MNP library, no hits were observed with 
activity against M. smegmatis at 10 or 20 g/mL. However, at 100g/mL, inhibitory 
activity was observed for some extracts, therefore this was used as the screening 
concentration. As previously stated the VUW MNP library was generated with a 
constant mass for each extract per well, and library screens were subsequently 
performed at the defined 100 g/mL concentration. The Z-factors for the VUW MNP 
screens were above 0.5 and therefore this screen can also be considered statistically 
significant (Figure 3.2). 
The VUW MNP library consisted of three library plates, RAK18_52A/B, 53A/B and 
53C/D. RAK18_52A/B was used to optimise screening concentrations for the assay and 
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due to this it was possible to only screen this plate only once rather than in duplicate as 
was done for RAK18_53A/B and 53C/D. As it so happened, the most active hits 
identified were those from RAK18_52A/B. These hits were validated in dose response 
assays against M. tuberculosis H37Ra and the MIC90 values are listed (Table 3.2). It 
should be noted that these validations allowed for false positives to be excluded due to 
the lack of activity observed in this phase of testing. A possible reason for these false 
positives may be due to the fact that these extracts may be active against M. smegmatis 
and not M. tuberculosis H37Ra. An alternative reason for these false positive could be 
due to the fact they were all picked from the library plate that was screened only once; 
therefore there was a higher chance of false positives coming through due to random 
growth in wells. Fortunately the validation of hits allowed for the exclusion of false 
positives at an early stage, which avoided investing time into samples that may 
eventually fall out at later stages of the project. 
Using the in-house libraries not only enabled for optimization of screening 
concentration but also allowed for screening the library in duplicate, as well as against 
S. aureus and E. coli. This allowed for the identification of samples that were 
specifically active against mycobacteria. Figure 3.3 identifies two such samples that 
showed specific activity against M. smegmatis. The two specific hits from the VUW 
MNP library screen were unfortunately not available in sufficient masses to allow for 
bioassay-guided fractionation.  
Towards achieving the goal of Aim I, Table 3.3 identifies the top hits selected after 
considering sample availability as well as activity. PTN 2_50B (Hen and Chicken 
Islands brown sponge) was collected near the Hen and Chicken Islands, New Zealand, 
and was stored frozen. The crude extract had an MIC90 of 62.5 mg/mL against 
M. smegmatis. This sponge (250 g) was extracted twice in MeOH (450 mL) and cyclic 
loaded onto HP20 and the column eluted using 20%, 40%, 60%, 80% and 100% acetone 
in water. One of the most active fractions ND4_29C (280 mg) displayed an MIC90 of 25 
g/mL, and was further fractionated using HP20ss (40 mL column), with mixtures of 
20%, 40%, 60%, 70%, 80%, 90% and 100% methanol in water and finally, 100% 
acetone, used to elute the column. This led to fraction EJA_94D (33.6 mg) with an 
MIC90 of 12.5 g/mL, which was purified using semi-preparative reversed-phase C18 
HPLC with 70% MeOH and 0.1% formic acid under isocratic conditions to give 
ND4_36I (2.3mg) with an MIC90 of 50 g/mL. As this sample did not show any major 
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improvement in activity and due to its low mass, it was not pursued any further in order 
to focus on other samples. 
Bioassay-guided fractionation work on the liver of Psychrolutes marcidus (Blob fish, 
collected by NIWA) led to the identification of a mixture of fatty acids as the bioactive 
component. GC-MS analysis was used to analyse and identify the major components of 
the bioactive fraction, following which those fatty acids that were commercially 
available were purchased and tested for bioactivity. This work is discussed in further 
detail in Chapter 4. 
Working with the Latrunculia sp. sponge, collected near Rimariki Island led to the 
isolation of a novel taurinated terpene. Based on the bioactivity of the initial 
fractionation, this taurinated terpene was believed to be the component responsible for 
the observed anti-mycobacterial activity. However, final purification of the bioactive 
fraction using size exclusion chromatography resulted in the separation of the taurinated 
terpene from the anti-mycobacterial component. This component was not isolated in a 
mass sufficient enough to allow for structure elucidation. Details of this work are 
further elaborated in Chapter 5. 
Bioassay-guided fractionation of a brown alga Xiphophora chondrophylla, collected 
near the Hen and Chicken Islands, led to the isolation of a new 1-deoxysphingoid. This 
compound has an MIC90 of 65.1 M against S. aureus, E. coli, M. smegmatis and 
M.  tuberculosis H37Ra. However, the bioactivity of the 1-deoxysphingoid was more 
potent versus mammalian cell lines. Therefore, the Saccharomyces cerevisiae gene 
knock-out library was used to identify pathways that were involved in the mechanism of 
action of this compound. Further details of this work are described in Chapter 6. 
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Chapter 4       Bioactive fatty acids 
from Psychrolutes marcidus   
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4.1  Background 
Following a screen against the NIWA library, the liver extract of the blob fish 
Psychrolutes marcidus was identified as being active. After subsequent validations in 
dose response assays, this sample was chosen to be pursued further. Upon collection of 
more specimens by NIWA, the livers were dissected and extracted to allow for isolation 
of any bioactive compounds responsible for inhibitory activity. This led to the 
identification of a mixture of fatty acids as the source of bioactivity. 
4.1.1 Fatty acids 
Fatty acids are ubiquitous in nature and play important roles within a cell such as energy 
reserves in the form of triglycerides, or in the cell membrane as phospholipids. Through 
the action of enzymes such as lipases, lipids can be cleaved from their polar head groups 
(such as sugars or phosphates), releasing free fatty acids [165]. It has been reported that 
free fatty acids (FFAs) possess a range of activities including antibacterial, anti-fungal, 
and cytotoxic properties [165]. Within biological systems, chain lengths ranging from 
10 to 28 carbons are common for fatty acids [165]. When there is one or more double 
bonds within the carbon chain, they are classed as unsaturated fatty acids. In humans, 
FFAs act as an innate defence against pathogens on skin and mucosal surfaces and it is 
believed that there are approximately 10-15 g of FFAs per square centimetre of skin 
[165, 166]. Their antibacterial action on the skin may be the result of direct killing of 
bacteria, or by decreasing the pH on the skin surface, making conditions unfavourable 
for bacterial growth [167, 168].  
Antimicrobial FFAs from a number of sources such as algae, plants and animals have 
been isolated using bioassay-guided fractionation [169-172]. FFAs are also believed to 
be the active component of some traditional remedies [171, 172].  
A general trend in literature indicates that antibacterial activity of FFAs depends on the 
carbon chain length, degree of unsaturation as well as the positioning and geometry of 
the double bond, with a cis geometry favouring more potent activity [173-175]. Most 
active FFAs have chain lengths of either 14 or 16 carbons [173].  Correlations have 
been observed identifying unsaturated FFAs as more active compounds compared to 
saturated FFAs of similar chain length [173]. In addition, a free carboxyl group is 
believed to be essential for activity [173, 176]. Gram-positive bacteria are more 
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susceptible to growth inhibition in the presence of FFAs compared to Gram-negative 
bacteria, however it should be noted that most research has only focused on Gram-
positive bacteria [175, 177, 178]. 
4.1.1.1 Nomenclature of fatty acids 
Fatty acids are named using set abbreviated nomenclature; the number of carbons in the 
chain is first stated followed by the number of double bonds. For example, palmitic acid, 
a saturated fatty acid with a chain of 16 carbon atoms, would be C16:0, whereas 
palmitoleic, which has the same chain length but one double bond is C16:1. In addition, 
the bond geometry is also stated. Therefore, for palmitoleic acid, C16:1, cis-9 would be 
used, which identifies a 16 carbon long chain, with one cis-double bond at the 9th carbon.  
4.1.1.2 Mechanism of action 
While there has been extensive literature published on the effects of FFAs, only the 
mechanisms that would lead to the most detrimental effects on a cell will be discussed.  
While the exact mechanisms of action are not fully elucidated, it has been proposed that 
FFA activity is potentiated in multiple ways. The presence of a hydrophilic polar head 
and a hydrophobic tail makes these molecules amphiphilic. Therefore, they can cause 
cell lysis by affecting membrane permeability as with detergents [179, 180]. Oleic acid 
has been shown to increase membrane fluidity in S. aureus [181].  
In altering membrane permeability, FFAs can affect processes integral to cell viability 
such as the electron transport chain and enzyme activity. Direct interaction with electron 
carriers, which disrupts the electron transport chain, or alteration of membrane fluidity, 
can also perturb cell homeostasis in bacteria [182, 183]. 
FFAs are believed to uncouple oxidative phosphorylation, which is based on research 
focusing on mitochondria and has been used to draw comparisons to antibacterial 
activity [165, 184, 185]. This is achieved by disrupting the proton motive force 
generated by the electron transport chain, which is essential for ATP synthase to convert 
ADP to ATP [186]. FFAs have been shown to directly interact with the permeability 
transition pore within the mitochondrial membrane, therefore uncoupling oxidative 
phosphorylation [187].  Further disruption of this process is believed to occur via the 
dissociation of the proton from the acid group of a FFA within the cytosol, thus 
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decreasing the pH within the cytosol. This is facilitated via anion transporters within the 
mitochondrial membrane [188].  
An alternative mechanism proposed for the activity of FFAs includes the direct 
interaction and inhibition of enzymes, with reports of unsaturated FFAs being more 
potent than saturated FFAs [189, 190]. Within the literature, FFAs have also been 
linked to inhibition of fatty acid biosynthesis, which is essential for maintaining 
membrane integrity within bacteria [191, 192].  
The varying susceptibility of bacteria to FFAs is  believed to be due to the differences in 
permeability of bacterial cell walls, which alters FFA access to the inner membrane 
[165]. Some bacteria are able to resist inhibition by FFAs, by modifying their cell wall 
to make it more charged and therefore more hydrophilic and unfavourable for FFA 
binding [193]. S. aureus has been shown to upregulate genes involved in cell wall 
synthesis in the presence of FFAs [183]. The presence of carotenoids allows for 
membrane stability, negating the effects of FFA. Strains of S. aureus with high levels of 
carotenoids have been reported to display more resistance to FFAs compared to strains 
with lower levels [181]. 
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4.2  Methods 
4.2.1 Extraction of material 
Blob fish were dissected and livers extracted. Livers (200 g) were cut into 1 cm3 sized 
pieces and soaked in methanol (~ 200 mL). Following overnight extraction, the 
methanol was decanted into a conical flask and the liver material was re-extracted with 
the same volume of methanol. The two extracts were treated separately and filtered 
using a Büchner funnel and Celite. The second extract was passed through an 80 mL 
HP20 column followed by the first. The eluents were combined and diluted two-fold 
with H2O before passing through the same column again. This was repeated until the 
original MeOH extract was diluted to 12.5% and passed through the column. Following 
cyclic loading, the column was eluted with 240 mL of 20% and 40% acetone in water 
followed by 60% and 100% acetonitrile in water, and finally 100% acetone was used to 
strip the column.  
From the 100% acetonitrile fraction (12.6 grams of oil, MIC90 2% v/v), 100 mg was 
further fractionated using a 10 mL DIOL column, eluting with 30 mL of 100% hexanes, 
75%, 50%, 25% mixtures of hexanes in EtOAc, 100% EtOAc, 75%, 50%, 25% 
mixtures of EtOAc and MeOH, 100% MeOH and column strip of 50% MeOH and H2O. 
Only the 100% hexanes and the column strip were collected in bulk, whereas the other 
eluents were collected in test tubes. Test tubes were dried and combined based on 
charring (5% H2SO4 in MeOH) of TLC (running condition 4:1:2 butanol: acetic 
acid:water). From the resulting fractions, ND4_43B (116.2 mg, MIC90 250 mg/mL) was 
separated by LH20 size exclusion chromatography using 50% MeOH/ 50% DCM. This 
gave ND5_96L as the active fraction (2.5 mg MIC90 250 g/mL). 
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4.2.2 Cyclic loading and column purification 
 
Scheme 4.1 Isolation scheme of fatty acids from Psychrolutes marcidus 
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4.2.3 GC-MS analysis of fatty acids  
A common method to analyse fatty acids is to derivatise them and generate fatty acid 
methyl esters (FAMEs), which are then analysed via GC-MS [194]. Fatty acid methyl 
esters were generated by adding 1 mL of a 10% solution of boron trifluoride in 
methanol to 100 g of ND5_96L. This mixture was heated for 10 minutes at 90 °C, 
followed by liquid-liquid partitioning with water and chloroform three times. The 
chloroform layer was dried for analysis by GC-MS (Integrated Bioactive Technologies 
group, Callaghan Innovation). Chloroform (45 mL) was added to the sample and 
analysis was conducted on a Shimadzu QP2010 GC-MS/FID, using a Thermo TGWaxA 
column (30 m, 0.25 mm i.d., 0.25 M film), with isothermal conditions at 210 °C, and 
the injector temperature set at 280 °C using a 50:1 split. Helium was used as the carrier 
gas. Mass spectrometry fragmentation patterns (electron impact ionisation at 70 eV in 
positive ion mode) as well as equivalent chain length values were used to identify peaks.  
4.2.1 Fatty acids 
The following fatty acids identified using GC/MS, were sourced from Sigma: eladic 
acid, petroselenic acid, oleic acid, cis-vaccenic acid, trans-vaccenic acid, linoleic acid, 
palmitic acid and palmitoleic acid; all fatty acids were of  > 99.0% purity. These fatty 
acids were either tested individually or in mixtures of two, three or four. Fatty acid 
mixtures were generated using equal proportions of each fatty acid within each 
respective mixture.  
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4.3  Results 
Using the methodology described in section 2.6, the results of the dose-response assays 
for the active fraction as well as fatty acids and their mixtures are listed below. Graphs 
were generated using GraphPad Prism v.5.0. Resazurin dye was used to measure 
bacterial metabolism after each assay was run, and fluorescence measurements (RFU) 
were used as a measure of growth. OD was used as measure of growth for the HL-60 
and HEK MTT assay as well as the S. cerevisiae assay. As stated earlier, where possible, 
IC50 values have been listed, however as sigmoidal curves were not achievable for all 
data, MIC90 values have been listed as well. 
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4.3.1 GC/MS results 
Table 4.1 GC/MS profile of FAMEs in ND5_96L 
 ND5_96L FAME  
Chain length ECL (16,18) % FA 
 13.84 0.1 
14:0 13.97 0.34 
15:0 14.99 0.27 
 15.5 0.17 
16:0 16.00 11.58 
16:1 n-9 16.27 2.05 
16:1 n-7 16.33 12.25 
16:1 n-5 16.45 0.19 
I17:0 16.51 0.34 
 16.60 0.22 
 16.69 0.18 
 16.93 0.19 
17:0 17.00 0.14 
17:1 17.29 1.64 
 17.41 0.29 
 17.49 0.37 
18:0 18.00 1.83 
18:1 n-9 18.25 52.25 
18:1 n-7 18.32 7.77 
 18.44 0.44 
 19.26 0.19 
 19.30 0.47 
20:1 20.16 0.28 
20:1 20.20 2.05 
Phthalate 20.72 3.91 
 22.57 0.49 
Fatty acid composition of ND5_96L determined by FAME analysis. Estimated chain 
length (ECL) values indicate the retention time of each fatty acid on the GC column in 
relation to their saturated fatty acid counterparts. 
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4.3.2 Bioactivity 
ND5_96L vs. stationary phase M. tuberculosis H37Ra
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Figure 4.1 ND5_96L vs. stationary phase M. tuberculosis H37Ra 
Dose response curve of ND5_96L using stationary phase assay conditions. RFU units 
were used as a measure of growth on the Y-axis. +/- value indicates standard error. 
MIC90 value is two-fold greater in stationary phase cells compared to actively growing 
cells. (n=1, triplicate) 
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ND5_96L vs HEK cells
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Figure 4.2 ND5_96L vs. mammalian cell lines 
MTT assay of ND6_96L against HL-60 (A) and HEK cell lines (B). The HEK cell 
line has been used as an indication of general cytotoxicity. OD was used as a measure 
of growth on the Y-axis. NA not achievable, +/- value indicates standard error.  
(n=1, duplicate)
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Table 4.2 Broad- spectrum activity of active mixture of fatty acids 
Microorganism Activity 
S. aureus - 
E. coli - 
P. aeruginosa - 
M. smegmatis + 
M. tuberculosis H37Ra + 
S. cerevisiae - 
HL60 cells + 
HEK cells - 
(+) indicates activity, (-) indicates no observed activity. Activity is defined by ≥90% 
growth inhibition observed at the highest concentrations tested (500-1000 g/mL). 
Table 4.3 Bioactivity profile of individual fatty acids 
Name Chain length MIC90 (g/mL ) 
Palmitic acid C16:0 250  
Palmitoleic acid C16:1 500  
Petroselenic acid C18:1, cis-6 ≥1000 
Oleic acid C18:1, cis-9 ≥1000 
Eladic acid C18:1, trans-9 500  
cis-vaccenic acid C18:1, cis-11 500  
trans- vaccenic acid C18:1, trans-11 500  
Linoleic acid C18:3, cis-19,12,15 NA 
MIC90 values of fatty acids against M. tuberculosis H37Ra. 
 
Table 4.4 Comparison of MIC90 values of artificial mixtures against M. tuberculosis 
H37Ra 
Name MIC90 (g/mL) 
cis mix 250  
trans mix 125  
ND5_96L 250  
Comparison of activities of the mixtures of the four fatty acids with either cis or trans-
vaccenic acid to ND5_96L. 
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Table 4.5 Bioactivity of fatty acid mixtures vs. M. tuberculosis H37Ra 
Name Chain lengths 
IC50 
(g/mL) ± 
std. err. 
Palmitic acid C16:0 66 +/- 1.1 
Palmitoleic acid C16:1, cis-9 274 +/- 1.1 
Eladic Acid C18:1, trans-9 301 +/- 1.1 
trans-vaccenic acid C18:1, trans-11 306 +/- 1.1 
cis-vaccenic acid C18:1, cis-11 166 +/- 1.1 
Palmitic/palmitoleic C16:0/ C16:1, cis-9 51 +/- 1.1 
Palmitic/eladic C16:0/C18:1, trans-9 50 +/- 1.1 
Palmitic/trans-vaccenic C16:0/C18:1, trans-11 48 +/- 1.1 
Palmitic/cis-vaccenic C16:0/ C18:1, cis-11 102 +/- 1.1 
Palmitoleic/eladic C16:1, cis-9/C18:1, trans-9 73 +/- 1.1 
Palmitoleic/trans-vaccenic C16:1, cis-9/C18:1, trans-11 64 +/- >1 
Palmitoleic/cis-vaccenic C16:1, cis-9/ C18:1, cis-11 104 +/- 1.3 
Eladic/trans-vaccenic C18:1, trans-9/ C18:1, trans-11 71 +/- 1.2 
Eladic/cis-vaccenic C18:1, trans-9/C18:1, cis-11 113 +/- 1.0 
Palmitic/palmitoleic/eladic C16:0/C16:1, cis-9/C18:1, trans-9 60 +/- 1.1 
Palmitic/palmitoleic/trans-
vaccenic 
C16:0/ C16:1, cis-9/C18:1, trans-11 68 +/- 1.1 
Palmitic/palmitoleic/cis-vaccenic C16:0/C18:1, trans-9/C18:1, cis-11 125 +/- >1 
Palmitic/eladic/trans-vaccenic 
C16:0/C18:1, trans-9/C18:1, trans-
11 69 +/- 1.1 
Palmitic/eladic/cis-vaccenic C16:0/C18:1, trans-9/ C18:1, cis-11/ 79 +/- 1.1 
Palmitoleic/eladic/trans-
vaccenic 
C16:1, cis-9/C18:1, trans-9/C18:1, 
trans-11 72 +/- 1.1 
Palmitoleic/eladic/cis-vaccenic 
C16:1, cis-9/C18:1, trans-9/C18:1, 
cis-11 81 +/- 1.3 
trans-vaccenic mix of the 
original 
C16:0/C16:1, cis-9/C18:1, trans-9/ 
C18:1, trans-11 76 +/- 1.1 
cis-vaccenic mix of the original 
C16:0/C16:1, cis-9/C18:1, trans-9/ 
C18:1, cis-11 102 +/- 1.1 
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4.4  Discussion 
4.4.1 Fractionation and isolation 
An initial crude fractionation was performed using HP20 (PSDVB) column 
chromatography (Scheme 4.1). Based on the anti-mycobacterial activity of the fractions 
generated, the 100% acetonitrile fraction was chosen for the next stage of purification, 
using DIOL normal phase chromatography. Based on its profile, the 75% hexanes / 
EtOAc fraction was selected to undergo the final stage of size exclusion 
chromatography using LH20 gel. Based on the bioactivity as well as the 1H NMR 
spectra of the preceding fractions, ND5_96L was identified as the most potent fraction, 
however it was apparent that it was still a mixture of fatty acids. 
4.4.2 Structural elucidation 
The initial method used to identify the structure of the bioactive compound was NMR 
spectroscopy. Using NMR, it was concluded that the most pure and active fraction, 
ND5_96L, was a mixture of C-18 fatty acids. Therefore, a range of C-18 fatty acid 
standards were purchased, spectra were acquired and these were compared to ND6_96L. 
Based on 1H and 13C NMR data, it was initially concluded that the sample was a 
mixture of oleic and cis-vaccenic acids (Figure 4.3 to 4.7). 
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Figure 4.3 Comparison of 13C NMR (CDCl3, 150 MHz) spectra of ND5_96L (top), 
cis-vaccenic (middle) and oleic acids (bottom) at full spectral width. 
 
Figure 4.4 Comparison of 13C NMR (CDCl3, 150 MHz) spectra of ND5_96L (top), 
cis-vaccenic (middle) and oleic acids (bottom) at a specific range of interest. 
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Figure 4.5 Comparison of 1H NMR (CDCl3, 600 MHz) spectra of ND5_96L (top), 
cis-vaccenic (middle) and oleic acids (bottom) at full spectral width. 
 
Figure 4.6 Comparison of 1H NMR (CDCl3, 600 MHz) spectra of ND5_96L (top), 
cis-vaccenic (middle) and oleic acids (bottom) at a specific range of interest. 
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Figure 4.7 Comparison of 1H NMR (CDCl3, 600 MHz) spectra of ND5_96L (top), 
cis-vaccenic (middle) and oleic acids (bottom) at a specific range of interest. 
 
Testing the C-18 fatty acid standards identified MIC90 values of 1000 g/mL for oleic 
acid and 500 g/mL for cis-vaccenic acid (Table 4.3). The lack of correlation of the 
activities of the standards to ND5_96L ( MIC90 250 g/mL) could be due to two factors; 
either the fatty acids in the mixture had not been correctly identified, or the fatty acids 
need to be present together in a certain ratio to be active. To address the issue of 
misidentification of the appropriate fatty acids, the mixture was methylated with a 10% 
solution of BF3 in methanol to generate the corresponding fatty acid methyl esters 
(FAMEs) for analysis by GC-MS. The FAME analysis identified the mixture as eladic 
(C18:1 trans-9) (52.3%), vaccenic (C18:1 cis or trans-11) (7.8%), palmitic (C16:0) 
(11.6%) and palmitoleic (C16:1 cis-9) (12.3%) acids (Table 4.1). This means the initial 
conclusion of the active mixture as a binary mixture of fatty acids was incorrect. 
Given vaccenic acid can exist in two different geometries, two sets of mixtures were 
generated for bioassay testing, one using cis-vaccenic acid while the other used trans-
vaccenic acid combined with the other three acids. All possible combinations of two or 
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three fatty acids, in addition to the individual fatty acids, were tested for their 
bioactivity against M. tuberculosis H37Ra (Table 4.5).  
4.4.3 Bioactivity 
In theory, the mixture of four fatty acids should be approximately as active as ND5_96L 
and based on the bioassay data this is the case with an MIC90 of 125 g/mL for the 
trans-vaccenic acid mixture and an MIC90 of 250 g/mL for the cis-vaccenic acid 
mixture (Table 4.4). These values are consistent with the observed activity of the 
‘natural mixture’ ND6_96L (250 g/mL), and based on this it could be concluded that 
the natural mixture contains cis-vaccenic acid. 
Testing the fatty acids individually identified palmitic acid as the most biologically 
active with an IC50 of 66 g/mL (Table 4.5). When comparing the IC50 value of palmitic 
acid (C16:0) to palmitoleic acid (C16:1) a four-fold difference is observed (Table 4.5), 
which is very unusual as it is generally believed that unsaturation of the alkyl chains 
improves antibacterial activity [173-175]. 
When comparing the anti-mycobacterial activities of the fatty acids tested in 
combinations, the most effective mixtures were those that contain two fatty acids, where 
one of the fatty acids is palmitic acid (Table 4.5). When comparing activities of cis vs. 
trans FFAs it is hard to draw a conclusion, as only two fold differences were observed 
when comparing either IC50 of MIC90 values. Surprisingly, when trans C18 fatty acids 
were mixed with palmitic acid in a 1:1 ratio, roughly a six-fold improvement in activity 
was observed (see Table 4.5). 
This result seems slightly unusual as it is generally believed that trans-fatty acids should 
display lower activity compared to cis-fatty acids. What seems more unusual is that the 
activities of the trans FFAs are enhanced by a saturated FFA [173-175]. The 
improvement in activity with palmitic acid is also observed in combination with 
palmitoleic acid, a C16 cis-fatty acid with a shift in IC50 from 274g/mL to 68 g/mL. 
The data (Table 4.5) illustrates that palmitic acid, a C16 fatty acid, is more active 
compared to C18 fatty acids. Furthermore, based on these results, it seems that this 
saturated C16 fatty acid is more active than unsaturated fatty acids. Research studying 
the effects of FFAs on fast growing mycobacteria has identified that as chain length 
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increased, activity decreased for saturated FFAs [171]. In addition, unsaturated FFAs 
tend to have better inhibitory activity with C16 chain lengths preferred over C18, 
however if C18 chains contained two double bonds the activity was comparable to that 
of the unsaturated C16 FFA [171]. As the aforementioned study focused on fast 
growing mycobacteria, a more relevant analogous comparison looking at slow growing 
mycobacteria identified a 2-4 fold  improvement in MIC values for palmitic acid (C16) 
compared to unsaturated fatty (C18) acids [170].  
Figure 4.1 illustrates the activity profile of the ND5_96L against stationary 
mycobacteria and mammalian cell lines. For the bacteriostatic assay, the highest 
concentration used was 250 g/mL and at this concentration 90% inhibition of growth 
was observed. When analysing activity against stationary phase mycobacteria, ideally 
higher concentrations of drugs or samples should be used, as it is believed mycobacteria 
are more tolerant to inhibition by drugs in this state [195]. This can be illustrated in the 
drop in activity of streptomycin in a bacteriostatic assay (MIC 0.39 M) compared to a 
stationary phase assay (MIC not achievable) (Appendix A). This assay showed that 
ND5_96L had an MIC90 of 500 g/mL (Figure 4.1), which is two-fold greater when 
compared to the bacteriostatic assay. Studying the activity of the mixture in HL-60 and 
HEK cells identified the mixture was two-fold more active in HL-60 cells than HEK 
cells when comparing MIC90 values (Figure 4.2). 
4.4.3.1 Palmitic acid and mycobacteria 
Based on the activity of fatty acids analysed, it was observed that palmitic acid had the 
most prominent activity. This section highlights work relating to palmitic acid and 
mycobacteria. One of the earliest studies in this area identified growth inhibitory effects 
at higher concentrations of the fatty acid [196]. However, when non-toxic 
concentrations were used, the saturated acid was incorporated into cells. Following 
assimilation of all the palmitic acid within the growth medium, further doses of non-
inhibitory concentrations of palmitic acid could be added to the media, which was in 
turn consumed. This assimilation process was dependent on aerobic conditions [196]. 
Studying the effects of complexing fatty acids with detergent to reduce their toxicity 
identified that when Triton WR1339 was added in a 2.5:1 ratio, the toxicity of palmitic 
acid was reduced. This was due to the detergent sequestering the fatty acids, making 
less available to inhibit bacterial growth [197]. Testing the effects of fatty acids in the 
80 
 
absence of the detergent against M. tuberculosis identified inhibition of growth by oleic 
and palmitic acids at 2 g/mL [197]. This inhibitory concentration is inconsistent with 
the work described here and that of others as stated below. In our assay the MIC (an 
observed maximum of 2% growth) was 1 mg/mL, with greater than 90% growth 
observed at the lowest tested concentration, 7.8 g/mL. 
The effects of palmitic acid at non-inhibitory concentrations on the metabolism of 
M. avium identified that this fatty acid is incorporated to form lipids, a majority of them 
being triglycerides [198]. A follow-up study focusing on the effects of the fatty acid on 
cell division identified that the acid increased the formation of clear virulent colonies 
compared to the cultures starved of palmitic acid, which selected for opaque 
non-virulent colonies [199]. 
A study of the anti-mycobacterial component of the hexane extract of Humulus lupulus 
identified palmitic, stearic and oleic acids as the major components. The growth 
inhibitory effect of these fatty acids on M. fortuitum identified an MIC of 512 g/mL 
for palmitic acid using a broth microdilution assay, however no activity was observed 
against M. smegmatis, M. phlei or M. aurum. In the same study oleic and linoleic acids 
proved more active with MIC’s ranging from 4-16 g/mL [200]. The reported activity 
for palmitic acid in the same study is more consistent with the study described here. 
However, the activities of oleic and linoleic acids do not match the results of this thesis 
with more than 90% growth observed at concentrations ranging from 4-16 g/mL.  
A similar study focusing on a native South African herbal remedy made from the root 
extracts of Pelargonium reniforme and P. sidoides identified in vitro activity from the 
hexanes fractions. Bioassay-guided fractionation identified that a mixture of fatty acids 
was responsible for this activity. Testing of the saturated and unsaturated components 
found an MIC of 256 g/mL against M. aurum for palmitic acid, which was inactive 
against M. smegmatis, M. fortuitum, M. abscessus or M. phlei. This study also identified 
unsaturated fatty acids as being more active than saturated fatty acids. They reported 
oleic acid MIC’s ranging from 4-256 g/mL, linoleic acid MIC’s ranging from 
2-32 g/mL and palmitoleic acid with MIC’s ranging from 4-16 g/mL for the different 
species of mycobacteria [171]. 
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Bioassay-guided isolation focusing on the anti-mycobacterial activity of a red alga, 
Polysiphonia virgata, identified a mixture of fatty acids from the dichloromethane 
extract as being responsible for activity. Studying the effect of individual fatty acids 
identified that the most active fatty acids were again unsaturated fatty acids with oleic 
acid having an MIC of 25 g/mL, and linoleic, myristic and lauric acids having MICs of 
50 g/mL against M. tuberculosis. Testing the acids against a strain of MDR-TB 
identified the same MIC values for linoleic, myristic and lauric acids, with oleic acid 
reported as inactive in this strain. This paper reported palmitic acid as inactive [201].  
A more recent study on the bioactivity of the hexane extract of fruit peel of 
Citrus aurantifolia (Mexican lime) identified fatty acids as the components responsible 
for activity, with MICs in the range of 25-50 g/mL for palmitic acid against 
M. tuberculosis H37Rv and three other mono-resistant strains of TB. Interestingly, this 
paper reported that the unsaturated fatty acids linoleic and oleic acid were slightly less 
active with MICs ranging from 50-100 g/mL. This study complements the results 
presented in this thesis, with the saturated acids identified as more active than the 
unsaturated, although the reported MIC for palmitic acid by the authors matches more 
closely to the observed IC50 of 66 g/mL described in this thesis [170]. 
4.4.4 General summary 
In general, current literature has suggested that unsaturated fatty acids tend to be more 
active than saturated ones. However, this work demonstrates that when looking at the 
activities of the fatty acids, palmitic acid, a C16 saturated fatty acid, displays greater 
activity than the C16 and C18 unsaturated fatty acids that have been tested.  
Also worth noting is the current view that cis fatty acids tend to be more active than 
trans fatty acids. When comparing the activities of cis-vaccenic to trans-vaccenic acids, 
this holds marginally true. However, the combinations of palmitic and trans-vaccenic 
acids gave the most effective IC50 value of all the different mixtures tested with a 
two-fold improvement in activity compared to the mixture of palmitic and cis-vaccenic 
acids.  
One trend that emerges from the literature is that unsaturated fatty acids tend to be more 
active against mycobacteria [171, 200, 201]. Assessing the inhibitory effects of fatty 
acids on mycobacteria has identified that for saturated FFAs, once the chain length 
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exceeds 14 carbons, the inhibitory effects decreases. This effect is overcome by 
introducing unsaturation within the chain [171]. 
There are conflicting views of the activity of palmitic acid against mycobacteria, 
nonetheless, this work identified fatty acids as moderate to weak inhibitors of 
mycobacteria, with palmitic acid causing the most inhibition. 
When reviewing the literature, invertebrates tend to be the major producers of 
secondary metabolites, which are utilised as a form of self-defence. Reports of 
secondary metabolites being produced by marine vertebrates are very rare, this can be 
seen by the paucity of reports from comprehensive reviews [89, 202, 203]. The most 
commonly reported classes of natural products from marine vertebrates are peptides and 
steroids. The peptide toxins grammistins were isolated from the soap fish  Grammistes 
sexlineatus [204]. From the dogfish shark Squalus acanthias, squalamine (41) and 
related aminosterols were identified, 41 is believed to be part of the host’s innate 
defence and was identified to have activity against Gram-positive and Gram-negative 
bacteria [205, 206]. Related to 41, is petromyzonamine disulfate (42), which was 
isolated from a sea lamprey along with two other migratory pheromones [207]. 
 
41 R1 = OH  R2 =  
42 R1 = OSO3Na  R2 =  
 
It is of no surprise therefore that the bioactive component of the blob fish liver extract 
was a mixture of primary metabolites, much like the examples of marine vertebrate 
derived compounds listed above. 
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Chapter 5       Rimarikiamide A from 
Latrunculia sp. 
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5.1 Background 
Screening the VUW MNP library identified the crude extract of a Latrunculia sponge 
(PTN_256C) as an active inhibitor against M. smegmatis and S. aureus at the screening 
concentration of 100 g/mL. The subsequent validation of the crude extract in 
M. tuberculosis H37Ra found it to be more active in H37Ra (MIC90 = 6.25g/mL), 
compared to M. smegmatis (MIC90 = 100g/mL) (Table 3.3). Bioassay-guided 
fractionation of this sponge led to the identification of a novel taurinated terpene with 
activity against cancer cells in vitro, in addition to other fractions with anti-
mycobacterial activity. This chapter describes the bioactivity, isolation and structure 
elucidation of the taurinated terpene. Furthermore this chapter gives an overview of 
taurinated marine natural products as well as known biological activities linked to the 
compounds.  
Taurinated marine natural products are common as the presence of taurine in marine 
organisms is ubiquitous [208, 209]. The bioactivity reported for most of the compounds 
is generally anti-cancer due to the common use of anti-tumor assays in screening for 
novel compounds. Using SciFinder® and MarinLit [210], a literature search was 
performed to identify published work on taurinated marine natural products. From this 
search it was evident that sponges predominate as a major source of taurinated 
compounds. Most instances of taurinated marine natural compounds tend to involve 
taurine groups linked to a long alkyl chain or long fatty acids. The focus of this 
literature review will be on marine natural products that have a taurine group attached 
via an amine functionality. Compounds where taurine has been completely incorporated 
into the backbone of the compound will not be discussed. The compounds discussed 
below are grouped based on the common functionalities and carbon skeletons they share. 
5.1.1.1 Taurinated fatty acid derivatives 
The taurinated compounds grouped in this class are either conjugates of fatty acids and 
taurine, or a major portion of their structure is derived from a fatty acid. A recent report 
highlighted the isolation of 2-heptadec-11-enamidoethanesulfonic acid (43), from a 
South China Sea sponge Axinella sp. [211]. The authors also re-isolated two known 
compounds 2-octadec-7-enamidoethanesulfonic acid (44) and 2-palmitamidoethanesulf-
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onic acid (45). Compound 45 was first isolated from a South China sea sponge 
Haliclona sp. [212]; there has been no reported bioactivity for any of these compounds.  
 
43 
 
 
44
45
Structurally related are two acylated taurine fatty acid derivatives, 
(all-Z-)-2-(icosa-5,8,11,14,17-pentaenoylamino)ethane sulfonic acid (46) from a star 
fish Certonardoa semiregularis, and 47 isolated from the sponge Erylus nobilis [213]. 
These two compounds were isolated guided by a brine shrimp lethality assay. An N-acyl 
taurine (48) was isolated from a sea urchin Glyptocidaris crenularis with a reported 
LD50 of 222 g/mL in a brine shrimp assay [214]. 
 
46 
 
47 
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48 
Irciniasulfonic acid B1 (49) and B2 (50), a mixture of two taurinated fatty acids isolated 
from a Japanese marine sponge Ircinia sp., restored sensitivity to vincristine in resistant 
cancer cells [215]. Taurolipids A (51), B (52), and C (53), isolated from the protozoa 
Tetrahymena [216],  have been reported to inhibit Clostridium perfringens sialidase 
enzyme (20 mU) by 50% at 140 and 110 pM  for 51 and 52, respectively [217]. This 
enzyme cleaves sialic acid from the cell surface and glycoproteins and has been 
implicated in virulence of bacteria [218].   
 
 
49 R=   
50 R=  
 
51 R1 = R2 = H 52 R1 = H, R2 = OH 53 R1 = R2 = OH 
Taurospongin A (54), an acetylenic lipid isolated from the Okinawan sponge 
Hippospongia sp., was shown to inhibit DNA polymerase and human 
immunodeficiency virus (HIV) reverse transcriptase [219]. Under normal settings, DNA 
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polymerase  plays a role in base excision repair, however, overexpression of variants 
of this enzyme have been linked to cancer [220]. 
 
54 
Carteriosulfonic acids A-C (55-57), isolated from a Carteriospongia sp. sponge 
collected in the Philippines, were shown to inhibit the kinase GSK-3, which is part of 
the Wnt signalling pathway. This pathway is involved in several human diseases 
including cancer [221, 222].  
 
55 R =  
 
56 R =  
 
57 R =  
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Tauro-pinnaic acid B (58), a novel taurinated fatty acid, was isolated from the 
Okinawan bivalve Pinna muricata. This compound displayed an IC50 of 90 M against 
cytosolic phospholipase A2, in a search for potential anti-inflammatory compounds 
[223]. 
 
 
58 
5.1.1.2 Bromopyrrole containing compounds 
This next set of seven taurinated compounds all contain a bromopyrrole functionality, 
with all but one compound also featuring guanidine. Tauroacidins A (59) and B (60), 
isolated from the Okinawan sponge Hymeniacidon sp., displayed inhibitory activity 
against EGF receptor kinase and c-erbB-2 kinase each with IC50 values of 20 g/mL 
[224]. The increased activity or overexpression of these kinases has been linked to 
different types of cancers [225]. 
 
59 
 
60 
 
Mauritamide A (61), was isolated from the Fijian sponge Agelas mauritiana [226], and 
congeners mauritamide B-D (62-64) were isolated from the Indonesian sponge 
A. linnaei [227]. Mauritamide D (64) lacks the commonly found guanidine moiety. 
None of the mauritamides have any bioactivity reported to date. 
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61 
 
62 
 
63 
 
64
 
Taurodispacamide A (65), isolated from a Mediterranean sponge A. oroides, displayed 
anti-histamine activity when tested in the guinea pig ileum assay [228]. Nagelamide H 
(66), isolated from an Agelas sp., exhibited antibacterial activity against 
Micrococcus luteus and Bacillus subtilis with respective MIC’s of 16.7 and 33.3 g/mL, 
in addition an IC50 of 46 M against protein phosphatase 2A was also reported [229]. 
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5.1.1.3 Aromatic compounds 
The taurinated compounds listed in this section contain aromatic functionalities as part 
of their structure. 2-[(Phenylacetyl)]aminoethanesulfonic acid (67), a conjugate of 
phenylacetic acid and taurine, was isolated from Colobometra perspinosa, an Australian 
crinoid, with a reported GI50 of 195 M against the MCF-7 breast-pleural effusion 
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adenocarcinoma cell line [230]. Pyridinebetaine B (68) was isolated from a Caribbean 
sponge, Agelas dispar [231].   
 
67 
 
68 
Secoadociaquinones A (69) and B (70), isolated from a Xestospongia sp. sponge from 
the Philippines, showed inhibitory activity against topoisomerase II [232]. This enzyme 
creates double strand breaks when uncoiling DNA during replication. Consequently, its 
activity is more prominent in actively replicating cells, such as cancer cells. As such, 
many cancer therapeutics target this enzyme [233].  
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70
Cribrostatin 7 (71), a novel taurinated isoquinoline derivative with an IC50 of 45 g/mL 
against human colon carcinoma (HCT 116) cells, was reported from a Petrosia sp. 
sponge, also collected in the Philippines [234].  
 
 
71 
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The heteroaromatic alkaloids nakijiamine C (72) and D (73), were isolated from an 
Okinawan sponge Suberites sp., with no reported bioactivity from these compounds 
[235]. Microxine (74), a taurinated purine derivative isolated from an Australian sponge 
Microxina sp., was reported to have inhibitory activity against cdc2 kinase with an IC50 
of 13 M [236]. This enzyme is involved in the cell cycle and its entry into mitosis 
[237].  
 
 
72 
 
73 
 
74
A trichostatin analogue, JBIR-110 (75) was reported from the marine sponge derived 
Streptomyces sp. strain RM72, with a reported IC50 value against HDAC1 of 74 M 
[238]. HDACs are involved in epigenetic activity; the enzyme is involved in condensing 
chromatin and therefore altering gene expression [239]. These types of inhibitors have 
been studied as potential anti-cancer agents [239]. From the sponge 
Leucetta microhaphis, the alkaloid (9E)-clathridine 9-N-(2-sulfoethyl) imine (76), was 
isolated [240]. 
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75 
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5.1.1.4 Miscellaneous taurinated compounds  
Mycosporine-taurine (77) was isolated from the sea anemone Anthopleura elegantissma 
in a study targetting compounds responsible for providing UV protection [241]. From 
the Okinawan ascidian Didemnidae sp., a novel chlorinated polyketide macrolide 
biselide D (78) was reported [242]. 
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5.1.1.5 Taurinated terpenoids 
This section highlights taurinated terpenes. Terpenes are linear or cyclised hydrocarbon 
chains comprised of repeating isoprene units. (+)-4-N-Methenetauryl-10-methoxy-
1,5,6,7-aromadendrane (79) and (-)-4-N-methenetauryl-10-methoxy-1,5,6,7
-aromadendrane (80), isolated from a South China Sea gorgonian coral 
Melitodes squamata, displayed inhibitory activity against B. subtilis and M. luteus at 
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25 g in a disk diffusion assay [243].  The bicyclic terpenoids, clathrimides A (81) and 
B (82), isolated from the sponge Clathria compressa [244], showed no activity against 
human embryonic stem cells (BG02), Gram-positive (Staphylococcus aureus including 
methicillin-resistant S.aureus) or Gram-negative (Escherichia coli and Klebsiella 
pneumonia) bacteria. 
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80 
 
81 R =  
82 R =  
 
Spongodine D (83), contains a pyridine functionality with inhibitory activity against 
human synovial phospholipase A2 (PLA2), and was isolated from a Vanuatu sponge 
Spongia sp. [245]. PLA2 is responsible for the release of free fatty acids, which are then 
metabolised to produce pro-inflammatory mediators [246]. Phorbasin D (84), a 
diterpene-taurine conjugate, was isolated from the Phorbas sp., Australian sponge. This 
compound was tested and reported as inactive against lung (A549) and breast (HT29 
and MDA-MB-231) cancer cell lines [247]. 
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Gukulenin E (85), a diterpene pseudo-dimer, was isolated from Phorbas gukulensis, a 
Korean sponge, with a reported LC50 of 0.32 and 0.11 M against K562 and A549 cell 
lines, respectively [248]. 
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5.1.1.5.1 Meroterpenes  
 
Meroterpenes are compounds that are of mixed biogenesis and contain a terpene 
attached to an aromatic functionality. Aplidone C (86) was isolated from the 
Mediterranean ascidian  Aplidium conicum and had no reported activity [249]. 
Siphonodictyal B1 (87) was isolated from a  Caribbean sponge, Aka coralliphagum, 
with  reported inhibitory activity against  S. aureus at 12 g/mL and cytotoxic activity 
against L929 mouse fibroblasts at 10 g/mL [250]. Nakijiquinone R (88), a 
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sesquiterpenoid quinone, was isolated from an Okinawan sponge belonging to the 
family Spongiidae. This compound displayed greater than 99% and 52% inhibition 
against EGFR and HER2 kinases at 1 mM, respectively [251].  
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Melemeleones A (89) and B (90) were isolated from the Solomon Islands sponge 
Dysidea avara. Melemeleone B displayed an approximate IC50 of 28 M in an assay 
against the pp60v-src PTK, a tyrosine kinase [252]. Tyrosine kinase inhibitors are 
important in the treatment of cancer progression [253]. An anti-inflammatory 
sequiterpene dysidine (91), was isolated from a Dysidea sponge from Vanuatu. This 
compound was shown to inhibit the activity of human synovial PLA2, with an IC50 of 
2.0 M [254].  
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5.1.1.6 Taurinated sterols 
The next set of six compounds are taurinated sterols, which have all been isolated from 
starfish. From Myxoderma platyacanthum, (92) and (93) were isolated [255].  
(20R,22E,24R,25S)-24-Methyl-3,6,8,15-tetrahydroxy-5-cholest-22-en-27-oic acid 
(94), was isolated from Astropecten triseriatus [256]. Minutoside B (95), isolated from 
Anasterias minuta, had inhibitory activity against Aspergillus flavus at concentrations 
between 20-60 g/mL in a disk diffusion assay [257].  Novaeguinosides B (96) and D 
(97), were isolated from Culcita novaeguineae, with reported  IC50 values of 7.9 and 9.5 
M against K-563 and BEL-7402 cell lines for 96 and 4.6 and 4.1M for 97 [258].  
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92 R =  
93 R =  
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94  R1 = R2 = H R3 = OH, sat. 
R4 =  
95  R1 =   
R2 = H R3 = OH, sat. 
R4 = 
96  R1 = SO3Na  
R2 =  
R3 = H, 
R4 = 
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5.2  Methods 
5.2.1 Extraction of sponge material 
Latrunculia sp. (350 g), was cut into ~1 cm3 sized pieces and extracted twice in 
methanol (450 mL). The two extracts were treated separately and filtered using a 
Büchner funnel and Celite. The second extract was passed through an HP20 column 
(140 mL) followed by the first. The eluents were combined and diluted two-fold with 
H2O before passing through the same column again. This was repeated until the original 
MeOH extract was diluted to 12.5% and passed through the column. Following this 
cyclic loading, the column was eluted with 420 mL volumes of 20%, 40%, 60%, 80% 
and 100% acetone in water. The 40% fraction was further fractionated using a 15 mL 
column of HP20ss resin, the column was eluted with 45 mL volumes of 50%, 60%, 
70%, and 80% MeOH and H2O solvent mixtures as well as 100% MeOH and 100% 
acetone. Following this, the 80% MeOH/H2O fraction was further purified using 
reversed-phase C18 semi-preparative column (Phenomenex Prodigy, 10.0 x 250 mm, 10 
m particle size), 35% acetonitrile/H2O at 4 mL/min. From the resulting fractions, 
ND4_34D and E were pooled together to give rimarikiamide A (98), (200 g) (Scheme 
5.1). Quantification of samples lower than 1 mg was performed as described in section 
2.7. 
Based on this initial isolation, a repeat isolation was attempted, using the remaining 
sponge sample. As the structure of rimarikiamide A had already been elucidated from 
the first isolation, it was evident that the lack of a chromaphore would make a repeat 
isolation via HPLC problematic. Therefore size exclusion chromatography using LH20 
was attempted using a 100 mL column, eluting with 100% MeOH to give rimarikiamide 
A (98) (133.7 g).  
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5.2.2 Isolation schemes for rimarikiamide A 
 
Scheme 5.1 Original isolation scheme for rimarikiamide A (98) from Latrunculia sp. 
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Scheme 5.2 Optimised isolation scheme for rimarikiamide A (98) from Latrunculia sp. 
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5.3  Results 
Using the methodology described in section 2.6, the results of the dose-response assays 
for rimarikiamide A are listed below. Graphs were generated using GraphPad Prism 
v.5.0. Resazurin dye was used to measure bacterial metabolism after each assay was run 
and RFU measurements were used as a measure of growth. OD was used as measure of 
growth for the HL-60 and HEK MTT assays. Where possible IC50 values have been 
listed, however as sigmoidal curves were not achievable for all data MIC90 values have 
been listed. 
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5.3.1 Antimicrobial activity 
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Figure 5.1  Loss of anti-mycobacterial activity of rimarikiamide A 
(A), dose response curve illustrating the loss of activity of rimarikiamide A. (B), dose 
response curve of the active fraction ND4_47D. RFU units were used as a measure of 
growth. 
(n=1, duplicate) 
 
5.3.2 Mammalian cell line assays 
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Figure 5.2 Rimarikiamide A vs human cell lines 
MTT assay of ND6_96L against HL-60 (A) and HEK cell lines (B). The HEK cell line 
was used as an indication of general cytotoxicity. OD was used as a measure of growth.  
(n=1, duplicate) 
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5.4  Discussion 
5.4.1 Fractionation and isolation 
Guided by bioassays against M. tuberculosis H37Ra, an initial crude fractionation using 
HP20 (PSDVB) column chromatography was performed, with the 40% acetone/H2O 
fraction taken to the next stage of purification (Scheme 5.1). HP20ss (PSDVB) column 
chromatography was used to further purify this fraction culminating with reversed-
phase C18 semi-preparative HPLC to purify the final bioactive fraction rimarikiamide A 
(200 g) (Scheme 5.1). 
To isolate more compound, the second half of the sponge was extracted and fractionated 
to the point of collecting the HP20ss 80% MeOH/H2O fraction (Scheme 5.2). As we 
could not rely on HPLC to guarantee the isolation of the compound due to the lack of a 
suitable chromophore, LH20 size exclusion chromatography was employed for the next 
stage of purification. Following size exclusion chromatography, the fractions of the 
second work up of the original sponge were combined based on TLC, and tested for 
activity (Scheme 5.2). This identified that the taurinated-compound initially believed to 
be responsible for activity was not the source of anti-mycobaterial activity, which can 
be observed when comparing the dose response curve of rimarikiamide A (98) to 
ND4_47D (Figure 5.1).  
5.4.2 Structural elucidation 
Negative ion HRESIMS was used to detect an [M-H]- ion at m/z 428.2469, which was 
suitable for the molecular formula C22H39NO5S (calcd m/z 428.2471, Δ = 0.0002), 
requiring four double bond equivalents. Both 1H and multiplicity edited HSQC NMR 
spectra in d6-DMSO revealed that 36 of the 39 protons were attached to 18 carbons, 
including five methines (C 124.5, 124.2, 121.3, 76.0, 29.8), eight methylenes (C 50.7, 
43.2, 39.3, 36.3, 35.5, 33.9, 26.2, 24.5), and five methyls (C 25.6, 19.4, 17.6, 16.1, 
11.3). The remaining four carbons in the molecule were quaternary carbons, which 
included an ester or amide carbonyl (C 171.0) and three olefinic carbons (C 137.4, 
134.9, 130.6). The three remaining protons were therefore exchangeable. The presence 
of an ester or amide and three olefinic methines accounted for all the double bond 
equivalents required by the molecular formula, therefore the molecule must be linear. 
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COSY and HMBC correlations established the connectivity for most of the structure. 
The terminal methyls (CH3-16: C 25.6, H 1.63); (CH3-20: C 17.6, H 1.55) showed 
HMBC correlations to the olefinic quaternary carbon C-15 (C 130.6) and its 
neighbouring olefinic methine C-14 (C 124.2, H 5.06). This was further supported by 
allylic COSY correlations from H3-16 and H3-20 to H-14. H-14 in turn showed a COSY 
correlation to the methylene proton resonances of C-13 (C 26.2, H 2.00), which in turn 
correlated to methylene C-12 (C 39.3, H 1.91). This established the first substructure 
below (Figure 5.3). 
 
Figure 5.3 Key COSY and HMBC correlations establishing substructure 1 
HMBC correlations from the methyl CH3-19 (C 16.1, H 1.54) to the olefinic methine 
C-10 (C 121.3, H 5.04), quaternary C-11 (C 134.9) and methylene C-12 helped 
further extend the substructure. This was further supported by HMBC correlations from 
C-12 to C-10, C-11 and C-19. COSY correlations observed from H-10 to H2-9 (C 33.9, 
H 2.08), H2-9 to the C-8 methine (C 76.0 H 3.77) and finally an allylic COSY 
correlation from H2-12 to the olefinic methine H-10 helped extend the substructure 
(Figure 5.4). 
 
Figure 5.4 Key COSY and HMBC correlations establishing substructure 2 
The chemical shifts of the C-8 methine (C 76.0,  3.77) were characteristic of a 
carbinol centre. Fortuitously a COSY correlation from H-8 to an exchangeable proton of 
an alcohol group (H 4.59) further supported the presence of this functional group 
(Figure 5.5).  
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Figure 5.5 Key COSY and HMBC correlations establishing substructure 3 
The substructure was extended by HMBC correlations from methyl CH3-18 (C 11.3 
H 1.51), to C-8, quaternary alkene C-7 (C 137.4) and olefinic methine C-6 (C 124.5 
H 5.22), and given the H3-18 is a singlet, it must be attached to C-7. This was 
supported by HMBC correlations from H2-9 to C-7. COSY correlations from H3-18 to 
the olefinic methine C-6, from H-6 to the methylene CH2-5 (C 24.5 H 1.95), and from 
H2-5 to CH2-4 (C 36.3 H 1.13, 1.26), supported by HMBC correlations from H-5 to C-
4, C-6 and C-7 allowed the addition of a further subunit to the proposed substructure 
(Figure 5.6). 
 
 
Figure 5.6 Key COSY and HMBC correlations establishing substructure 4 
HMBC correlations from the methyl doublet CH3-17 (C 19.4 H 0.82) to the methine 
CH-3 (C 29.8 H 1.82), methylenes CH2-4 and CH2-2 (C 43.2 H 1.81, 2.02) in 
addition to COSY correlations from H3-17 to H2-2 and H-3 and from H2-2 to H-3 
extended the established alkyl chain. This was further supported by HMBC correlations 
from H-3 to C-4 and C-17 as well as from H2-2 to C-3, C-4 and C-17 (Figure 5.7). 
 
Figure 5.7 Key COSY and HMBC correlations establishing substructure 5 
Further HMBC correlations from H2-2 and H-3 to the C-1 carbonyl (C 171.0), in 
addition to the HMBC correlations of the C-21 methylene (C 35.5 H 3.27), to C-1, 
helped assign the position of the carbonyl carbon. The chemical shifts of CH2-21 and of 
C-1 (C 171.0) were indicative of an amide functionality, supported by a COSY 
correlation from H2-21 to the exchangeable amide proton (H 7.68). HMBC correlations 
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from the exchangeable amide proton to C-1 and COSY correlation from H2-21 to H2-22 
(C 50.7 H 2.50) further extended the carbon skeleton (Figure 5.8). 
 
 
Figure 5.8 Key COSY and HMBC correlations establishing substructure 6  
The substructure established to this point accounted for all the carbons required by the 
molecular formula, leaving SO3H. As all branching termini had been accounted for, the 
SO3H group must be attached to C-22 (C 50.7), which would account for the downfield 
shift of this carbon resonance. 
To confirm the geometry of the alkenes, a 2D ROESY experiment was performed, to 
determine the spatial positions of the methyls. The chemical shifts of the olefinic 
methyls C-18, C-19 and C-20 (C 11.3, 16.1 and 17.6) were indicative of E rather than Z 
geometries, which would have approximate chemical shifts of 25.0 ppm [259], this 
further confirmed the proposed E geometry for the alkenes in rimarikiamide A (98) 
(Figure 5.9). The planar structure of 98 was therefore as shown in Figure 5.9. 
 
Figure 5.9 Key ROESY correlations establishing the alkene geometry of 
rimarikiamide A (98). 
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Table 5.1 1H (600 MHz) and 13C (150 MHz) NMR data (d6-DMSO) for 
rimarikiamide A (98). 
 
98 
Position C 
1JCH 
(Hz) H (J in Hz) COSY HMBC 
1 171.0 
    2a 43.2 122 1.81 m, 1H 2b,17 1,3,4,17 
2b 
 
120 2.02 m, 1H 2a,3,17 1,3,4,17 
3 29.8 122 1.82 m, 1H 2b,17 1,4,17 
4a 36.3 121 1.13 m, 1H 4b,5 
 4b 
 
122 1.26 m, 1H 4a,5 
 5 24.5 122 1.95 m, 2H 4,6 4,6,7 
6 124.5 152 5.22 (t,7.0 Hz, 1H) 5,18 8,18 
7 137.4 
    8 76.0 142 3.77 (dd, 4.1, 6.5 Hz, 1H) 8-OH,9 
 9 33.9 122 2.08 (t, 6.7 Hz, 2H) 8,10,19 7,8,10,11 
10 121.3 153 5.04 m, 1H 9,12,19 12,19 
11 134.9 
    12 39.3 122 1.91 s, 2H 10,13 10,11,13,14,19 
13 26.2 113 2.00 m, 2H 12,14,16,20 12,14,15 
14 124.2 151 5.06 m, 1H 13,16,20 
 15 130.6 
    16 25.6 125 1.63 s, 3H 13,14,20 14,15,20 
17 19.4 120 0.82 (d, 6.1 Hz, 3H) 2a,b,3 2,3,4 
18 11.3 123 1.51 s, 3H 6 6,7, 8 
19 16.1 125 1.54 s, 3H 9,10 10,11,12, 
20 17.6 126 1.55 s, 3H 14,16 14,15,16 
21 35.5 142 3.27 m, 2H 1-NH,22 1,22 
22 50.7 134 2.50 m,2H 21 21 
1-NH 
  
7.68 (t, 5.8 Hz, 1H) 21 1 
8-OH 
  
4.59 (d, 4.0 Hz, 1H) 8 9 
 
Unfortunately, a lack of material at this point prevented establishing the configuration 
of the C-8 alcohol and C-3 methyl positions. The distance between C-8 and CH3-17 as 
well as the flexible nature of the chain prevented the relative configuration from being 
established. Thus, the configurations of C-3 and C-8 remain unknown. 
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One possible method to elucidate the configuration is through the use of electronic 
circular dichroism (ECD). When looking at the structure of 98 the two chiral centers (C-
3 and C-8) give rise to four possible diastereomers as part of two enatiomeric pairs 
(RR/SS and RS/SR). The ECD curves could be predicted for each of the four possible 
configurations and compared to the actual curve of 98. This would allow us to deduce 
the absolute configuration of the natural product [260]. However as there is no CD 
instrument available at VUW this approach was not possible. It should also be noted 
that calculating ECD spectra can lead to erroneous data when dealing with flexible 
molecules, where different conformers can give enatiomeric spectra [261]. Therefore 
the best way to elucidate the absolute configuration would be through the synthetic 
route.  
5.4.3 Biogenesis 
 
As rimarikiamide A is a novel taurinated diterpene, a biogenesis of (98) is proposed 
below. The two main building blocks to the terpenes are dimethylallyl pyrophosphate 
(DMAPP) and isopentenyl pyrophosphate (IPP), which could be products of the 
mevalonate pathway or the mevalonate-independent pathway [262]. DMAPP and IPP 
are condensed together by geranyl diphosphate synthase to give geranyl diphosphate 
(GPP) [262]. GPP and IPP are then condensed by farnesyl diphosphate synthase to 
generate farnesyl diphosphate (FPP), which is further condensed with IPP to give 
geranylgeranyl diphosphate (GGPP) [262]. GGPP is proposed to be hydrolysed to 
generate the alcohol geranylgeraniol, which is oxidised to produce the carboxylic acid. 
At this point a thioesterase could act upon the carboxyl to generate a thioester. The next 
step could involve the reduction of the double bond closest to the carbonyl via a 
reductase. Following this the oxidation of the C-8 carbon after the second isoprene unit 
could occur, introducing the hydroxyl functionality. The last two aforementioned steps 
could also occur in the opposite order, without a directed study there is no clear way of 
stating which step comes first. A final taurination step where taurine replaces the 
thioester linked enzyme is proposed to generate 98 (Figure 5.10). Compared to all the 
described taurinated terpenoids in section 5.1.1.5, 98 is a simple linear diterpene, 
without any cyclisation or any aromatic constituents. The simplicity of the molecule 
would mean a synthetic route should be fairly plausible, which would allow for the 
absolute configuration to be resolved. 
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Figure 5.10 Proposed biogenesis of rimarikiamide A (98). 
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5.4.4 Reported compounds from Latrunculia sp. 
To date, a range of compounds have been isolated from Latrunculia sponges of these, 
four classes emerge as the most common, these are the latrunculins, trunculins, 
discorhadbins and callipeltins. 
The latrunculins are a class of actin depolymerizing agents [263]. Latrunculin A (99) 
and B (100), isolated from Latrunculia magnifica, later re-classified as Negombata 
magnifica [264], have displayed cytotoxic effects on cell lines at sub-micromolar 
concentrations [265]. Studies indicate 99 binds to G-actin monomers [266], and both 99 
and 100 have been shown to modulate actin stress filaments, altering the cytoskeleton 
and affecting cell morphology [267]. 
 
99 
 
100
Trunculins A (101) and B (102) were isolated from an Australian Latrunculia sp. later 
re-classified as either Dicarnus or Sigmaceptrella sp. [264],  and were active against 
Bacillus subtilis as well as Saccharomyces cerevisiae  [268]. 
 
101 R = H 
102 R = CH3
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The discorhabdins belong to a class of compounds termed pyrroloiminoquinones, these 
molecules have displayed various bioactivities such as antibacterial, anti-viral, anti-
malarial, cytotoxic and anti-tumour activity [269]. The highly potent low micro- to 
nano-molar level of activities of these compounds made them of high interest, however, 
the lack of selectivity of these compounds prevented them progressing as anti-cancer 
agents [269]. These compounds have also displayed activity against M. tuberculosis in 
addition to a range of Gram-positive and Gram-negative bacteria [269].   Below is the 
structure of discorhabdin C (103) the first reported discorhabdin, isolated from a New 
Zealand Latrunculia sp. [270]. For further information on this class of compounds, 
please refer to two extensive reviews by Hu et al. and Antunes et al.  [264, 269]. 
 
103 
Callipeltins F-I are peptides isolated from Latrunculia sp. from Vanuatu which have 
been have been reported to have anti-Candida activity at 1 mM [271]. Below is the 
structure of Callipeltin F (104). 
 
104 
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As these four classes of molecule represent the four most common classes of 
compounds isolated from Latrunculia sp., it is possible that very low levels of any of 
these compounds could be responsible for the anti-tubercular activity. To identify if any 
of these compounds were present in the bioactive fractions, 1H NMR signals of 
ND4_47D+E were compared to identify signature resonances to indicate the presence of 
any of these compounds. However, none of the diagnostic signals for any of these 
compounds were identifiable in the 1H NMR spectra of the active fraction (Figure 5.11). 
 
Figure 5.11 1H NMR (CD3OD, 600 MHz) spectrum spectra of ND4_47D+E. 
 
 
5.4.5 Bioactivity 
With only minimal amounts of 98 remaining, and with no anti-mycobacterial activity 
linked to this compound, it was decided to investigate the effects of this compound in 
mammalian cell line assays. Comparison of IC50 data from the HL-60 and HEK cell line 
assays indicated an interesting result. HL-60 cells were chosen to represent cancer cells, 
while HEK cells were chosen to exhibit the general mammalian cytotoxic effects of the 
compound. The effectiveness of compounds can be judged by their therapeutic index 
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(TI), which is the general cytotoxicity divided by the desired activity. Therefore, the 
IC50 value in HEK cells (61.1 M) divided by the IC50 in HL-60 cells (9.8 M) would 
identify a rough therapeutic index of 6 for rimarikiamide A (Figure 5.2). This is 
indicative of specificity for in vitro anti-cancer activity compared to generic toxicity. TI 
is an indicator of the potential of drug candidates [272]. High TI’s are generally ideal at 
the early stages of drug development to avoid progression of candidates that may fall 
out further downstream of the development process [272]. As a compound may have an 
ideal TI value in vitro, in vivo higher levels of the compound may be required, which 
could lead to undesired side effects, thus over interpretation of the TI value should be 
cautioned [272]. Compounds can be modified to allow for improvements in the TI. 
However the lack of sufficient compound meant that any further work such as 
mechanism of action studies could not be performed. 
5.4.6 Future work 
To carry out further studies of the bioactivity of rimarikiamide A, more compound will 
be required, and identifying an efficient route for synthesis will aid in this avenue of 
research. However, before any future work can be done, the relative and absolute 
configuration of the molecule must be elucidated. Pursuing the synthetic route to 
generate two of the possible four stereoisomers and comparing optical rotation data and 
NMR spectra of the synthesized compound to that of the natural product will confirm 
the planar structure and will establish the configuration of the natural product. These 
studies are currently underway in our laboratory. 
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Chapter 6       3-Epi-xestoaminol C 
from Xiphophora chondrophylla. 
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6.1  Background 
Screening the VUW_MNP extract library also identified a brown alga Xiphophora 
chondrophylla as a hit, which displayed inhibitory activity against all three species of 
bacteria that were screened (Figure 3.3). Since the crude extract displayed similar levels 
of activity against M. tuberculosis H37Ra (MIC90 ≥200 g/mL) as M. smegmatis 
(MIC90 ≥200 g/mL) (Table 3.3), the fractionation process was guided by assays 
against M. smegmatis. As stated earlier, the strain of M. smegmatis used allows for 
faster assay times and the kanamycin resistance marker allows for antibiotic use to 
overcome contamination issues. Once the bioactive compound was isolated, the goal 
would be to validate it against M. tuberculosis H37Ra and, should it prove potent 
enough, its activity against clinical isolates would also be analysed. The compound’s 
cytotoxic activity against mammalian cell lines would also be studied to evaluate its 
potential as an anti-tubercular drug. This work led to the isolation of a new 
1-deoxysphingoid, a class of molecules also known as 2, 3 amino alcohols. This chapter 
discusses the isolation and structure elucidation of the new amino alcohol as well as 
early mechanism of action studies. In addition, an overview of marine derived amino 
alcohols as well as known biological activities linked to these compounds is also 
described.  
6.1.1 Marine derived amino alcohols 
Amino alcohols or 1-deoxyshpingoids are a class of compounds that contain hydroxyl 
and amino functional groups on hydrocarbon chains of a lipid. Their isolation has 
predominantly been associated with tunicates [273-282]. The range of activities these 
compounds have displayed include anti-cancer, antimicrobial and anti-fungal activities 
[273-282]. The first reported isolation of an aliphatic amino alcohol was from a 
Xestospongia sp. sponge [283] followed by the isolation of xestoaminols from another 
Xestospongia [284]. Of all the reports to date, the isolation of aliphatic amino alcohols 
from marine algae is unprecedented. 
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6.1.1.1 Alkyl chains with varying levels of 
unsaturation 
This section describes amino alcohols with varying alkyl chain lengths and unsaturation 
levels, which represent the most common class of amino alcohols. The first reported 
isolation of aliphatic amino alcohols was in 1988, with 2-(S)-aminotetradecan-5,7-dien-
3-(S)-ol (105) and 2-(S)-aminotetradecan-5,7-dien-3-(R)-ol (106) from a Papua-New 
Guinea Xestospongia sp. sponge. These compounds possessed inhibitory activity 
against Candida albicans at 19 g/mL in a disk diffusion assay [283]. Similarly another 
group of aliphatic amino alcohols, xestoaminols A-C (107-109) were isolated from a 
Fijian Xestospongia sp.. Compound 107 displayed activity against the bacteria S. aureus, 
S. pyogens and E. coli, and the fungi C. albicans and Trichphyton mentagrophytes in 
disk diffusion assays at 100 g/mL. In addition, both 107 and 109 displayed extremely 
weak inhibitory activity in a reverse transcriptase assay at 1 mg/mL [284]. 
 
105 
 
106 
 
107 R =  
108 R =   
109 R =  
(2S, 3R)-2-Aminododecan-3-ol (110) was reported from the ascidian Clavelina oblonga 
and displayed anti-fungal activity against C. albicans with an MIC of 0.7 g/mL [273]. 
Crucigasterins 277, 275 and 225 (111-113) were first isolated in 1993 from a 
Mediterranean tunicate Pseudodistoma crucigater with moderate activity reported 
against L1210, B. subtilis  and S. cerevisiae [277].   
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113
Crucigasterins A-E (114-118) were also isolated from P. crucigater, with 115 
displaying the best activity of 50 g/mL against E. coli and C. albicans, while 118 was 
active at 100 g/mL against E. coli [276].  
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115 
 
116 
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Closely related to the crucigasterins are the haloaminols A-C (119-121), isolated from a 
Haliclona sponge from the Great Barrier Reef, which have been reported to inhibit the 
growth of E. coli, B. subtilis, C. albicans, T. mentagrophytes and C. resinae [285]. The 
researchers also identified haloaminol D (122) isolated as the N-acetyl derivative. 
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119 
 
120 
 
121 
 
122
Obscuraminols A-F (123-128), also closely related to the crucigasterins and 
haloaminols, were isolated from the ascidian Pseudodistoma obscurum. These 
compounds were reported to be active against P388, A-549 and HT-29 cell lines with 
IC50 values of 0.5, 0.2 and 0.5 g/mL respectively [278].    Haloaminol D and 
Obscuraminol A are in fact the same compound, however 122 was initially isolated as 
the N-acetyl derivative only four months prior to the isolation of 123. 
 
 
123 
 
124 
 
125 
 
126 
 
127 
 
128
121 
 
Clavaminols A-F (129-134) were isolated from the ascidian Clavelina phlegrae. The 
most potent of these aliphatic amino alcohols, 129, had an IC50 value of 5 g/mL 
against a gastric tumour cell line (AGC cells), lung cancer cell line (A-549) and a breast 
cancer cell line (T47D). In addition, 129 was shown to inhibit cell growth by inducting 
apoptosis in the G1-S phase of the cell cycle in Jurkat cells [275].  
 
129 R1 = NH2 R2 = H R3 =   
130 R1 = NH2 R2 = H R3 =   
131 R1 = NHAc  R2 = H R3 =   
132 R1 = NHAc  R2 = H R3 =   
133 R1 = NHAc R2 = H R3 =   
134 R1 = NH2 R2 = Ac R3 =   
 
The final example in this class of amino alcohols, spisulosine or ES-285 (135), has 
drawn much interest. Initially isolated from the marine mollusc Spisula polynyma, this 
compound has drawn major interest due to its activity against solid tumours such as 
colorectal, renal and prostate tumors, amongst others, for which it progressed to phase 1 
clinical trials [286-289].   
 
135 
The first trial indicated doses ranging from 4-128 mg/m2 were manageable and showed 
no dose limiting toxicities. However, at 256 mg/m2 one of the four patients receiving 
treatment displayed neurotoxicity, a side effect responsible for the fatality of one of the 
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three patients treated at 200 mg/m2. Overall this study reported that at 128 mg/m2 
patients achieved desired pharmacokinetic and pharmacogenetic changes [289]. 
In all the clinical trials, only moderate anti-tumor activity was observed, in addition to 
side effects which included elevated hepatic and neural toxicities, anaemia, 
lymphopenia, asthenia and nausea. This led to the discontinuation of the clinical 
development of this compound [286-288]. 
The mode of action for 135 has not been fully elucidated, although the research to date 
proposes that the compound may work through multiple pathways. The induction of cell 
death in vitro has been shown to occur as a result of disruption of actin cell fibres; this 
destabilization of the cytoskeleton has been shown to not affect the microtubules of 
cells [290]. The activation of caspase 3 and 12, the phosphorylation of p53 and the 
activation of isoforms of protein kinase C (PKC) have all been shown to induce atypical 
cell death [291]. Further work in a prostate cancer cell line PC-3 focusing on the effects 
of spisulosine on PKC indicated the activation of the isoform PKC [292], increasing 
ceramide levels, which has been linked to induction of apoptosis [293-295]. The most 
recent research has focused on how ES-285 affects ceramide levels in MDA MB 468 
breast cancer cells. Treating cells with the compound, as well as analogues, caused an 
increase in N-C18 1-deoxyceramide levels, indicating ES-285 as the preferred substrate 
for acylation [296], a quality that identifies this compound as a probe for ceramide 
synthase activity.  
6.1.1.2 Cyclised amino alcohols 
This section describes the limited number of amino alcohols that contain cyclic 
structures. The pseudodistomins A (136) and B (137), isolated from the tunicate 
Pseudodistoma kanako in 1986, represent the first amino alcohols to be reported. These 
cyclic piperidine alcohols inhibited the growth of mouse leukaemia cell lines L1210 
with IC50  values of 2.5 and 0.4 g/mL, and L5178Y with values of 2.4 and 0.7 g/mL, 
respectively [280, 297]. Pseudodistomin C (138) was later isolated from P. kanoko, with 
reported activity against the L1210 cell line and a human epidermoid carcinoma (KB 
cells) with IC50 values of 2.6 and 2.3 g/mL, respectively.  Shortly after, 
pseudodistomins D-F (139-141) were reported from the ascidian P. malgrava [281]. In 
addition to the re-isolation of 137 and 138, the authors reported the activity of 137-141 
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against S. cerevisiae at a range of concentrations between 110-200 g/mL in a zone of 
inhibition assay [281]. 
 
136 A R = R1, 137 B R = R2, 138 C R = R3, 139 D R = R2, 140 E R = R2, 141 F R = R3 
Containing a fused bicyclic ring as part of the linear chain, amaminols A (142) and B 
(143) were reported from a tunicate belonging to the family Polyclinidae, with IC50 
values of 2.1 g/mL  against P388 murine leukaemia cells [274]. 
 
142 R =  143 R =  
 
6.1.1.3 , -Double headed amino alcohols 
This section covers compounds with amino alcohol polar head groups at both ends of 
the chain. Leucettamols A (144) and B (145) were isolated from the sponge 
Leucetta microraphis, with moderate activity reported against B. subtilis [298]. 
Leucettamol A was recently reported to inhibit the interaction of Ubc13 with Uev1A, 
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with an IC50 of 50 g/mL. This inhibition is believed to increase p53 levels and 
therefore makes an ideal target for anti-cancer agents, [299].  
 
144 
 
145
BRS1 (146),  isolated from an Australian calcareous sponge, is very closely related to 
the leucettamols, with reported inhibition of PKC activity with an EC50 of 98 M [300]. 
The final example for compounds belonging to this group is rhizocalinin B (147), 
isolated from a North-Western Australian sponge Oceanapia sp. with no reported 
bioactivity [301].  
 
 
146 
 
147
In addition to having the bis-amino alcohol head groups, the compounds listed below 
also contain carbohydrates as part of their structure. Rhizochalin (148) was isolated 
from a Madagascan sponge Rhizochalina incrustata with reported inhibitory activity 
against S. aureus [302]. Rhizochalinin A (149), also isolated from R. incrustata, is a 
sphingolipid aglycone that has anti-leukemic activity against human monocytic THP-1 
cells, with a reported IC50 of 7.5 M [303]. Rhizochalin B (150) was isolated from a 
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North-Western Australian sponge Oceanapia sp. [301], while rhizochalins C (151) and 
D (152) were isolated from R. incrustata [304]. There has been no reported activity for 
rhizochalins B-D.  
 
 
148 
 
149 
 
150, 151, 152,  
 
Isorhizochalin (153) is an epimer of rhizochalin also isolated from R. incrustata, 
although no bioactivity has been linked to this compound [305]. 
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153 
Oceanapiside (154), another sphingolipid, was isolated from the South Australian 
sponge Oceanapia phillipensis. This compound varies from the rhizochalins near the 
terminus that contains the glucose, with true sphingosine head-group unlike that found 
in the rhizochalins. Oceanapiside has a reported MIC of 10 g/mL against Candida 
glabrata [306]. 
 
154 
Calyxoside (155) isolated from a Calyx sponge is a sphingolipid that was reported to 
have inhibitory activity in rad 52 and 51 knock outs of S. cerevisiae strains at 62 and 
36 g/mL, respectively, in a zone of inhibition assay. In addition, it has reported 
activities against the HFF, MRC-5, SW480, HT-29, Saos-2, DLD-1 and H460 cell lines 
with IC50 values between 3-20 g/mL [307]. It also contains a formal sphingosine head. 
 
155 
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6.2  Methods 
6.2.1 Extraction of algae 
Xiphophora chondrophylla (300 g) was extracted twice with  methanol (MeOH, 400 mL) 
that was cyclic loaded onto a 120 mL HP20 column, following which the column was 
eluted with 360 mL mixtures of 20%, 40%, 60%, 80% and 100% acetone in water. 
Except for the 100% acetone, all other fractions were back loaded onto 60 mL columns 
and eluted with 180 mL of MeOH followed by 180 mL of acetone, fractions were dried 
down in vacuo and transferred to pre-weighed vials. Based on bioactivity, the 40% 
acetone fraction was further pursued, half of the mass (350 mg) was fractionated using a 
40 mL HP20ss column, eluting with 120 mL of 30%, 40%, 50%, 60%, 80% and 100% 
mixtures of MeOH in H2O; the 30%-60% fractions were collected in test tubes. Guided 
by bioassays, test tubes 43-46 (50% MeOH fractions, 17.8 mg) were fractionated a 
further three times using LH20 size exclusion chromatography using 90% MeOH/H2O. 
The final fractionation was performed using a 1 mL DIOL column and eluted with 3 mL 
volumes of 0%, 25%, 50%, 75% and 100% mixtures of ethyl acetate (EtOAc) in 
hexanes followed by 25%, 50%, 75% and 100% MeOH in EtOAc, finally the column 
was stripped with 50% and 75% H2O in MeOH to give 3-epi-xestoaminol C (156) (0.9 
mg). 
Based on the results of the initial isolation, an optimised method was used on the second 
half of the 40% acetone fraction. The remaining 40% HP20 fraction (350 mg) was 
separated on a 30 mL DIOL column, eluting with 90 mL volumes of 0%, 25%, 50%, 75% 
and 100% mixtures of EtOAc in hexanes followed by 25%, 50%, 75% and 100% 
MeOH in EtOAc, finally the column was stripped with 50% H2O in MeOH. The 0%, 25% 
and 50% EtOAc in hexanes and 25%, 50%, 75% and MeOH in EtOAc elutions were 
collected in test tubes. Test tubes 47-50 (25% MeOH/ EtOAc) were pooled together 
(248.1 mg) and separated further on a 25 mL DIOL, eluting with 75 mL volumes of the 
same solvent mixtures for the earlier column. 1H NMR identified test tubes 6-13 to 
contain 3-epi-xestoaminol C, the combined mass (185 mg) was dissolved in 
dichloromethane and partitioned against 1 M HCl, the organic layer was collected and 
dried, the acidic aqueous layer was then neutralised with 1 M NaOH and this was 
partitioned against dichloromethane again. Following the HCl and NaOH washes, a 
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total of 117 mg was isolated, which was divided into thirds and fractionated on three 
DIOL columns using the same eluting conditions for all columns, 0%, 50% and 100% 
mixtures of EtOAc in hexanes (collected in bulk) followed by 25%, 50% and 100% 
MeOH in EtOAc (collected in test tubes), finally the column was stripped with 50% 
H2O in MeOH. This afforded a total of 58 mg of 3-epi-xestoaminol C (156) (test tubes 
5-7). 
3-Epi-xestoaminol C: []25D -6.19 (c 0.42, CHCl3); IR max 3367, 2954, 2871, 1602 cm-1; 
CD3OD NMR data see Table 6.2; 
1H NMR (CDCl3, 600 MHz) 3.65 (1H, t, J = 8.5 Hz, 
H-3), 3.32 (1H, m, H-2), 1.56 (1H, m, H-4b), 1.53 (1H, m, H5-b), 1.40 (1H, m, H-4a), 
1.38 (3H, d, J = 6.6 Hz, H-1), 1.35 (1H, m, H-5a), 1.27 (2H, m, H-13), 1.25 (14H, m, H-
6 to H-12), 0.88 (3H, t, J = 7.0 Hz, H-14); 13C NMR (CDCl3, 150 MHz) 73.0 (C-3), 
53.3 (C-2), 33.6 (C-4), 32.1 (C-12), 29.88-29.52 (C-6 to C-11), 25.5 (C-5), 22.9 (C-13), 
15.8 (C-1), 14.3 (C-14) ; HRESIMS m/z 230.2467 [M+H]+ (calcd for C14H32NO, 
230.2478).  
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6.2.2 Isolation schemes for 3-epi-xestoaminol C (156) 
 
Scheme 6.1 Original isolation scheme for 3-epi-xestoaminol C (156) from Xiphophora chondrophylla. 
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Scheme 6.2 Optimised isolation scheme for 3-epi-xestoaminol C (156) from Xiphophora chondrophylla. 
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6.2.3 Derivatisation reactions  
6.2.3.1 Oxazolidinone derivative 
3-Epi-xestoaminol C (156) (3 mg) was stirred with 1,1’ carbonyldiimidazole (CDI, 3 
mg, 1.4 equiv.) for 24 h in DCM. Monitoring via TLC (running conditions 1:1 
MeOH:EtOAc) showed the reaction had not gone to completion, therefore further CDI 
(7 mg, 3.3 equiv.) was added to the reaction, after 2 h the reaction had gone to 
completion. The reaction mixture was partitioned against H2O three times and the 
organic layer was dried, yielding 4.9 mg. This sample was purified using a 1 mL DIOL 
column eluting the column with 3 mL volumes of 50% hexanes in ethyl acetate which 
afforded oxazolidinone ND5_83A (157, 2.8 mg, 93% yield). 
 
157 
Oxazolidinone (157): []25D -43.3 (c 0.18, CHCl3); IR max 3285, 2922, 2853, 1747, 
1541 cm-1; 1H NMR (CDCl3, 600 MHz)  5.18 (1H, s, NH), 4.09 (1H, ddd, J = 7.9, 6.4, 
4.8 Hz, H-3), 3.57 (1H, quin, J = 6.2 Hz, H-2), 1.71 (1H, m, H-4b), 1.62 (1H, m, H-4a), 
1.48 (1H, m, H-5b), 1.37 (1H, m, H-5a), 1.28 (2H, m, H-13), 1.27 (3H, d, J =  6.2 Hz, 
H-1), 1.26 (12H, m, H-6 to H-11), 1.25 (2H, m, H-12), 0.88 (3H, t, J = 7.0 Hz, H-14); 
13C NMR (CDCl3, 150 MHz) 158.97 (C-15), 84.4 (C-3) 53.7 (C-2), 34.3 (C-4), 32.1 
(C-12), 29.76-29.46 (C-6 to C-11), 25.0 (C-5), 22.84 (C-13), 20.82 (C-1) 14.3 (C-14); 
HRESIMS m/z 256.2264 [M+H]+ (calcd for C15H30NO2, 256.2271) 
6.2.3.2 Acetylation 
3-Epi-xestoaminol C (10 mg) was reacted with a 1:1 mixture of pyridine and acetic 
anhydride (3 mL) for 3 h at room temp and monitored via TLC. The reaction evaporated 
in vacuo and dissolved in DCM (20 mL) following which the organic layer was 
partitioned against 1 M HCl, 1 M NaOH and H2O, yielding 7 mg of diacetyl-3-epi-
xestoaminol C (158, 70% yield). 
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158 
Diacetyl-3-epi-xestoaminol C (158): []25D -23.0 (c 0.1, CHCl3); IR max 3297, 2923, 
2854, 1740, 1652, 1460, 1373 cm-1; 1H NMR (CDCl3, 600 MHz)  5.53 (1H, d, J =  9.3 
Hz, NH), 4.85 (1H, ddd, J = 7.6, 5.9, 4.1 Hz, H-3), 4.20 (1H, dqd, J = 9.3, 6.8, 4.1 Hz, 
H-2), 2.09 (3H, s, OAc, H-18), 1.99 (3H, s, NAc, H-16), 1.52 (2H, m, H-4), 1.28 (2H, m, 
H-13), 1.27 (2H, m, H-5) 1.25 (2H, m, H-12) 1.24 (12H, m, H-6 to H-11), 1.10 (3H, d, J 
= 6.8 Hz, H-1), 0.87 (3H, t, J = 7.0 Hz, H-14); 13C NMR (CDCl3, 150 MHz)  171.1 (C-
17), 169.6 (C-15), 76.6 (C-3), 47.4 (C-2), 32.1 (C-12), 31.7 (C-4), 29.78-29.5 (C-6 to C-
11), 25.4 (C-5), 23.6 (C-16), 22.8 (C-13), 21.2 (C-18), 18.7 (C-1), 14.3 (C-14); 
HRESIMS m/z 314.2693 [M+H]+ (calcd for C18H36NO3, 314.2690) 
6.2.3.3 Monodeacetylation 
Diacetyl-3-epi-xestoaminol C (158, 7 mg) was reacted with 5 mg of KCO3 in MeOH (3 
mL) at 0 °C for 30 min followed by room temperature for 16 h. The reaction was 
monitored via TLC (10% MeOH 90% DCM), following which the reaction mixture was 
evaporated and re-dissolved in EtOAc (15 mL). This was partitioned against H2O three 
times to yield 4.7 mg of N-acetyl-3-epi-xestoaminol C (159, 67% yield). 
 
159 
N-Acetyl-3-epi-xestoaminol C (159): []25D -6.3 (c 0.16, CHCl3); IR max 3477, 2924, 
2854, 1652 cm-1; 1H (CDCl3, 600 MHz) 5.68 (1H, d, J = 8.54 Hz, NH), 3.97 (1H, dqd, 
J = 8.6, 6.8, 3.2 Hz, H-2), 3.53 (1H, q, J =  4.4, 3.7 Hz, H-3), 2.00 (3H, s, NAc, H-16), 
1.44 (1H, m, H-4), 1.41 (1H, m, H-5b), 1.34 (1H, m, H-5a), 1.29 (2H, m, H-13), 1.25 
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(14H, m, H-6 to H-12), 1.19 (3H, d, J = 6.5 Hz, H-1), 0.88 (3H, t, J = 7 Hz, H-14); 13C 
(CDCl3, 150 MHz) 170.3 (C-15), 75.0 (C-3), 49.1 (C-2), 34.6 (C-4), 32.1 (C-12), 
29.8-29.5 (C-6 to C-11), 25.8 (C-5), 23.7 (C-16), 22.9 (C-13), 18.5 (C-1), 14.3 (C-12) 
HRESIMS m/z 272.2581 [M+H]+ (calcd for C16H34NO2, 272.2584) 
6.2.3.4 R and S- Mosher’s esters 
Two aliquots of N-acetyl-3-epi-xestoaminol C (159) (1.5 mg each) were treated with 
EDCI (7.3 mg, 8.6 equiv) and DMAP (1.41 mg, 2.1 equiv) dissolved in dry DCM under 
argon. To each flask 9.02 mg aliquots of either (R )-(+)--methoxy--
trifluoromethylphenylacetic acid or (S)-(-)--methoxy--trifluoromethylphenylacetic 
(MTPA) (7 equivalents) acid were added. Reactions were monitored via TLC over 22 h 
(10% MeOH, 90% DCM). Upon completion, reaction mixtures were washed with 
0.01M HCl followed by 0.01 M NaOH and finally H2O before performing HPLC 
purification of the R (160) and S esters (161) using a C18 analytical column 
(Phenomenex Prodigy, 4.6 x 250 mm, 5 m particle size) at a flow rate of 1 mL/min (5 
min at 30% MeCN, 15 min ramp to 100% MeCN, 5 min at 100% MeCN, 2 min ramp 
down to 30% MeCN, 5min hold at 30% MeCN) to give R (160, 0.6 mg) and S (161, 1.2 
mg) esters. 
 
160 
R-ester (160): []25D 0 (c 0.04, CHCl3); IR max 3378, 2924, 2854, 1746, 1651 cm-1; 1H 
NMR (CD3OD, 600 MHz) 7.55 (2H, m, H-24), 7.45 (2H, m, H-22), 7.44 (1H, m, H-
23), 5.5 (1H, s, NH), 5.11 (1H, ddd, J = 7.6, 5.6, 4.6 Hz, H-3), 4.17 (1H, qd, J = 6.9, 5.5 
Hz, H-2), 3.54 (3H, s, OMe, H-19), 1.83 (3H, s, NAc, H-16), 1.64 (2H, m, H-4), 1.34 
(3H, m, H-5b, H-6), 1.31 (2H, m, H-5a, H-13b), 1.29 (1H, m, H-13a), 1.28 (12H, m, H-
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7 to H-12), 0.99 (3H, J = d, 6.9 Hz), 0.90 (3H, t, J = 7 Hz, H-14); 13C NMR (CD3OD, 
150 MHz) 172.7 (C-15), 167. 5 (C-17), 133.4 (C-18), 130.9 (C-23/25), 129.5 (C-24), 
128.7 (C-22/26), 125.8 (C-21), 86.1 (C-20), 79.7 (C-3), 56.1 (C-19), 47.7 (C-2), 33.1 
(C-12), 31.5 (C-4), 30.75-30.4, 26.1 (C-6 to C-11), 30.48 (C-5), 23.8 (C-13), 22.6 (C-
16), 16.8 (C-1), 14.5 (C-14); HRESIMS m/z 488.2979 [M+H]+ (calcd for C26H41F3NO4, 
488.2982). 
 
161 
 
S-ester (161): []25D -17.5 (c 0.13, CHCl3); IR max_3335, 2925, 2854, 1746, 1651 cm-1; 
1H NMR (CD3OD, 600 MHz) 7.55 (2H, m, H-24), 7.44 (3H, m, H-22, H-23), 5.5 (1H, 
s, NH), 5.11 (1H, ddd, J = 8.0, 6.4, 4.0 Hz, H-3), 4.2 (1H, quin, J = 6.8 Hz, H-2), 3.55 
(3H, s, OMe H-19), 1.9 (3H, s, NAc, H-16), 1.59 (1H, m, H-4b), 1.54 (1H, m, H-4a), 
1.32 (1H, m, H-13b), 1.29 (1H, m, H-13a), 1.28 (2H, m, H-12), 1.27-1.19 (12H, m, H-6 
to H-11), 1.15 (2H, m, H-5), 1.13 (3H, d, J = 6.9Hz, H-1), 0.90 (3H, t, J = 6.9Hz, H-14)l; 
13C NMR (CD3OD, 150 MHz) 172.7 (C-15), 167.5 (C-17), 133.5 (C-18), 130.9 (C-
23/25), 129.5 (C-24), 128.5 (C-22/26), 125.8 (C-21), 85.9 (C-20), 79.5 (C-3), 56.2 (C-
19), 48.1 (C-2), 33.1 (C-12), 31.3 (C-4), 30.74-30.3 (C-6 to C-11), 25.7 (C-5), 23.8 (C-
13), 22.7 (C-16), 17.0 (C-1), 14.5 (C-14); HRESIMS m/z 488.2979 [M+H]+ (calcd for 
C26H41F3NO4, 488.2982) 
6.2.4 Sensitive mutant screen 
A random mutant library with 32 x 384-well plates comprising of 7680 Tn611 
M. smegmatis transposon mutants was generated by Richard Campen (VUW). These 
mutants were pinned into corresponding assay plates containing 100 L LB Kan20 
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(section 2.1.1.2) and incubated for 72 h, these plates were then sub-inoculated into 
corresponding LB Kan20 plates for a further 24 h, following which the 24 hour cultures 
were pinned into plates with LB Kan20 and 2 g/mL of 3-epi-xestoaminol C (156). 
These plates were incubated for 48 h after which 20 L of 0.03% resazurin (w/v) was 
added to plates and measured for fluorescence after 2 h or colour change was visible 
(from blue to purple/pink).  
Hits were mutants that identified growth sensitivity, % growth was measured for each 
well. Using Microsoft Excel the wells with the most sensitivity to growth were ranked 
to identify the top 120 mutants. These mutants were split into half and were picked from 
library wells and grown in 100 L volumes in two 96-well plates. After culturing plates 
for 72 h, 70 L of 80% glycerol was added to these plates to generate freezer stocks of 
these cultures to a final concentration of 33% glycerol. For screening, the glycerol 
plates were pinned into 100 L of LB Kan20 to grow for 48 h, these cultures were 
sub-inoculated into fresh 100 L LB Kan20 plates and grown for a further 24 h. These 
cultures were pinned into plates containing LB Kan20 and 2 g/mL of 3-epi-xestoaminol 
C (156) and incubated for 48 h after which OD measurements as well resazurin 
measurements were taken. From this screening out of the top 60 hits, 17 hits were 
validated in dose response assays and from the second 60 hits, 14 hits were validate in 
dose response assays.  
6.2.5 Resistant mutant generation and screen 
protocol 
A pool of random Tn611 mutants was generated using a modification of the methods 
described by Gilhot and Perez [129, 308]. In brief, these mutants were generated as 
follows: a pcG70 vector carrying the Tn611 transposon was electroporated into 
M. smegmatis mc2155 following which cells were plated onto LB Kan20 plates at 30 °C. 
Colonies were picked and grown in LB Kan20 at 30 °C for 48 h at 200 RPM. This 
allows for the replication and generation of a large pool of transposon mutants. These 
cultures were transferred to a 41 °C incubator for 24 h, this ceases transposition events. 
Glycerol was then added to cultures to achieve a final concentration of 30% in order to 
generate freezer stocks of mutants. For the control strain the plasmid pRC10 was 
electroporated into M. smegmatis mc2155 and glycerol stocks were made. Following 
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electroporation, colony forming units (CFUs) were counted in order to have an accurate 
gauge of the number of cells plated out in a 100 L aliquot of cells. 
Agar plates were made up to either 10, 7.5 of 3.75 g/mL of 3-epi-xestoaminol C (156), 
following which 100 L of transposon mutants were plated out. This was performed in 
duplicate. Control strains of pRC10 were also plated out. 
6.2.6 G2-M block assay 
In brief, using 24-well plates 1A9 cells were diluted to a final cell concentration of 1 x 
105 in a final volume of 500 L. The drug concentrations used were IC99, IC 50 and IC10 
to allow for analysis at concentrations at which complete death, 50% cell death and a 
concentration at which no major inhibition occurs. Caution was taken not to exceed the 
final DMSO concentration of 0.5% per well to avoid inhibition of cell growth due to 
solvent effects. Cells were incubated with drug over 16 h at 37 °C 5% CO2 before 
labelling cells with propidium iodide and performing fluorescence activated cell sorting 
(FACS) analysis. 
 
6.2.7 S. cerevisiae bioassay methods 
6.2.7.1 Yeast strains, media and chemicals.  
The Saccharomyces cerevisiae deletion library (Open Biosystem) was generated from 
strain BY4741 (MATa haploid: his3∆1 leu2 ∆met15 ∆ura3 ∆0). The yeast deletion 
library was stored in -80 °C and grown in yeast extract (10 g/L)-peptone (20 g/L)-
dextrose (20 g/L) (YPD) agar. 3-Epi-xestoaminol C (156), was dissolved in DMSO to 
give a 500 µg/mL working stock before use. 
6.2.7.2 Screening for 3-epi-xestoaminol C sensitivity 
and resistance in liquid medium.  
Replications and inoculation of yeast cells were run using the Singer RoToR HDA©. 
Yeast knockout mutants were tested in 96-well plates containing Synthetic Complete 
(SC) (1.7g/L yeast nitrogen base, 1 g/L monosodium glutamate, 2 g/L amino acid 
mixture) broth media in each well. Yeast were incubated for 20 h at 30 °C and then 
inoculated into 96-well plates containing 200 µL SC with 0.8 g/mL final concentration 
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of 3-epi-xestoaminol C (156), and the appropriate volume of DMSO (solvent control). 
Plates were sealed with gas permeable seals and incubated for 16 h at 30 °C.  Optical 
density (OD) was measured at 590 nm (OD590) using Perkin Elmer EnVision 2102 
Multilabel Reader, the 16th hour OD590 was normalised to the OD590 at 0
th hour. The 
screen was done in triplicate, with the % residual growth of drug treated cells measured 
in comparison to DMSO treated cells using Microsoft Excel. 
Hits were selected using a t test with a Bonferroni correction adjusting the p value to 
0.017. Using this selection criterion, sensitive strains that displayed less than 70% 
residual growth and resistant strains that had greater than 130% growth in comparison 
to DMSO controls were chosen for validation. Using the same selection criterion, these 
hits were validated again in triplicate to identify the hits for generating a network map. 
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6.3  Results 
6.3.1 Bioassay data 
Using the methodology described in section 2.6, the results of the dose-response assays 
for 3-epi-xestoaminol C (156) are listed below. Graphs were generated using GraphPad 
Prism v.5.0. Resazurin dye was used to a measure bacterial metabolism after each assay 
was run, and fluorescence measurements (RFU) were used as a measure of growth. OD 
was used as measure of growth for the HL-60 and HEK MTT assays. OD measurements 
were also used for all S. cerevisiae assays. Where possible IC50 values have been listed, 
and as stated earlier as sigmoidal curves were not achievable for all data, MIC90 values 
have been listed as well. 
6.3.1.1 Antimicrobial assays 
Table 6.1 3-Epi-xestoaminol C SAR work 
Compound MIC90 (g/mL) in M. tuberculosis 
H37Ra 
3-epi-xestoaminol C (156) 15  
Oxazolidinone (157) ≥ 60 
Diacetyl-3-epi-xestoaminol C (158) IA 
N-acetyl-3-epi-xestoaminol C (159) IA 
R-Mosher’s ester (160) IA 
S-Mosher’s ester (161) IA 
Bioactivity of derivatives of 3-epi-xestoaminol C against M. tuberculosis H37Ra using 
growth inhibition assays. IA:  inactive at the highest concentration tested (60 g/mL). 
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Figure 6.1 Antimicrobial activity of 3-epi-xestoaminol C (156). 
Antimicrobial activity of 3-epi-xestoaminol C (156) against a range of microorganisms, 
using growth inhibition assays, compound has been diluted two fold before addition of 
cultures. Assay durations ranged from 16 h for E. coli, S. aureus and S. cerevisiae to 7 
days for M. tuberculosis H37Ra. Percentage growth signal inhibition on the Y-axis is 
relative to controls measured. NA: not achievable. (n=1, triplicate) 
 
  
B 
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3-epi-xestoaminol C vs. stationary phase M. tuberculosis H37Ra
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Figure 6.2 Stationary phase assay 
Inhibitory effects of 3-epi-xestoaminol C (156) against stationary phase cultures of M. 
tuberculosis H37Ra. Compound was serially diluted two fold in PBS before 30 day old 
cultures washed and re-suspended in PBS were added to plates. (n=1, triplicate) 
 
6.3.1.2 Mammalian cell line assays 
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3-epi-xestoaminol C vs. HEK cells
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Figure 6.3 3-epi-xestoaminol C (156) vs. mammalian cell lines 
The bioactivity of 3-epi-xestoaminol C (156) in HL-60 (A) and HEK cell lines (B). 
The HEK cell line has been used as a representative of general cytotoxicity. OD was 
used as a measure of growth. (n=1, duplicate) 
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Figure 6.4 Network map of hits from yeast chemical genetics screening of 3-epi-xestoaminol C (156). 
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6.4  Discussion 
6.4.1 Fractionation and isolation 
PTN2_93D, a brown algae identified as Xiphophora chondrophylla, was observed as 
being active against all three species of bacteria screened using the VUW MNP library. 
As the crude extract displayed similar levels of activity against M. tuberculosis H37Ra 
and M. smegmatis, M. smegmatis was used for the subsequent bioassays. As the 40% 
acetone fraction from the initial HP20 fractionation had the highest mass and displayed 
the best MIC90 of 50 g/mL, it was taken to the next stage of purification. Half of the 
mass of this fraction was separated using HP20ss and based on the activity profiles of 
test tubes 43-46 (15.6 g/mL, 17.8 mg) and 47-54 (15.6 g/mL, 78.2 mg), they were 
further pursued. Attempts to purify the 78.2 mg fraction using reversed phase (C18) 
HPLC did not achieve any separation. Guided by bioassays, the 17.8 mg fraction was 
separated a further three times using LH20 size exclusion chromatography. Ultimately 
using a DIOL column for the last purification led to the identification of an amino 
alcohol 3-epi-xestoaminol C (156) as the compound responsible for bioactivity.  
In order to isolate more of the active compound to elucidate its relative and absolute 
configurations, a more refined isolation scheme was employed to separate the second 
half of the 40% acetone fraction (Scheme 6.2). Testing the purified compound using the 
optimised method identified a consistent MIC90 of 15 g/mL in all microbes tested 
(Figure 6.1). 
6.4.2 Structural elucidation 
HRESIMS analysis indicated an [M+H]+ adduct ion at m/z 230.2467, suitable for the 
formula C14H32NO (calcd for 230.2478), and having no double bond equivalents. The 
1H, 13C and multiplicity-edited HSQC NMR spectra in CD3OD (Table 6.2) revealed 32 
protons attached to 14 carbons, including two methyls (C 16.1 and 14.5), ten 
methylenes (C 34.7, 33.1, 30.8-30.5, 26.4, 23.8) an oxymethine (C 73.2) and an 
aminomethine (C 53.5).  
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The connectivity from C-1 to C-5 was elucidated using a continuous sequence of COSY 
correlations from the terminal methyl doublet (C-1: C 16.1, H 1.27) to the 
aminomethine (C-2: C 53.5, H 3.09), to the oxymethine (C-3: C 73.2, H 3.44), and to 
the C-4 methylene (C-4: C 34.7, H 1.40, 1.56). HMBC correlations from H-3, H-4a 
and H-4b to C-5 (C 26.4, H 1.39, 1.54) provided further evidence for this proposed 
substructure (Figure 6.5).  
 
Figure 6.5 Key COSY and HMBC correlations establishing substructure 1 
Similarly, the connectivity from C-14 to C-12 was established based on the COSY 
correlations from the methyl triplet (C-14: C 14.5, H 0.91) to the methylenes C-13 (C 
23.8, H 1.31) and C-12 (C 33.1, H 1.29) to provide a second substructure (Figure 6.6).  
 
Figure 6.6 Key COSY and HMBC correlations establishing substructure 2 
HMBC correlations into a methylene envelope (C 30.8-30.5, H 1.30) as well as the 
number of carbons and hydrogens required by the molecular formula provided strong 
evidence for the proposed structure of a long alkyl chain connecting the two proposed 
sub-structures (Figure 6.7). 
 
Figure 6.7 Proposed planar structure 
To provide further evidence for the connection between the two termini, a 1D TOCSY 
experiment was performed in CDCl3. Irradiation of H-3 (H 3.65) and H2-4/5 (H 
1.56/54) resulted in TOCSY transfer of energy to H3-14 (H 0.88), while irradiation of 
H3-14 resulted in TOCSY transfer of energy to H-4/5. This provided unequivocal 
evidence for the connectivity of the two proposed sub-structures of the amino alcohol 
(Figure 6.8) (for TOCSY spectra refer to Appendix D page 189). 
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Figure 6.8 TOCSY correlations 
From a literature search using MarinLit [210] and SciFinder©, the carbon connectivity 
was the same as the known amino alcohol xestoaminol C (109), first reported by 
Jiménez and Crews from a Xestospongia sp. sponge [284]. However, further analysis of 
the 1H NMR spectrum of 156 (CDCl3) identified several significant differences to that 
reported by Crews for 109 (156:1.38 ppm, H3-1; and 3.65 ppm, H-3; 109: 1.15 ppm, 
H3-1; 3.95 ppm, H-3)  [284]. One possible explanation for this shift in resonance could 
be a different configuration, therefore these findings warranted further investigation into 
the compound isolated.  
To identify the relative stereochemistry of the amino alcohol, it was reacted with 1,1’ 
carbonyldiimidazole (CDI) to generate the oxazolidinone derivative (157). The coupling 
constant between H-2 and H-3 was approximately 6.5 Hz, diagnostic of a trans 
relationship between the protons of the five membered ring system [274]. In comparison   
a cis relationship would have a coupling constant of approximately 7.3 Hz. 
The trans relationship of these protons can be accounted for if the amine and hydroxyl 
group were syn to each other in the acyclic system. To confirm the trans relationship in 
the oxazolidinone, a 1D-NOE experiment was performed, irradiating H-1, H-2, H-3, H-
4a and H-4b. Irradiating H-3 enhanced H-1 while irradiation of H-4a and b led to the 
excitation of H-2, confirming the trans relationship in the cyclic system. This therefore 
indicated that 156 has a syn relationship between NH2-2 and OH-3, which differed from 
xestoaminol C (109) that has a trans relationship.  
 
 
Figure 6.9  correlations of oxazolidinone 157.  
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With enough evidence to support a different relative configuration in 156 to 109, 
Mosher’s method was used to solve the absolute configuration, which was carried out in 
three stages. Amino alcohol 156 was first treated in a 1:1 mixture of pyridine and acetic 
anhydride to acetylate the amine and hydroxyl groups, generating the diacetyl derivative 
(158). Following acetylation, the hydroxyl group was deprotected using base hydrolysis 
with KCO3 in MeOH to afford N-acetyl-3-epi-xestoaminol C (159), which was treated 
with R and S- MTPA acids to yield the R (160) and S (161) Mosher’s esters.  
 
 
158 R1 = R2 = Ac 159 R1 = Ac R2 = H 
 
160 R1 = Ac R2 = R-MTPA 161 R1 = Ac R2 = S-MTPA 
 
When analysing the changes in 1H chemical shifts of the Mosher’s esters in CDCl3, an 
interesting result was observed (Figure 6.10). Under normal circumstances, the  shifts 
flanking the ester would either be solely positive or negative depending on the 
positioning of the phenyl ring. However, a mixture of shifts was observed at the amino 
terminal end of the compound (Figure 6.11). Hydrogen bonding between the carbonyl 
group of the ester and the amide proton may have caused a conformational change from 
that required to adequately study each side, as evidenced by the different couplings 
observed for H-3, indicated by different multiplicities (Figure 6.10). This proposed 
intramolecular bonding could directly affect the shielding and desheilding effects of 
MTPA, obscuring interpretation of data. 
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Figure 6.10 Change in multiplicity of the oxymethine 1H NMR resonance for R-
ester (160, top panel) and S-ester (161, bottom panel) in CDCl3 (600 MHz). 
 
 
Figure 6.11  1H NMR data of MTPA esters 160 and 161 in CDCl3 (600 MHz). 
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In order to disrupt the effects of intramolecular hydrogen bonding, NMR analysis was 
performed in the polar deuterated solvent CD3OD. As expected, the oxymethine 
resonance no longer varied between the R and S-esters and both had roughly the same 
multiplicity (Figure 6.12). Furthermore, comparison of 1H NMR data from the two 
esters indicated that the intramolecular bonding was no longer causing a 
misinterpretation of the data (Figure 6.15).  
 
Figure 6.12 1H NMR oxymethine resonance for R-ester (160, top panel) and S-ester 
(161, bottom panel) in CD3OD (600 MHz). 
Analysing the multiplicities in CD3OD (Figure 6.12), it can be observed that they match 
that of the S-ester in CDCl3 (Figure 6.10), and therefore it can be deduced that the R-
ester was the cause of the issues in interpretation due to intramolecular bonding. 
Using Mosher’s method, and performing the analysis in the appropriate deuterated 
solvent provided unequivocal evidence for the absolute stereochemistry of 
3-epi-xestoaminol C. The  values on either side of the ester were either solely 
positive or solely negative (Figure 6.13), and based on the  shifts, it was possible to 
elucidate the absolute structure as 2-S-aminotetradeca-3-S-ol. Figures 6.14 and 6.15 
illustrate the shifts observed in the 1H NMR spectra of the R and S-esters. 
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160 R = R-MTPA    161 R = S-MTPA 
Figure 6.13 H shiftsbetween MTPA esters 160 and 161 of N-acetylated 
xestoaminol C in CD3OD. 
 
 
Figure 6.14 Oxy- and aminomethine region, 1H NMR spectra for the R-ester (160, 
top panel) and S-ester (161, bottom panel) in CD3OD (600 MHz)  
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Figure 6.15 Aliphatic region, 1H NMR spectra for the R-ester (160, top panel) and 
S-ester (161, bottom panel) in CD3OD (600 MHz). 
 
To futher confirm these results, 19F NMR analysis of the esters was performed as 
originally proposed by Mosher [309, 310]. In this method it was proposed that if the 
phenyl ring was on the same side as the most bulky substituent of the ester, then 
coplanarity is lost resulting in a shift of the CF3 from the desheilding zone to the 
sheilding zone of the carbonyl (Figure 6.16).  
 
Figure 6.16 Steric effects influencing 19F NMR shifts 
In this figure the phenyl ring of S-MTPA ester is on the same side as the most bulky 
substituent. This results in the loss of coplanarity and the resulting shift in sterics moves 
CF3 to the sheilding zone of the carbonyl. 
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Based on the 1H NMR shifts observed from the R and S- MTPA esters (Figure 6.13), it 
is expected that for the R-ester the phenyl ring is on the same side as the N-acyl group. 
If this holds true, the steric interaction of the phenyl ring and the bulky N-acyl group 
would cause the CF3 to resonate further up-field [311]. Consequently, the resulting shift 
in the S-ester would be at higher ppm, and this is exactly what was observed (Figure 
6.17).  
 
 
Figure 6.17 19F NMR shifts (280 MHz) in CD3OD for the R-ester (160, top panel) 
and S-ester (161, bottom panel) in CD3OD. 
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Table 6.2 1H (600 MHz), 13C (150 MHz) NMR data of 3-epi-xestoaminol-C (156) 
(CD3OD). 
 
C H (J in Hz) COSY HMBC 
1 16.1, CH3 1.27 (d, 6.7 Hz) 2 2,3,7 
2 53.5, CH 3.09 (quin, 6.8 Hz) 1,3 1,3,4 
3 73.2, CH 3.44 (ddd, 8.5, 7.0, 3.0 Hz) 2,4a,b,  1,4,5  
4a 34.7, CH2 1.40, m 3,4b 3,5 
4b 
 
1.56, m 3,4a 5,9 
5a 26.4, CH2 1.39, m  2,3 
5b 
 
1.54, m  6 
6-11 30.5-30.8, CH2 1.30, m  
 12 33.1, CH2 1.29, m 14 13 
13 23.8,CH2 1.31, m 14 12,14 
14 14.5, CH3 0.91 (t, 7.0 Hz) 12,13 12,13 
 
6.4.3 Compounds from the genus Xiphophora 
 
Algae belonging to the genus Xiphophora have not been extensively studied in the field 
of marine natural products chemistry. The majority of studies on this genus are marine 
ecological studies focusing on topics such as ammonia, urea and nitrate uptake, or 
phylogenetics as well as surveys of the species of algae from different intertidal zones. 
However, there has been one reported study that involved the isolation of a 
Penicillium sp. fungus from Xiphophora gladiata, which led to the isolation of two 2-
pyridones (162 and 163) [312]. 
 
162       163
The isolation of 162 and 163 was a result of the research group’s focus on 
compounds isolated from fungi, and therefore the metabolites of the algae were not 
investigated. As X. gladiata belongs to the same genus as X. chondrophylla, it is 
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possible that amino alcohols may also be present in X. gladiata, however this 
remains to be investigated. 
The amino alcohols xestoaminol A-C (107-109) were first reported by Jiménez and 
Crews as stated earlier. To elucidate their configurations, xestoaminol A was 
derivatised to form an oxazolidinone, the coupling constant between H-2 and H-3 
was approximately 7.5 Hz, suggestive of a cis relationship between the protons of 
the five membered ring system. Based on these results, Jiménez and Crews proposed 
the 2S*, 3R* stereochemistry for xestoaminol A. The proposed 2S*, 3R* 
stereochemistry for xestoaminol C (109) was based on similarities of the C-2 and C-
3 carbons chemical shifts of xestoaminol C to xestoaminol A [284]. As stated earlier 
in section 6.4.2, the relative stereochemistry of 3-epi-xestoaminol C (156) was also 
elucidated by generating the oxazolidinone derivative and the coupling constant 
measured was 6.5 Hz, which indicated a trans relationship between H-2 and H-3 in 
157 [274]. Sata et al. have previously used differences in coupling constant to 
elucidate the relative configuration of two epimers, amaminols A (142) and B (143) 
which differ at the 2-position [274]. It should be noted that the absolute 
configuration of 109 was elucidated as 2S, 3R for the two stereogenic centers, 11 
years later using Mosher’s method [278].  
The research described in this thesis applied established and accepted methods to 
elucidate the relative and absolute configurations of 3-epi-xestoaminol C. Sata et al. 
as well as Jiménez and Crews formed the oxazolidinone derivative of their respective 
amino alcohols and then measured the coupling constants between the oxymethine 
and aminomethines. Sata et al. measured the differences between two different 
epimers and showed that a coupling constant of 6.5 Hz indicated a trans relationship 
and 7.3 Hz indicated a cis relationship within the oxazolidinone ring [274]. This 
translates to the opposite when considering the respective linear forms, i.e. a cis 
relationship for the oxazolidinone indicates a trans relationship for the underivatised 
form. 
Garrido et al. applied Mosher’s method for elucidating the absolute stereochemistry 
xestoaminol C by [278]. With a few minor differences the same approach was 
applied to elucidate the absolute configuration of 156. Garrido et al. identified an R 
configuration for the C-3 center, thus elucidating the absolute configuration of 
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xestoaminol C as 2S,3R [278]. Using the methods detailed, the compound isolated 
from X. chondrophylla was identified as the C-3 epimer of xestoaminol C.  
Amino alcohols or 1-deoxysphingoids, tend to be isolated from sponges and 
ascidians, which makes this the first report of the isolation of this class of 
compounds from algae. The closest reports from marine algae involve the isolation 
of sphingosine derivatives from the red alga Laurencia nidifica and the green alga 
Ulva fasciata [313, 314]. This research has therefore identified the presence of 
sphingoids from brown algae for the first time. 
6.4.4 Bioactivity 
The crude extract of X. chondrophylla had an MIC90 value of 200 g/mL, and after 
purification the pure compound had an MIC90 of 15 g/mL (65.1 M), an overall 13-
fold improvement in activity. This activity is consistent in all species of bacteria 
studied (Figure 6.1), except Pseudomonas aeruginosa which was resistant to the 
highest concentration tested (60 g/mL). In addition to the growth inhibition assay, 
the compound was tested against stationary phase M. tuberculosis H37Ra, yielding 
an MIC90 of 65.1 M in this assay as well (Figure 6.2). This hints to the possibility 
of a generic mechanism of action, possibly a detergent-like activity, which is not 
unexpected when considering the structure of the compound, the polar head and non-
polar tail, which make for an ideal membrane disruptor.  
When the compound was investigated for its activity against mammalian cell lines 
the results proved more interesting. Comparison of the HL-60 (IC50 8.8 M) to the 
HEK (IC50 18.0 M) data proves a slight specificity of the compound towards the 
HL-60 cancer cell line compared to the HEK cell line, which was used as a control to 
measure general toxicity (Figure 6.3). Though the therapeutic index of this 
compound is 2, which is very low and far from ideal, this may still warrant future 
studies to investigate this compound. Furthermore, the availability of 156 in such a 
high mass as well as the observed activity against S. cerevisiae allowed profiling of 
its mechanism of action using yeast chemical genetics, which may shed light on the 
current understanding of how 1-deoxysphingoids cause their observed activity.  
When studying the effects the compound has on 1A9 cells transitioning from G2 to 
M-phase, 3-epi-xestoaminol C (156) does not inhibit this stage of the cell cycle (this 
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work was done with the help of Dr. Arun Kanakkanthara, Appendix A, page 173). 
The mechanism of action to induce cell death could be via alternative ways 
mentioned earlier for ES-285, such as disruption of actin cell fibres causing the 
destabilization of the cytoskeleton of the cell [290], activation of caspase 3 and 12, 
the phosphorylation of p53 and activation of isoforms of protein kinase C (PKC), 
inducing atypical cell death [291], or alternatively by causing ceramide induced 
apoptosis via activation of PKC [292-295].  
6.4.4.1 SAR study 
Table 6.1 displays the results of the basic SAR work done on 3-epi-xestoaminol C. 
Testing oxazolidinone derivative 157 against M. tuberculosis H37Ra resulted in a 
drop in the MIC90 to 60 g/mL. This suggests that the polar head is crucial for 
bioactivity. The diacetyl and N-acetyl derivatives generated for carrying out 
Mosher’s analysis were also tested for activity. This indicated that modification to 
both the NH and OH resulted in a loss of activity with a maximum of 80% inhibition 
observed at the highest tested concentration of 60 g/mL. Solely modifying the NH 
via the addition of an acetyl group also resulted in complete loss of activity. A clear 
trend is therefore noted, where any modifications to the polar head group causes a 
decrease in activity. This loss of activity is further highlighted by the bioactivity 
results of the Mosher’s esters with both showing a lack of activity at the highest 
concentration tested (60 g/mL) (Table 6.1). 
6.4.5 Mechanism of action 
In order to elucidate the mechanism of action of this compound in mycobacteria, 3-
epi-xestoaminol C was screened against a library of random transposon mutants. The 
top 120 mutants were selected and testing them for sensitivity followed by validation 
of 31 mutants using dose response curves did not identify any mutants that were 
more sensitive to the compound. This may indicate that either this compound targets 
an essential gene, which would explain why no specific mutant was identified, or 
alternatively that this compound acts as a detergent, which could also explain its 
activity against a range of microbes. 
In an alternative approach, the generation of resistant mutants was attempted. This 
involved the generation of random transposon mutants that were grown on plates at a 
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range of concentrations for over four weeks. However, growth was only observed at 
the non-inhibitory concentration, with no growth of mutants observed at 
concentrations above 7.5 g/mL. 
6.4.5.1 Chemical genetics 
To gain further understanding of how the compound interacts in a eukaryotic system, 
the powerful tool of yeast genetics was used to identify pathways that this compound 
interacts with to generate the observed biological effect. A synthetic genetic array 
(SGA) was performed in a liquid assay system optimised to allow for minimal use of 
drug. The chemical genetics results described in this section were obtained by Nazmi 
H. Fadzilah. 
Chemical genetics employs a library containing 4800 non-essential gene deletion 
mutants of Saccharomyces cerevisiae (baker’s yeast).[315] The library was screened 
at the IC20 concentration as this ensures for bioactivity as well as allowing for the 
identification of mutants that are the most sensitive to drug treatment. A dose 
response assay in S. cerevisiae identified an IC50 of 17.1 µM, and an IC20 of 3.5 µM. 
The library of non-essential mutants was grown for 16 h in the presence of 3-epi-
xestoaminol C at the IC20 concentration. Hits were selected using a t test with a 
Bonferroni correction adjusting the p value to 0.017. Using this selection criterion, 
sensitive strains which displayed less than 70% residual growth and resistant strains 
that had greater than 130% growth in comparison to DMSO controls were chosen for 
validation. This identified 805 hits, using the same selection criterion validation of 
the 805 hits had identified 28 mutants of significance (two of which were of dubious 
annotation and therefore excluded). 
This resulted in 12 networks representing 19 genes involved in known pathways and 
one network with seven genes as part of unknown pathways (Figure 6.4). The largest 
number are genes were involved in unknown processes, followed by genes involved 
in lipid metabolism (AIM6, PLB3, CRC1, SPS19 and OPI1), and actin cytoskeleton 
organization (AKL1, RHO2 and SLA1) (Figure 6.4).  
As sphingolipids are believed to regulate lipid metabolism, it is expected that this 
process should be affected by 3-epi-xestoaminol C [316]. Another process that was 
expected to appear in our network map was actin cytoskeleton organization, as it has 
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been previously suggested that ES-285 prevents the formation of actin stress fibres 
by decreasing the activity of Rho proteins [290]. Our results correlate with the 
possible mechanisms of action reported for ES-285.  
Furthermore, as this type of study has not been performed before for 
1-deoxysphingoids, it sheds further light on other possible pathways that may be 
involved in the mechanism of action of 1-deoxysphingoids. These new pathways 
include RNA catabolism, protein targeting and phosphorylation, amongst others 
(Figure 6.4). Studying how 1-deoxysphingoids interact with these new and unknown 
pathways may allow for a better understanding of the mechanism of action of these 
compounds. In addition, 156 may also help in identifying what role these unknown 
pathways play within cells. Interestingly, mutants in the ceramide synthase pathways 
did not appear in this screen, this may be due to the statistical cut off used to identify 
hits. It would therefore be interesting to pick individual mutants involved in 
ceramide synthesis and study the phenotypic effects when they are exposed to 3-epi-
xestoaminol C (156). 
6.4.6 Future directions 
As the HPLC attached to an ELSD was available for use near the end of this study, a 
repeat isolation assisted by the ELSD may help in purifying 3-epi-xestoaminol C in 
fewer and less laborious steps. As the 1-deoxysphingoids have been linked to 
alteration of ceramide levels as was the case for ES-285, it would be interesting to 
study the effect of 156 on mutants involved in this pathway. Studying the effects of 
compounds with the same configuration, however with varying levels of saturation 
would also be of interest.  
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Chapter 7       Concluding remarks 
  
158 
 
Marine natural products research has led to the isolation of a plethora of novel 
compounds. The recent improvement in culturing methods of microbes once 
believed to be unculturable as well as genome mining methods is sure to lead to the 
identification of more unique compounds. Dereplication issues are a common 
problem in this field, the isolation of known compounds is a frustrating waste of time 
and resources that can be overcome using unique isolation methods. However, when 
pursuing bioactivity, the goal is often to isolate the bioactive, which may be a known 
compound. 
The research described in this thesis employed a classic approach of bioassay-guided 
fractionation using whole cell assays. Whole cell assays are better suited for 
screening of crude extract as the complex nature of crude extracts can often interfere 
with more sensitive targeted biochemical assays. 
The NIWA and VUW MNP libraries were screened to select extracts with 
potentially new anti-tubercular compounds. These screens led to the identification of 
a number of hits of which five were chosen due to availability, activity, and amount.  
Due to time constraints as well as loss of activity, eventually three samples were 
pursued. As stated before, a common issue encountered is re-isolation of known 
compounds, which was observed with one sample that resulted in the isolation of 
common fatty acids from the active extract of blob fish liver. 
Another common issue often encountered is low sample mass for the isolated 
compound. The fractionation of the Latrunculia sponge led to isolation of a novel 
compound, however the compound responsible for anti-mycobacterial activity was 
unable to be purified and identified. This compound was present at such low levels 
that it was impossible to elucidate any structural information. Furthermore, even 
rimarikiamide A (98) was not isolated in sufficient amounts to allow for the 
elucidation of relative and absolute configuration. The next step will be to synthesize 
two of the four possible stereoisomers and compare optical rotation and NMR data to 
the natural product to confirm the absolute configuration of the natural product, as 
well as further investigate its bioactivity. 
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The isolation work performed on the brown algae Xiphophora chondrophylla led to 
the isolation of a new compound, 3-epi-xestoaminol C (156) this compound was 
equally active against all strains of bacteria except Pseudomonas aeruginosa.  
Xestoaminol C (109) was first isolated from a Xestospongia sp. sponge. The spectral 
data reported by Jiménez and Crews correlated very closely to the data of 156, with 
the exception of a signature methyl doublet and oxymethine. The relative 
stereochemistry of the amino alcohol was identified by locking the compound’s 
amine and alcohol moieties in an oxazolidinone ring followed by measuring the 
coupling constant between the amino- and oxymethine, as well as from 1D NOE 
experiments. Generating the Mosher’s esters allowed characterisation of the absolute 
configuration of the compound; this validated the fact that this compound has a 
different configuration from 109, and is therefore a new compound.  The bioassay 
data generated from this work and crude SAR analysis identified the polar head as 
crucial for activity.  
This compound proved to be a better cytotoxic agent towards HL-60 cells. Therefore 
the next logical step was to study the effects of this compound on eukaryotic cells. A 
model organism that allows for genome wide analysis at VUW was the S. cerevisiae 
gene deletion set. This was employed to perform SGA studies which led to the 
identification of 13 categories that represented pathways 3-epi-xestoaminol C 
interacts with, two of which were expected, one represented unknown pathways and 
the others were novel. This study therefore highlights cellular processes yet to be 
implicated in the mechanism of action of 1-deoxysphingoids, which will require 
further studies on the mutants identified. As 1-deoxysphingoids have also been 
shown to affect ceramide levels within cells, studying how mutants involved in this 
pathway interact with 3-epi-xestoaminol C may also be of value to gain a better 
understanding of these compounds. 
The X. chondrophylla project saw the progress of a sample from the crude stages 
through to a pure compound, following which derivatives were made to elucidate the 
absolute stereochemistry, which aided in performing SAR studies. Finally, the SGA 
work in S. cerevisiae ensured the overarching three goals of my thesis were achieved. 
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It is interesting to note that all the compounds isolated through this work share 
similar features. These compounds all have polar head groups and long hydrophobic 
chains, which may be due to the assay used in this approach. 
Looking at the activities of palmitic acid and 3-epi-xestoaminol C against 
M. tuberculosis H37Ra, it is apparent that a polar head group is important for 
compounds such as these. Although the exact reason for this was not investigated, 
the presence of a polar head as well as a non-polar tail may allow for better solubility 
of the compound, which would allow for more of it to be in solution and would aid 
in traversing both hydrophilic and hydrophobic environs. Furthermore the 
amphiphilic nature of the compound may allow for better permeation through the 
bacterial cell wall or alternatively cause lysis of cells due to detergent type activity. 
When looking at chain length it seems that C14-16 carbon chains may be effective as 
observed with the activity of 3-epi-xestoaminol C and palmitic acid. It would be 
interesting to study the effects of other C14 fatty acids to better understand the 
effects of chain lengths.  When looking at level of unsaturation it can be observed 
that having saturated chains is more favoured.  
If this project were to be redesigned and performed again, a better possible approach 
could include performing the library screens directly against M. tuberculosis H37Ra. 
Due to the increased bioactivity observed in the crude extract of Latrunculia sp. 
sponge against M. tuberculosis H37Ra, the implied specificity may hint at the 
possibility of other specific hits being overlooked. In addition, a counter screen could 
be introduced by screening the extract against HEK cells. Although crude extracts 
may have higher toxicity due to the possibility of higher levels of surfactants present, 
it may allow for a better selection of hits to be made. 
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Appendices 
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Appendix A: 
NIWA library screening raw data 
Table 7.1 Raw data of NIWA library screen vs. M. smegmatis 
Plates 12, 13 and 14 were kindly donated by NIWA and screened for anti-
mycobacterial activity. Top hits highlighted in yellow, positive control in red and 
negative control in green. Wells are represented as either P12, 13 or 14 followed by 
the well number for plates 12, 13 and 14 respectively. Standard error (std error) 
values are also listed for each sample. 
Well number 
GFP 
average 
GFP  
std error 
Resazurin 
average 
Resazurin 
std error 
P12C11 95.29507 0.785983 86.38034 3.157086 
P12E9 95.23894 0.81616 86.08682 2.949949 
Positive 94.17888 0.805538 86.0707 1.28972 
P12D2 95.44557 0.774508 85.98647 2.898718 
P12B11 95.22699 0.795667 85.63803 3.24214 
P12H5 95.29462 0.798398 84.61087 2.82355 
P12A5 95.18794 0.741449 84.50358 2.231667 
P12H8 94.91964 0.883313 84.38737 3.549344 
P12F4 94.65777 0.900614 83.94367 3.177821 
P14D8 79.84463 10.39383 79.52913 6.688682 
P12C5 92.33131 3.153455 74.69969 9.574227 
P14A10 76.53547 13.60222 74.00939 12.16117 
P12H2 65.38177 30.07546 72.72987 10.19009 
P14C8 74.31914 15.79287 72.54576 14.13008 
P14F6 85.78419 4.406677 71.18628 16.53152 
P12E7 80.54696 14.88215 70.23149 13.03872 
P12G7 88.10912 7.205349 70.19471 12.21514 
P13C4 86.06836 9.197341 69.88816 17.19673 
P12G11 91.05706 4.254647 67.37275 14.86076 
P12B4 82.64904 12.74172 66.18606 17.17667 
P12D11 49.1333 45.78911 66.1028 11.47069 
P12B10 79.7254 15.5422 64.57238 15.22279 
P12E1 73.53752 21.89476 63.24637 20.81483 
P14G1 87.61734 4.389685 62.15067 8.500751 
P14G4 87.94448 1.672556 60.93931 19.99167 
P13C3 88.19733 7.070043 60.48392 25.30041 
P13F3 80.15213 15.23033 59.29562 27.22728 
P14H3 89.10644 1.622557 59.17182 26.97998 
P14B1 51.06214 40.52924 47.83945 23.17653 
P13F2 61.09333 33.45879 45.45379 24.96453 
P12D4 57.49756 32.63582 39.50918 33.59945 
P12D6 63.57766 28.34269 38.3046 35.8992 
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P14A7 70.86429 9.036251 36.84229 27.03343 
P13G3 69.56712 24.46582 35.55058 31.69946 
P14C9 49.30522 23.41664 33.04114 28.47672 
P12D5 68.03184 21.56482 32.43605 35.22354 
P14D11 -15.7199 42.80098 29.93673 2.796792 
P12C6 70.14362 12.3702 28.00977 34.27149 
P12A9 82.31134 8.054148 26.9769 33.4664 
P13B2 71.13187 23.20145 26.87892 34.10814 
P14C7 53.16032 12.48884 25.55587 8.495419 
P14G5 63.19724 11.91114 25.42668 22.88006 
P14B8 47.98046 16.84785 25.13695 7.053966 
P14E7 49.87826 15.84849 25.01259 1.765235 
P14E8 3.435204 12.42514 24.75312 11.46179 
P14D6 68.49973 11.54012 24.21785 1.913252 
P14E6 53.46062 23.30951 23.97877 5.462849 
P14B7 47.95174 13.52469 23.912 16.88196 
P14G10 31.32469 21.25331 22.74761 3.867035 
P14G7 36.47978 32.63412 21.95137 1.840131 
P14E4 51.67138 20.94187 21.71609 2.734935 
P14E11 19.13935 24.94786 21.40771 6.166837 
P14F10 -8.16547 48.91745 21.11393 6.880446 
P14C6 50.46009 22.35922 21.05689 3.309809 
P14E9 44.116 16.96219 20.98442 11.91788 
P13B5 46.76197 48.55091 20.52903 65.74664 
P14E5 -10.3081 33.59287 20.29615 8.892144 
P14F8 27.96623 26.44523 19.7249 4.788833 
P14F4 21.3651 36.61031 19.7137 6.165707 
P14G8 27.28424 34.13498 19.39925 2.782101 
P14B2 60.67015 19.44923 19.18749 4.301774 
P14C2 64.68015 13.99315 18.60105 6.759065 
P12H9 75.27249 13.65901 18.58306 38.66039 
P14C5 60.94756 9.250122 17.6841 2.371108 
P14G6 -2.55169 48.03772 17.61007 6.378801 
P14G2 14.21108 34.27734 17.41164 15.3916 
P14A8 33.91814 17.58041 17.33406 3.371426 
P14F5 37.62318 36.35582 17.25284 4.997432 
P14G3 27.32602 35.76232 17.24924 3.812852 
P14F11 28.84561 29.12361 17.21426 5.242239 
P14B5 56.666 10.1577 17.19392 6.036702 
P12F5 69.06763 11.45544 17.10833 30.20712 
P12D10 70.23466 14.68935 17.00887 37.72978 
P13F10 56.6338 14.76691 16.75626 20.25039 
P14C10 56.85615 7.524538 16.68879 1.451631 
P14C12 69.56004 2.807874 16.60262 18.89024 
P13D5 69.32286 11.68947 16.27412 16.58991 
P14D5 72.3954 1.938687 15.82492 9.756835 
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P12G12 29.23471 35.89494 15.61437 4.148292 
P14C4 45.91544 28.8453 15.39723 5.21136 
P14E1 15.81121 23.72353 15.35797 11.95728 
P14H9 37.37998 27.72498 15.33101 4.833102 
P13E5 74.45022 2.457501 15.32738 18.02214 
P14F3 22.31453 27.11177 15.21476 6.446794 
P13E10 57.1752 22.91158 14.78389 15.13841 
P13B7 60.70775 9.274539 14.6302 23.13163 
P13D8 69.07614 9.93776 14.34612 20.50569 
P14E2 39.19593 26.29932 14.34283 7.568437 
P14C1 18.0416 24.64411 13.96777 14.86596 
P13C5 78.82951 4.784819 13.96105 19.45644 
P13G5 69.64096 20.74357 13.85236 38.74775 
P14C3 41.04125 26.34051 13.28868 8.387458 
P13B1 44.52683 43.27951 13.23391 21.78682 
P14D2 53.9266 12.1028 13.13169 6.563468 
P14B12 39.33416 28.3577 13.02601 11.31142 
P13G4 82.65762 4.760891 12.9056 16.7919 
P14D3 37.14536 25.56468 12.75301 5.807382 
P13E6 74.49791 5.151318 12.69926 21.36707 
P14H8 41.57048 23.14885 12.29052 4.769722 
P14B9 29.04049 6.906667 12.2193 10.47905 
P13C7 78.14485 7.030314 12.09265 20.67555 
P12D8 31.1107 39.33485 11.93888 28.49429 
P13C8 64.07387 10.25899 11.73318 24.61139 
P13F7 62.11512 9.044507 11.68964 14.1738 
P14F9 15.18114 27.34339 11.55868 2.146023 
P14D7 61.08407 2.7064 11.54734 19.75837 
P14H12 47.13213 14.99895 11.54464 14.61622 
P13A8 61.05464 7.360603 11.5295 22.66638 
P14B3 32.47928 18.86657 11.50742 1.90807 
P14H6 21.26094 27.86608 10.82551 4.592332 
P13A4 66.99853 11.48356 10.52092 22.08381 
P13E3 78.61078 4.938423 10.43951 22.96065 
P13G6 52.02614 6.498841 9.989098 20.71243 
P13B11 54.63023 16.13409 9.873841 21.80595 
P14D12 28.13839 20.54754 9.866753 15.01883 
P13B3 57.62392 12.70165 9.59344 21.62048 
P14E12 31.85651 18.16397 9.459336 5.571199 
P12F2 16.11191 16.22787 9.288915 14.8254 
P13G8 64.9466 6.885534 9.151431 23.37667 
P13D2 65.69508 7.682957 9.033771 21.50588 
P14H5 8.680589 33.75608 8.947887 3.791927 
P13D10 59.33892 19.75762 8.860935 19.83009 
P14B10 42.78492 17.36829 8.721749 8.617814 
P13D9 67.43655 11.37215 8.599439 26.26022 
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P13H6 64.21682 11.16812 8.413744 21.63533 
P12A8 64.69136 10.25722 8.397333 20.10236 
P12C7 62.57825 10.58206 8.321585 30.69887 
P13C10 67.70048 9.27671 8.225073 23.17331 
P12A11 54.71581 9.358774 8.057547 20.18418 
P14H1 53.34001 4.460681 8.033757 21.58946 
P13H11 75.21667 10.63116 7.962502 43.87446 
P14A2 7.278837 13.2975 7.830901 9.951199 
P13F8 50.79972 10.11439 7.669997 19.27028 
P14H4 39.53698 10.33974 7.567364 6.568749 
P13F5 63.48538 8.849496 7.222446 17.27257 
P13H7 53.19039 16.20456 7.126441 17.85725 
P13H5 61.16707 3.049284 7.115328 18.58506 
P14D1 38.08819 34.61624 6.814165 13.30402 
P13F9 55.4294 5.015927 6.763839 21.76425 
P13G10 55.28635 14.76988 6.726579 15.25053 
P12C3 48.60107 8.431397 6.590149 5.760599 
P13B10 57.43152 11.83799 6.363667 21.5196 
P13D6 65.51006 19.01638 6.350273 21.98976 
P12E2 71.85173 4.66917 6.344223 24.93408 
P12D3 71.1574 8.609529 6.30302 28.15031 
P13C9 69.56654 10.48855 6.297048 16.53759 
P12C10 68.00201 9.616971 6.231508 19.17401 
P13E11 76.31375 3.70551 6.045135 23.55996 
P12E5 68.61907 6.330934 5.557262 21.98866 
P12A6 57.71936 1.301973 5.064177 17.58 
P14C11 10.60718 21.81412 4.982768 10.29458 
P13E2 61.23323 16.43361 4.822049 22.9139 
P14A5 -16.4687 48.64646 4.746931 17.85379 
P13D7 70.92203 6.410861 4.41082 17.24668 
P13E7 61.03934 19.52656 4.409845 24.14269 
P13B4 79.59598 4.024533 4.342918 25.83868 
P12F3 44.8628 36.53872 4.22125 36.011 
P13D1 24.00031 31.74321 4.153307 5.733589 
P12E8 79.68616 1.521917 4.14307 26.70217 
P14F2 14.52617 26.40959 4.131409 24.03614 
P14F12 48.08661 7.866409 3.837718 16.40139 
P13E12 23.79505 33.47606 3.778476 15.28476 
P14B4 33.99386 13.52558 3.422502 14.01213 
P14A11 11.06668 16.55673 3.297886 7.922972 
P12B5 52.1512 38.33371 3.127009 41.4558 
P12H10 81.29384 4.204137 2.823713 28.91615 
P14A12 30.34584 19.23776 2.793087 6.21532 
P12B6 54.66647 9.987044 2.664445 25.24767 
P14H2 13.92118 27.26741 2.573717 9.559425 
P12F10 79.05507 1.653811 2.544383 24.63217 
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P13B6 59.98612 11.40872 2.488611 22.66604 
P13H4 33.22263 11.54821 2.4225 16.63882 
P13F1 40.5449 7.502826 2.131612 11.72879 
P12F6 52.24805 15.40515 2.119675 11.85613 
P13E8 35.6204 19.22529 2.092663 27.56439 
P13F4 68.62508 5.490216 2.042568 22.91815 
P12C4 63.50569 8.143879 1.884164 25.27153 
P13A5 62.4339 3.883837 1.85076 41.17196 
P13B9 59.88139 10.3023 1.752514 31.54771 
P12A3 35.56098 7.305887 1.672668 13.25954 
P12A10 52.13727 10.13055 1.435534 17.48855 
P13H10 67.46127 6.511313 1.431417 16.00071 
P13G11 41.55106 23.23634 1.134434 20.43297 
P12D7 61.20281 16.86063 1.081377 26.45987 
P13D3 80.97955 1.981237 1.068096 26.38719 
P13C6 76.1625 3.490828 1.031579 24.7379 
P12B8 51.07312 14.2143 0.986961 22.11304 
P13C2 78.06332 4.960391 0.933395 25.76688 
P13C11 53.87485 8.696173 0.789122 18.37219 
P12D9 53.58877 6.771584 0.703301 23.69749 
P13E9 57.01774 6.927957 0.675407 21.78598 
P14H10 19.79333 29.65136 0.662297 7.325898 
P14A1 52.57091 3.656583 0.616609 26.74211 
P12H4 34.7322 17.46375 0.574882 28.7213 
P12C2 30.27995 11.51482 0.393493 11.53775 
P13H9 62.3895 2.493845 0.064536 15.2876 
P13G9 62.55288 13.77852 0.001952 21.21672 
P12E3 47.98199 23.28462 -0.7108 16.20891 
P12E11 73.93991 6.194231 -0.9781 22.24723 
P12H7 65.96385 12.26945 -1.00993 23.9661 
P12B1 69.93618 8.805625 -1.12423 17.49904 
P12B7 53.76263 2.034971 -1.13119 19.9671 
P14F7 33.10686 5.167287 -1.28679 21.95373 
P14B11 68.00783 7.936257 -1.29373 28.44095 
P14A3 0.583484 15.13281 -1.37645 22.08034 
P14A4 9.124315 35.75554 -1.41311 12.09699 
P12E6 62.86929 18.59965 -1.56159 18.83752 
P14H11 21.08003 26.82509 -1.62077 3.884184 
P13H2 29.7638 18.18381 -1.72577 21.89342 
P14G11 11.23583 15.66973 -1.7408 4.112302 
P12B9 54.0754 1.867384 -2.42683 18.78046 
P13D11 22.45504 2.907022 -2.48612 28.57463 
P12C8 55.44219 10.50015 -2.57503 15.96577 
P13H8 75.14213 7.815239 -2.59829 21.20335 
P14D10 28.18139 11.26894 -2.62771 16.64255 
P12H6 60.53709 4.946292 -2.65674 16.26725 
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Negative -1.6E-15 1.04E-15 -2.74431 2.744315 
P13F6 12.81342 38.15991 -2.82903 22.87259 
P12F8 72.08113 6.79015 -3.06318 23.90158 
P14A9 2.276 10.23496 -3.19931 19.05033 
P14A6 12.33946 15.24049 -3.2443 16.26517 
P14E10 7.978985 19.19814 -3.48289 19.87775 
P13H1 48.59927 19.5299 -3.65957 17.3299 
P12G9 76.25165 2.058681 -3.67557 26.36751 
P14F1 32.11258 30.8922 -4.10634 16.84287 
P14D9 24.72489 6.711745 -4.26301 23.80922 
P12B12 34.76547 39.41461 -4.27627 9.297359 
P12F7 70.16464 7.793636 -4.33108 16.42393 
P12G2 60.79392 20.11073 -4.41381 21.2987 
P13A9 48.55745 11.63737 -5.04958 8.261878 
P14G12 43.73585 32.16446 -5.19446 23.06536 
P12G8 69.28146 7.119817 -5.33807 27.94992 
P14G9 25.99625 19.62383 -5.50316 17.5543 
P14B6 42.80862 3.91153 -5.75594 27.53277 
P13G7 46.48067 17.87033 -5.83064 25.21456 
P14E3 11.85072 6.362463 -5.90241 20.92926 
P13A10 66.15942 8.439018 -6.01168 25.72006 
P13H3 12.10762 25.54477 -6.23194 21.08624 
P14H7 -7.08517 17.56731 -6.30445 20.40175 
P12G4 75.53395 3.990711 -6.44333 25.79118 
P12B2 51.80511 11.88245 -6.79739 19.93671 
P12G3 78.85571 3.758784 -6.98983 25.07222 
P12G6 74.16993 4.408778 -7.33904 27.2574 
P12G10 74.40513 4.569056 -7.37694 27.74614 
P12C9 51.26161 14.80368 -7.39038 37.42863 
P13A11 36.57503 20.32198 -7.66617 23.99213 
P12E4 53.62801 11.61941 -7.94973 8.836291 
P13E4 65.3128 14.90984 -8.39176 23.83041 
P13F11 66.52103 1.827431 -8.51001 25.53271 
P13B12 70.02164 4.281268 -8.9044 2.921295 
P12H3 45.39753 39.3663 -9.0057 14.54912 
P12H11 69.3944 9.255719 -9.23519 26.14936 
P14D4 18.07649 29.50043 -9.58947 24.40286 
P12G5 75.83877 3.947214 -10.0791 28.68455 
P13A12 47.13184 0.562767 -10.547 8.076361 
P13B8 69.55005 1.087336 -10.9057 15.64739 
P13E1 72.67067 9.20003 -11.3864 9.612788 
P13G12 56.09426 9.868374 -11.6851 7.481183 
P12F11 70.29524 1.079568 -12.1406 25.01625 
P12A4 57.60193 10.34467 -12.5505 9.768548 
P13A3 49.4022 15.62358 -13.9029 28.20824 
P12B3 61.98406 11.2399 -14.0016 30.86147 
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P13A7 34.23005 14.97206 -14.9375 25.28122 
P12A2 50.93835 8.329339 -15.6527 31.23382 
P12F9 42.43112 15.97481 -17.0093 15.5608 
P13A6 62.16428 4.181207 -17.1228 44.78536 
P13A2 47.25156 10.37642 -17.8695 28.98473 
P12E12 56.76999 7.364205 -18.9406 3.793946 
P13A1 46.68483 2.310021 -19.1867 13.46318 
P13F12 76.88013 0.700357 -19.2921 10.16751 
P12E10 29.92259 37.12848 -19.8402 12.0464 
P13D12 55.02205 12.21098 -20.6057 13.36992 
P13C12 47.46493 29.56519 -20.8498 6.125715 
P12H1 48.19581 9.363045 -23.1262 24.56357 
P13H12 12.01996 17.51483 -23.9993 23.24625 
P13G2 16.64483 19.67116 -26.3061 32.82964 
P12F12 44.35305 12.37506 -28.4174 16.9287 
P12F1 47.2474 11.47322 -29.6369 14.3363 
P12A7 44.48769 14.79392 -31.7808 6.799194 
P12G1 69.45505 3.245193 -31.8402 7.978208 
P12C12 62.69667 16.04693 -31.9423 11.03574 
P13D4 61.82762 12.19567 -33.2304 36.61669 
P12D1 48.25377 20.44374 -33.4047 12.65876 
P12C1 65.50274 7.063881 -37.7655 16.60946 
P12A12 38.54574 8.3305 -39.7585 8.580804 
P12H12 12.05098 24.78073 -45.1262 40.06738 
P12D12 51.24517 6.066775 -49.5603 27.39543 
P13G1 38.28933 19.71935 -51.7756 22.4385 
P12A1 23.71434 11.1765 -54.5519 54.92307 
P13C1 28.31176 33.08247 -57.5063 58.08748 
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VUW MNP library screening raw data 
 
Table 7.2 Raw data of VUW MNP library screen vs. M. smegmatis 
Top hits highlighted in yellow, positive control in red and negative control in green. 
Plates RAK18_52A/B, 53A/B and 53C/D were screened against M. smegmatis as 
stated earlier RAK18_52A/B was not screened in duplicate therefore no standard 
deviation (std dev) value are listed for extracts from this plate. Std dev is used 
instead of standard error as standard error values is applicable for triplicate data. 
RAK18_52 A/B represented as RAK1852 followed by the respective well number. 
RAK18_53A/B represented as RAK18A followed by the respective well number. 
RAK18_53C/D represented as RAK18C followed by the respective well number. 
 
Well number 
GFP 
average 
GPF  
std dev 
Resazurin 
average 
Resazurin 
std dev 
RAK1852D5 82.51134 
 
86.33764 
 RAK1852D7 82.29852 
 
84.95481 
 RAK1852G6 81.28371 
 
84.82935 
 RAK1852H7 81.93423 
 
84.08974 
 RAK1852B5 82.48722 
 
83.98016 
 RAK1852G2 83.40519 
 
83.86051 
 RAK1852D8 82.61491 
 
83.76624 
 RAK18CH8 88.25275 2.492621 80.87763 0.734711 
RAK18AD7 87.31818 0.149184 78.43139 1.641461 
Positive 86.92569 2.794045 78.12862 5.72208 
RAK18AA11 85.72099 0.54014 74.28695 0.237072 
RAK18AE6 78.32324 8.843107 52.21352 27.78748 
RAK1852G12 78.8809 
 
41.2392 
 RAK18CG8 62.80922 24.57021 39.83496 45.13486 
RAK1852G1 62.75679 
 
31.20559 
 RAK18CC10 60.35443 13.82721 26.96934 34.5404 
RAK1852G9 43.6266 
 
22.82428 
 RAK18CF10 54.17289 13.87771 21.88638 7.693616 
RAK1852G7 31.59895 
 
21.81058 
 RAK18CD7 49.98409 15.10035 21.58811 1.318869 
RAK1852G3 44.64637 
 
21.58543 
 RAK1852E9 37.43063 
 
21.04569 
 RAK1852C9 61.86191 
 
20.79466 
 RAK1852H12 56.28451 
 
20.73401 
 RAK18CF7 39.27054 16.71114 19.8724 7.734189 
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RAK18CD6 43.65879 12.61971 18.84471 7.782954 
RAK1852F8 41.61507 
 
18.39029 
 RAK18CC4 38.4603 6.25646 18.30972 0.086892 
RAK1852G8 47.00231 
 
17.86712 
 RAK18CE4 47.10365 16.12104 17.40278 4.279494 
RAK18AD6 46.50234 15.32 17.22348 9.320529 
RAK18CD11 39.32563 8.246603 16.76528 4.730476 
RAK18CE6 45.73882 18.35168 16.57323 10.01583 
RAK1852G11 43.14526 
 
16.37191 
 RAK18CG5 25.97592 39.92709 16.26847 0.591971 
RAK18CB7 34.60375 6.208976 15.99004 1.254972 
RAK18CB5 28.84004 23.9779 15.88827 0.04278 
RAK18AE7 61.49888 6.629442 15.85789 9.75534 
RAK18CC5 44.09384 5.974945 15.66845 3.851974 
RAK1852F9 30.20816 
 
15.56943 
 RAK1852C7 41.64167 
 
15.36025 
 RAK18CF5 37.79198 29.84378 15.2449 4.505259 
RAK18CE11 48.44091 2.063985 14.87257 8.80086 
RAK18CC9 43.08292 9.864415 14.75548 1.130829 
RAK18CD3 25.37132 12.49168 14.58015 6.087665 
RAK18CF3 40.54543 18.34584 14.36066 4.67791 
RAK18CD4 38.59718 9.979407 14.35189 12.69731 
RAK18CB6 41.31467 9.555635 14.2968 2.334622 
RAK1852F3 18.98356 
 
14.04147 
 RAK18CG3 38.91149 14.82204 14.03498 4.153189 
RAK18AB5 37.5093 19.65451 13.80519 4.430898 
RAK1852D9 -0.42405 
 
13.5773 
 RAK1852F2 -2.52531 
 
13.38082 
 RAK18CE3 32.87118 5.11551 13.25755 4.092863 
RAK18CE10 44.37084 8.91691 13.24639 8.578496 
RAK1852G10 43.68512 
 
13.20478 
 RAK18AC4 39.07579 11.82997 13.03168 3.172523 
RAK18AF6 46.50283 10.27338 12.94231 2.156692 
RAK18CG6 31.17505 4.672351 12.92744 1.885358 
RAK18CF9 38.95533 21.41062 12.8467 4.86981 
RAK18AG1 41.24539 29.82615 12.77045 15.59249 
RAK18AC8 37.92471 17.9055 12.66563 3.207292 
RAK18CF8 44.56399 14.30857 12.66233 5.333487 
RAK1852H2 26.73171 
 
12.65593 
 RAK18CE8 40.45081 6.147955 12.595 11.34503 
RAK18CB11 29.96592 0.952737 12.5565 3.123463 
RAK18CG7 33.10349 19.54638 12.31101 0.764271 
RAK18CC6 48.80099 9.638707 12.03279 8.855017 
RAK1852H5 34.93849 
 
11.8828 
 RAK18AB8 44.77955 12.36526 11.82948 1.666298 
RAK18CB4 37.25737 12.81713 11.82043 2.358022 
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RAK1852A9 13.5793 
 
11.48219 
 RAK18CE5 40.57995 16.65375 11.30892 11.64201 
RAK18CC1 54.5389 6.189958 11.183 2.062172 
RAK18CB9 24.35392 5.51662 11.14215 1.17628 
RAK18CE2 35.62878 3.671658 11.06653 5.279631 
RAK1852C4 44.99575 
 
10.87405 
 RAK18CB8 42.4589 12.07647 10.72786 0.043497 
RAK1852C8 25.35723 
 
10.70004 
 RAK18CG2 23.10204 24.08118 10.5254 2.620404 
RAK18AD11 6.681053 31.8454 10.50397 10.6675 
RAK1852G4 43.38859 
 
10.45328 
 RAK18AD8 42.50065 1.771551 10.39133 7.766189 
RAK18CE7 44.62251 22.53877 10.26418 2.268317 
RAK18AF7 48.19767 16.46289 10.04269 9.697508 
RAK18CF11 32.25211 3.666043 9.943542 8.772544 
RAK18CC11 23.73454 13.20087 9.925965 1.371286 
RAK18CC8 39.47905 20.25609 9.833364 3.769109 
RAK1852H3 35.3471 
 
9.791177 
 RAK18CB10 35.93593 14.53557 9.557172 6.739276 
RAK18CG10 35.993 26.48967 9.384845 1.807702 
RAK18CA7 27.20761 11.24038 9.379337 4.720824 
RAK18CH10 30.17527 13.92102 9.182157 11.48433 
RAK18CA6 25.0981 34.55846 9.099836 3.663083 
RAK18CC7 35.07491 30.47901 9.030643 1.813343 
RAK1852B7 54.14604 
 
8.948965 
 RAK1852A10 28.73898 
 
8.904786 
 RAK18AH4 26.33717 19.60195 8.819939 14.93681 
RAK18CH2 15.53336 2.192368 8.771624 6.578632 
RAK1852D4 34.93919 
 
8.519383 
 RAK18AC9 7.212093 12.72296 8.512579 1.67748 
RAK18CD8 36.16599 5.225469 8.494863 9.418876 
RAK18CF1 43.94552 12.94351 8.365288 6.558098 
RAK18AG6 25.03923 0.789772 7.868625 2.268652 
RAK1852G5 34.29895 
 
7.867839 
 RAK1852E7 51.68121 
 
7.853403 
 RAK18AG7 46.76334 24.68317 7.746715 4.128095 
RAK1852H11 23.93061 
 
7.725226 
 RAK18CA3 29.31859 13.31378 7.569492 3.033543 
RAK18CB2 16.42576 1.2311 7.452216 2.652107 
RAK18CH7 33.19343 11.03563 7.299778 8.886059 
RAK18AA3 37.28179 14.72419 7.222739 1.578026 
RAK18AH3 31.27687 5.289814 7.057244 3.935705 
RAK1852E4 37.31997 
 
7.03425 
 RAK18CG4 34.74121 15.33369 6.984139 1.921967 
RAK18CF2 21.73172 11.09809 6.981507 10.75625 
RAK1852A3 23.35777 
 
6.957131 
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RAK18CH5 33.66798 14.86288 6.942604 6.816235 
RAK18CA5 34.44111 15.19794 6.931589 3.247933 
RAK18CG9 28.45219 11.31215 6.843277 0.070078 
RAK18AF3 22.40652 7.444122 6.70158 13.23768 
RAK1852H4 43.34248 
 
6.668901 
 RAK18AG5 43.12163 4.664573 6.612338 6.895605 
RAK18CA1 60.67739 5.464107 6.417738 11.39781 
RAK18AH6 24.60597 15.1173 6.369117 6.603738 
RAK18CA4 27.5695 22.09493 6.350291 6.073261 
RAK18AH7 45.46937 0.591618 6.31376 10.67808 
RAK18CE9 14.61035 40.4074 6.299608 1.603988 
RAK18CE1 63.42 7.432334 6.105656 9.977392 
RAK18CC12 53.13311 1.716488 6.056883 2.523299 
RAK1852E3 33.95454 
 
6.035378 
 RAK18AG12 37.4429 20.45551 5.979747 0.954379 
RAK18AB12 35.50482 23.77472 5.956387 11.27223 
RAK1852F10 9.737147 
 
5.861956 
 RAK18AE5 57.3575 8.644206 5.832018 8.076328 
RAK1852H8 10.38767 
 
5.810317 
 RAK1852H9 36.52259 
 
5.784546 
 RAK1852B9 28.5822 
 
5.656369 
 RAK18CA10 26.64784 7.684994 5.635112 2.967397 
RAK18AE11 34.31452 19.35108 5.589142 0.43874 
RAK18CA8 27.08561 1.497708 5.542429 1.66355 
RAK18AF12 32.5208 16.52901 5.528628 3.723113 
RAK1852F11 30.86223 
 
5.4191 
 RAK18CA2 1.223262 45.65745 5.287721 3.660894 
RAK18CD2 23.35751 1.332938 5.193092 1.669427 
RAK18CD9 41.33375 23.41621 5.167979 2.879564 
RAK18CD5 19.13102 1.057542 5.105608 13.0501 
RAK18CF6 34.90949 10.74338 4.936552 4.301336 
RAK18AC6 37.26106 8.716831 4.838043 0.262285 
RAK18CB3 17.34306 19.77998 4.796711 8.537323 
RAK18AF5 37.94824 10.5327 4.79034 2.841401 
RAK18AD9 1.142218 7.697591 4.786374 1.883591 
RAK1852D10 33.72469 
 
4.608182 
 RAK18CD10 30.58667 4.002616 4.415699 12.47103 
RAK18AG3 40.74942 17.08258 4.354143 0.981454 
RAK1852A12 36.23474 
 
4.341587 
 RAK18CG12 48.34821 1.777344 4.185734 2.055925 
RAK18CA12 45.63538 3.622087 4.169079 1.060737 
RAK18CH9 26.98868 1.196705 3.994208 6.954887 
RAK18CA9 26.46577 10.15487 3.902579 1.996798 
RAK1852F6 31.71352 
 
3.816351 
 RAK18CD1 42.90091 12.06179 3.642459 8.126461 
RAK1852B10 32.85283 
 
3.559221 
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RAK18AE4 36.00865 13.30036 3.5313 3.035798 
RAK18CA11 35.08207 0.156968 3.511606 4.793009 
RAK18CC3 9.339796 21.06663 3.308806 3.413138 
RAK18CE12 56.49319 9.311254 3.257728 5.234882 
RAK1852D11 28.21366 
 
3.247062 
 RAK18AH5 34.5343 10.56111 3.244301 2.190558 
RAK1852A11 13.27461 
 
3.212668 
 RAK18CG11 20.58392 3.106348 3.18032 6.079504 
RAK18CH6 2.026747 2.656611 2.974406 7.80542 
RAK18CG1 35.21885 13.69045 2.922377 0.335708 
RAK18AB3 33.19032 11.31146 2.831559 1.151677 
RAK18CH4 22.10564 4.257631 2.784111 3.676249 
RAK18AE10 40.97388 0.586597 2.702233 5.538246 
RAK1852H10 32.09944 
 
2.6427 
 RAK18AC12 26.08682 15.27571 2.619875 11.35434 
RAK18AG2 23.3445 17.59309 2.45287 0.261224 
RAK1852B1 19.16339 
 
2.449645 
 RAK18CB12 36.54129 5.752983 2.440765 5.117247 
RAK18CC2 12.15135 17.3535 2.310045 6.849242 
RAK18AE2 35.09948 8.516478 2.083469 6.950927 
RAK18AA10 39.61308 5.143171 2.025051 5.119686 
RAK18AF2 13.06663 6.515053 1.903731 10.461 
RAK18AD10 19.20469 8.58081 1.706661 4.976488 
RAK18CH11 25.4635 18.03673 1.700377 11.90163 
RAK18CH3 12.98827 25.94547 1.631092 0.233987 
RAK18AE3 29.61926 30.09737 1.377858 11.51169 
RAK18AA9 9.107801 17.83364 1.223838 7.841813 
RAK18AB9 16.14871 7.001322 1.171749 4.285827 
RAK18AG11 25.67891 3.957708 0.992288 4.036634 
RAK1852C6 53.59519 
 
0.78379 
 RAK1852H6 32.59602 
 
0.78379 
 RAK18AH2 6.720081 23.87637 0.692042 0.39497 
RAK1852F4 20.25943 
 
0.64108 
 RAK18AA5 26.95119 0.39597 0.537887 0.175219 
RAK1852A1 19.12317 
 
0.464357 
 RAK1852A5 7.751871 
 
0.42377 
 RAK1852A2 31.78198 
 
0.265171 
 RAK18AD3 6.729815 9.866928 0.181802 1.809977 
RAK18AE12 37.37279 20.09251 0.056468 0.418971 
Negative -3E-15 5.59E-15 2.84E-15 3.89E-15 
RAK18AF11 26.33552 12.44472 -0.05612 7.400697 
RAK18AF1 24.00114 6.522307 -0.18053 4.742422 
RAK18AC3 25.21636 14.04352 -0.25865 0.38762 
RAK18AE1 27.51207 10.3161 -0.28578 4.21642 
RAK18CD12 49.20714 0.853602 -0.4331 4.111115 
RAK18AF4 27.20402 14.37533 -0.5966 20.17942 
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RAK18AF9 18.09764 24.6521 -0.67438 11.77507 
RAK18AB6 46.21676 0.334301 -0.75874 11.49639 
RAK18AD1 29.46976 18.97909 -0.86904 1.072651 
RAK18AA6 39.8147 0.584787 -0.9598 2.391276 
RAK18AG4 37.55022 0.01991 -1.01646 3.350942 
RAK18AB10 24.1238 11.79857 -1.02203 10.6011 
RAK18AD12 21.25354 7.169368 -1.2628 1.676767 
RAK18AA7 39.52037 13.7623 -1.35869 0.724543 
RAK1852E1 32.45254 
 
-1.50761 
 RAK18AA1 35.75929 21.90377 -1.51005 5.884542 
RAK18AE8 41.74214 9.733895 -1.52283 15.52196 
RAK18AE9 -0.41931 54.80276 -1.56743 20.57051 
RAK1852A6 24.64428 
 
-1.81056 
 RAK18AH9 18.17687 43.73469 -1.96815 2.740514 
RAK18AB4 30.54428 13.07372 -1.99401 1.181503 
RAK1852B6 35.49998 
 
-2.00201 
 RAK1852F1 34.28081 
 
-2.12521 
 RAK1852A7 14.05921 
 
-2.18027 
 RAK1852E6 38.86789 
 
-2.38712 
 RAK18AD5 22.01684 37.56784 -2.4592 14.40564 
RAK1852H1 20.79624 
 
-2.56741 
 RAK18AD2 28.86165 16.17891 -2.70755 0.700842 
RAK18AG9 18.95324 19.94399 -2.72205 14.41937 
RAK18AH10 5.739257 0.799466 -2.80551 0.622771 
RAK18AC10 15.20642 2.990794 -2.84881 14.5402 
RAK18AD4 22.78329 8.821005 -2.86509 8.614111 
RAK18AA8 32.99255 5.673311 -2.87797 11.01093 
RAK18CF4 48.18199 13.88986 -3.05744 5.139073 
RAK18AB11 22.3611 14.16701 -3.17642 3.068798 
RAK18AH1 28.21666 16.50828 -3.24822 6.158713 
RAK18AA12 34.7098 14.96365 -4.01141 6.415065 
RAK18CH12 32.50313 9.541595 -4.07263 9.542489 
RAK18AF10 25.91422 14.70727 -4.1228 1.729383 
RAK18AF8 34.45813 5.627901 -4.21142 16.53235 
RAK1852E8 2.674997 
 
-4.43389 
 RAK18AH12 32.71475 10.57416 -4.47234 0.615571 
RAK18AC11 27.25304 0.372096 -4.86194 0.409552 
RAK18CB1 17.40274 16.69361 -4.92256 13.15581 
RAK18AG10 19.18288 16.19178 -5.16962 0.978594 
RAK18AC1 25.46507 8.67867 -5.29521 7.674458 
RAK1852D12 19.96291 
 
-5.34074 
 RAK1852C1 46.85089 
 
-5.60544 
 RAK18AC5 28.45948 8.570964 -6.33864 19.13271 
RAK1852A4 9.629672 
 
-6.43095 
 RAK18AA4 18.58409 1.197894 -6.63394 2.948968 
RAK1852C2 39.57375 
 
-6.73817 
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RAK18AB1 24.96809 10.69279 -6.89769 0.527962 
RAK18AC2 24.18161 8.432652 -7.29601 6.497312 
RAK18AB7 33.56221 29.0952 -7.36759 20.2746 
RAK18AH11 -6.39996 24.00148 -7.50226 14.69246 
RAK18AB2 33.68643 9.540991 -7.86444 9.194541 
RAK18CH1 22.20906 11.19038 -8.68446 1.955926 
RAK18AA2 7.372359 9.452771 -9.21463 2.771314 
RAK18AC7 15.8392 39.01105 -9.67571 20.9994 
RAK1852F12 26.92394 
 
-10.3629 
 RAK18AH8 27.36875 10.97076 -10.8755 17.81443 
RAK18CF12 23.06386 14.98629 -11.641 0.434402 
RAK1852E2 59.21263 
 
-20.1123 
 RAK1852E10 32.41725 
 
-24.7939 
 RAK1852D1 66.17376 
 
-25.3368 
 RAK1852F5 46.0063 
 
-25.8884 
 RAK1852B11 33.04011 
 
-28.8941 
 RAK18AG8 45.88341 15.66059 -29.7372 16.09452 
RAK1852B8 53.89066 
 
-29.9097 
 RAK1852D6 62.61566 
 
-30.8714 
 RAK1852A8 42.47381 
 
-32.3404 
 RAK1852D2 64.59845 
 
-33.3008 
 RAK1852B2 54.27409 
 
-33.5476 
 RAK1852C5 59.30343 
 
-33.5801 
 RAK1852D3 64.28844 
 
-33.8877 
 RAK1852B3 40.79783 
 
-34.6267 
 RAK1852F7 62.8487 
 
-35.4226 
 RAK1852C3 62.76392 
 
-35.9771 
 RAK1852E5 62.48796 
 
-37.2181 
 RAK1852B4 62.5174 
 
-38.3427 
 RAK1852C10 58.65113 
 
-38.7962 
 RAK1852E11 58.51209 
 
-39.3114 
 RAK1852E12 31.53805 
 
-41.141 
 RAK1852C11 39.84829 
 
-41.1927 
 RAK1852B12 59.0764 
 
-52.5119 
 RAK1852C12 57.55604 
 
-53.5649 
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Increased resistance of stationary phase mycobacteria 
Streptomycin vs M. tuberculosis H37Ra
25 M starting
-2 -1 0 1 2
0
50
100
150
Log [streptomycin]
R
F
U
 (
%
)
 
A 
Streptomycin vs stationary M. tuberculosis H37Ra
200 M starting
-1 0 1 2 3
0
50
100
150
Log [streptomycin]
R
F
U
 (
%
)
 
 
A) dose response curve of streptomycin in a growth inhibition assay. B) dose response 
curve of streptomycin against stationary phase H37Ra. 99% inhibition is observed at 
0.4 M of streptomycin in log phase H37Ra (A), however  at this concentration  there  
is still 50% growth observed in stationary phase bacteria (B). Graph generated using 
GraphPad Prism v.5.0. It is noted that the graph shape for B is not sigmoidal, however it 
is still evident that compared to log phase bacteria, stationary phase bacteria are more 
resistant to inhibiton. This is made evident when observing the fact the even at the 
starting concentration of 200 M approximately 10 times more than that used for log 
phase cells, there is still 15% residual metabolism measure.  
  
B 
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G2-M block assay 
 Sample 
  
Ungated 
  
apoptotic 
  
G0 
  
G2-M 
  
other 
  
S 
  
total G2-M 
Count Count Count Count Count Count Count 
% 
compared 
to total 
Specimen_001_Tube_001.fcs 10341 2038 4551 1999 8303 1616 8139 24.6 
Specimen_001_Tube_002.fcs 10414 2473 5176 1455 7941 1168 7805 18.6 
Specimen_001_Tube_003.fcs 10428 2411 4613 1705 8017 1562 7875 21.7 
Mean 10394 2307 4780 1720 8087 1449 7940 
 SD 46.7 235 344 272 191 245 176 
  
 
The samples show no significant difference at any concentration of 156 
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Appendix B: Fatty acid mixture from Psychrolutes marcidus 
1H NMR (CDCl3, 600 MHz) spectrum of fatty acid mixture from the MeOH liver 
extract of Psychrolutes marcidus 
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13C NMR (CDCl3, 150 MHz) spectrum of fatty acid mixture from the MeOH liver 
extract of Psychrolutes marcidus 
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GC/MS Chromatograms of ND5_96L FAME analysis 
  
Full GC trace of ND5_96L FAME (Integrated Bioactive Technologies group, Callaghan Innovation). 
2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 min
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
uV(x10,000)
 Chromatogram
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Zoom in of relevant section of GC trace of ND5_96L FAME, with relevant labels for peaks of interest (Integrated Bioactive Technologies group, 
Callaghan Innovation).
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0 12.5 13.0 min
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
uV(x1,000)
 Chromatogram
20:1 phthalate 
18:1n-7 
18:1n-9 
18:0 17:1 
16:1n-7 16:0 
16.1n-9 
14:0 
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Appendix C: NMR spectra of rimarikiamide A (98) 
 
1H NMR (DMSO-d6, 600 MHz) spectrum of rimarikiamide A (98)  
183 
 
 
13C NMR (d6 DMSO, 150 MHz) spectrum of rimarikiamide A (98)  
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gCOSY NMR (DMSO-d6, 600 MHz,) spectrum of rimarikiamide A (98)  
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Multiplicity-edited HSQC NMR (DMSO-d6, 600 MHz,) of rimarikiamide A (98) 
showing methylenes in blue and methyls and methines in red. 
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gHMBC NMR (DMSO-d6, 600 MHz,) spectrum of rimarikiamide A (98). 
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2D ROESY NMR (DMSO-d6, 600 MHz,) spectrum of rimarikiamide A (98). 
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2D ROESY NMR (DMSO-d6, 600 MHz,) spectrum of rimarikiamide A (98) specific 
range of interest. 
 
  
189 
 
 
2D ROESY NMR (DMSO-d6, 600 MHz,) spectrum of rimarikiamide A (98) specific 
range of interest. 
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Appendix D: NMR spectra of 3-epi-xestoaminol C (156) 
 
1H NMR (CD3OD, 600 MHz) spectrum of 3-epi-xestoaminol C (156).  
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13C NMR (CD3OD, 150 MHz) spectrum of 3-epi-xestoaminol C (156). 
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gCOSY NMR (CD3OD, 600 MHz) spectrum of 3-epi-xestoaminol C (156).  
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Multiplicity-edited HSQC NMR (CD3OD, 600 MHz) spectrum of 3-epi-xestoaminol C 
(156) showing methylenes in blue and methyls and methines in red. 
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gHMBC NMR (CD3OD, 600 MHz) spectrum of 3-epi-xestoaminol C (156). 
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1D TOCSY NMR spectrum (CDCl3, 600 MHz, 200 ms spin-lock mixing time) of 3-epi-
xestoaminol C (156). Irradiation of H-3 (H 3.65) and H-4/5 (H 1.55) resulted in 
TOCSY transfer of energy to H3-14 (H 0.88), indicated by circles in the bottom two 
panels. Irradiating H3-14 resulted in TOCSY transfer of energy to H-4/5, indicated by a 
circle in the top panel.  
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1H NMR (CDCl3, 600 MHz) spectrum of oxazolidinone (157). 
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13C NMR (CDCl3, 150 MHz) spectrum of oxazolidinone (157). 
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1D NOE NMR spectra (CDCl3, 600 MHz) spectrum of oxazolidinone (157). Irradiating 
H-2 (H 3.57) resulted in NOE transferr to H-4a (H 1.62) and H-4b (H 1.71) 
indicated by the circle in the top panel. Irradiating H-3 (H 4.09) resulted in NOE 
transfer to H3-1 (H 1.27) indicated by the circle in the bottom panel.  
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1H NMR (CDCl3, 600 MHz) spectrum of diacetyl-3-epi-xestoaminol C (158). 
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13C NMR (CDCl3, 150 MHz) spectrum of diacetyl-3-epi-xestoaminol C (158).  
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1H NMR (CDCl3, 600 MHz) spectrum of N-acetyl-3-epi-xestoaminol C (159).  
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13C NMR (CDCl3, 150 MHz) spectrum of N-acetyl-3-epi-xestoaminol C (159).  
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1H NMR (CD3OD, 600 MHz) spectrum of the R- Mosher’s ester (160).  
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13C NMR (CD3OD, 150 MHz) spectrum of the R- Mosher’s ester (160).  
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1H NMR (CD3OD, 600 MHz) spectrum of the S- Mosher’s ester (161).  
206 
 
 
13C NMR (CD3OD, 150 MHz) spectrum of the S-Mosher’s ester (161).  
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Appendix E: Chemical genetics mutant hits 
Top 28 S. cerevisiae mutants identifed for chemcial genetic profiling. 
Residual 
Growth P-values ORF Gene Name Description 
64.9 0.000 YNL202W SPS19 
Peroxisomal 2,4-dienoyl-CoA reductase; auxiliary 
enzyme of fatty acid beta-oxidation; homodimeric 
enzyme required for growth and sporulation on 
petroselineate medium; expression induced during 
late sporulation and in the presence of oleate 
57.0 0.003 YOL011W PLB3 
Phospholipase B (lysophospholipase) involved in 
lipid metabolism; hydrolyzes phosphatidylinositol and 
phosphatidylserine and displays transacylase activity 
in vitro; PLB3 has a paralog, PLB1, that arose from 
the whole genome duplication 
40.6 0.004 YJL216C IMA5 
Alpha-glucosidase; specificity for isomaltose, 
maltose, and palatinose, but not alpha-
methylglucoside; member of the IMA isomaltase 
family; not required for isomaltose utilization, but 
Ima5p overexpression allows the ima1 null mutant to 
grow on isomaltose 
60.5 0.004 YDR032C PST2 
Protein with similarity to a family of flavodoxin-like 
proteins; induced by oxidative stress in a Yap1p 
dependent manner; the authentic, non-tagged protein 
is detected in highly purified mitochondria in high-
throughput studies; protein abundance increases in 
response to DNA replication stress; PST2 has a 
paralog, RFS1, that arose from the whole genome 
duplication 
43.2 0.004 YNL090W RHO2 
Non-essential small GTPase of the Rho/Rac family of 
Ras-like proteins; involved in the establishment of 
cell polarity and in microtubule assembly 
64.8 0.005 YDR257C RKM4 
Ribosomal lysine methyltransferase; specific for 
monomethylation of Rpl42ap and Rpl42bp (lysine 
55); nuclear SET-domain containing protein 
57.4 0.006 YDR193W YDR193W 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental 
and comparative sequence data 
45.3 0.006 YDR183W PLP1 
Protein that interacts with CCT (chaperonin 
containing TCP-1) complex; has a role in actin and 
tubulin folding; has weak similarity to phosducins, 
which are G-protein regulators 
62.65 0.007 
YLR361C-
A YLR361C-A Putative protein of unknown function 
46.8 0.008 YBR059C AKL1 
Ser-Thr protein kinase; member (with Ark1p and 
Prk1p) of the Ark kinase family; involved in 
endocytosis and actin cytoskeleton organization 
61.1 0.013 YDR272W GLO2 
Cytoplasmic glyoxalase II; catalyzes the hydrolysis of 
S-D-lactoylglutathione into glutathione and D-lactate; 
GLO2 has a paralog, GLO4, that arose from the 
whole genome duplication 
58.5 0.013 YNL235C YNL235C 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental 
and comparative sequence data; partially overlaps the 
verified ORF SIN4/YNL236W, a subunit of the 
mediator complex 
69.4 0.014 YBL007C SLA1 
Cytoskeletal protein binding protein; required for 
assembly of the cortical actin cytoskeleton; interacts 
with proteins regulating actin dynamics and proteins 
required for endocytosis; found in the nucleus and cell 
cortex; has 3 SH3 domains 
43.8 0.016 YIL010W DOT5 
Nuclear thiol peroxidase; functions as an alkyl-
hydroperoxide reductase during post-diauxic growth 
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61.5 0.017 YDR183W PLP1 
Protein that interacts with CCT (chaperonin 
containing TCP-1) complex; has a role in actin and 
tubulin folding; has weak similarity to phosducins, 
which are G-protein regulators 
63.6 0.019 YBL008W HIR1 
Subunit of the HIR complex; HIR is a nucleosome 
assembly complex involved in regulation of histone 
gene transcription; contributes to nucleosome 
formation, heterochromatic gene silencing, and 
formation of functional kinetochores 
69.1 0.019 YBR276C PPS1 
Protein phosphatase; has specificity for serine, 
threonine, and tyrosine residues; has a role in the 
DNA synthesis phase of the cell cycle 
61.3 0.025 
YAL064C-
A TDA8 
Putative protein of unknown function; null mutant is 
sensitive to expression of the top1-T722A allele; not 
an essential gene 
62.9 0.026 YDL237W AIM6 
Putative protein of unknown function; required for 
respiratory growth; YDL237W is not an essential 
gene 
66.5 0.029 YJL191W RPS14B 
Protein component of the small (40S) ribosomal 
subunit; required for ribosome assembly and 20S pre-
rRNA processing; mutations confer cryptopleurine 
resistance; homologous to mammalian ribosomal 
protein S14 and bacterial S11; RPS14B has a paralog, 
RPS14A, that arose from the whole genome 
duplication 
35.3 0.029 YHL020C OPI1 
Transcriptional regulator of a variety of genes; 
phosphorylation by protein kinase A stimulates Opi1p 
function in negative regulation of phospholipid 
biosynthetic genes; involved in telomere maintenance; 
null exhibits disrupted mitochondrial metabolism and 
low cardiolipin content, strongly correlated with 
overproduction of inositol 
61.8 0.030 YBL017C PEP1 
Type I transmembrane sorting receptor for multiple 
vacuolar hydrolases; cycles between the late-Golgi 
and prevacuolar endosome-like compartments 
65.6 0.031 YOR300W YOR300W 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental 
and comparative sequence data; overlaps with verified 
gene BUD7/YOR299W; mutation affects bipolar 
budding and bud site selection, though phenotype 
could be due to the mutation's effects on BUD7 
50.1 0.033 YPR042C PUF2 
mRNA-binding protein; member of the PUF protein 
family, which is defined by the presence of Pumilio 
homology domains that confer RNA binding activity; 
preferentially binds mRNAs encoding membrane-
associated proteins; PUF2 has a paralog, JSN1, that 
arose from the whole genome duplication 
54.6 0.034 YOR100C CRC1 
Mitochondrial inner membrane carnitine transporter; 
required for carnitine-dependent transport of acetyl-
CoA from peroxisomes to mitochondria during fatty 
acid beta-oxidation 
69.1 0.037 
YMR105W-
A YMR105W-A Putative protein of unknown function 
48.4 0.046 YKL053W YKL053W 
Dubious open reading frame; unlikely to encode a 
functional protein, based on available experimental 
and comparative sequence data; partially overlaps 
verified ORF ASK1 
46.8 0.049 YBR071W YBR071W 
Protein of unknown function found in the cytoplasm 
and bud neck; mRNA expression may be regulated by 
the cell cycle and/or cell wall stress; overexpression 
of YBR071W affects endocytic protein trafficking 
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